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EGF receptors were identified on peritubular cells and Leydig cells of normal human testis using
immunohistochemistry with monoclonal antibodies EGF-R1, EGF-R and F4. In a radioligand
exchange assay the binding site for EGF on human testicular tissue was characterised as having a
Kd of 1.18 ± 0.32 nM with approximately 528 ±116 fmoles binding sites per mg of protein. The
molecular weight of the receptor/ligand complex, identified by crosslinking and SDS-page gel
electrophoresis was approximately 125 kDa. This may represent a proteolysed form of the receptor
complex. Competition studies illustrated that of the peptides tested, only EGF and TGF-a were
specific for the EGF binding site.
In cancerous testicular tissue EGF receptors were not identified on seminoma and
Leydig cell tumours but that they were located, by both immunohistochemical and biochemical
techniques on teratoma tumours. The EGF receptor on teratoma cells was characterised using the
Tera-2 cell line. The EGF receptor was a high affinity site with a Kd of 0.21 ± 0.08 nM, with
approximately 6.73 ± 0.81 x 10^ binding sites per cell. Molecular characterisation was performed
by Western Blot Analysis employing the monoclonal antibodies EGF-R 1 and F4. The receptor
was identified in both the 170 and 125 kDa form. Competition studies with other peptides clarified
once again the specificity which EGF and TGF-a have for the receptor site.
EGF and TGF-a were both present in normal testicular tissue at 5.16 ± 0.97 ng
and 2.76 ± 0.15 ng per gram of wet human testicular tissue respectively. The concentrations of
androstenedione, DHT and testosterone in human testicular tissue were 0.46 ± 0.13 nmoles,
0.29 ± 0.06 nmoles and 15.58 ± 2.55 nmoles per gram of dry human testicular tissue,
respectively.
EGF and TGF-a were also secreted by Tera-2 cells at concentrations of
2.40 ± 0.33 pg and TGF-a at 2.55 ± 0.78 pg per ml of culture media. TGF-a and EGF both
competed for the EGF binding site previously identified on the Tera-2 cells. EGF did not alter
thymidine incorporation by the cells when incubated over 24 hours at concentrations ranging from
0.3 to 100 nM. TGF-a however, increased thymidine incorporation by approximately 2-fold when
employed at concentrations greater than 3 nM over 7 hours in culture. The maximum increase in
thymidine incorporation was apparent after 24 hours employing a concentration of 100 nM
TGF-a. Mybolerone was found to have no effect on thymidine incorporation or EGF receptor
expression when Tera-2 cells were incubated in concentrations from 0.3 to 100 nM for 24 hours. It
was therefore postulated that Tera-2 cells are not androgen sensitive.
The results of these studies indicate that EGF and TGF-a may be involved in
testicular cell-cell communication and in the development of testicular cancer.
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Increasing awareness that growth factors are regulators of cell growth (Rose et al,
1975; Tonelli and Sorof, 1980; Zetterberg et al, 1984; Schlessinger et al, 1988) has
prompted this investigation to study the involvement of specific growth factors in the
control of normal testicular function and in the development of testicular cancer.
Spermatogenesis, one of the main functions of the testis, involves multiple germ cell
division. The possibility of the involvement of growth factors in the uncontrolled
division of such germ cells (which is characteristic of some germ cell tumours) must
therefore be considered. As yet very little work has been performed to evaluate the
contribution of growth factors to the proliferation and differentiation of testicular
cancer. However numerous papers have been published on the involvement of certain
growth factors and their receptors in other types of cancer such as breast (Osborne et
al, 1980; Imai et al, 1982; Fitzpatrick et al, 1984a; Sainsbury et al, 1985a; Harris
et al, 1987), lung (Berger et al, 1987a), prostate (Maddy et al, 1989) and bladder
(Neal et al, 1985; Berger et al, 1987b; Harris et al, 1987). It was therefore with
similar objectives in mind that this study was undertaken to investigate the possible
role of epidermal growth factor (EGF) and its receptor in the normal functioning of
the testis and in the proliferation and differentiation of testicular cancer.
It has already been postulated, and to some extent established, that
certain growth factors do play a role in testicular function (Ritzen, 1983; Tres et al,
1986; Radford et al, 1987; Skinner and Moses, 1989, Skinner et al, 1989a; Skinner,
1990; Bartlett et al, 1990). EGF is thought to be specifically involved in
spermatogenesis (Bartlett et al, 1990), the process which describes differentiation of
germ cells to spermatozoa (described in section 1.4.7). Similarly EGF has also
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recently been shown by Teerds et al (1990) to be involved in differentiation of
germinal cells during which transforming growth factor-a (TGF-a) was found to be
secreted.
Stem germ cells as well as differentiating to become spermatozoa also
proliferate to maintain renewal of germ cells. The process of cell proliferation
involves the development of all cell components leading eventually to division of the
cell into two new cells. Four phases are usually recognised: Gl- S- G2- M; G1 is a
gap or pause after stimulation where the cell appears relatively inactive although there
is some biochemical activity; S is the phase of synthesis, particularly of
deoxyribonucleic acid (DNA), to double the normal amount, although other
components also increase; G2 is a second gap period; and M is the stage of mitosis in
which the nucleus breaks down and chromosomes separate into two individual
groups, the nuclear membranes then reform about each group, and the whole cell
divides into two identical cells. Cells may also move out of the division cycle into a
resting phase known as GO.
In cancer the control of cell proliferation is deranged. Comparative studies of
growth of both normal and cancerous cells have helped to identify significant
regulatory events which are required for cell division. Such studies have also enabled
scientists to identify growth factors, hormones, nutrients e t c.. which the cells
require for growth either in the normal or cancerous state, or both. It is to be hoped
that an increased understanding of the mechanisms responsible for and the factors
involved in the control of normal proliferation and differentiation of cells will aid in
the treatment and cure of cancer. At the moment particular attention has been focused
on the role of growth factor involvement in both abnormal and normal growth control
(Deuel, 1987; Tauber and Tauber 1987; Waterfield, 1989), whereas previously
particular attention had been paid to hormone involvement in cancer (Leake et al,
1979; 1981). It now appears that both hormones and growth factors are of importance
2
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in the growth of certain types of cancer (Fitzpatrick et al, 1984b; Sainsbury et al,
1985b; 1985c; Goustinefa/, 1986; Lippman et al, 1986; 1987; Boluffer etal,
1990). As spermatogenesis is dependent on testosterone (Sharpe et al, 1988a) and
EGF is also linked to germ cell development (Bartlett et al, 1990) both the
concentration of androgens and EGF within normal and cancerous testicular tissue
may be of relevance in the understanding of testicular function.
Other findings regarding the involvement of EGF and its receptor in
cancer have been reported. In 1984 Downward reported having discovered an
oncogene (the name given to delineate a gene capable of causing cancer) which
showed a resemblance to the gene for the EGF receptor. Since then numerous studies
have been performed with the aim of evaluating the possible role of EGF and its
receptor in various types of cancer. Transforming growth factor-a has also been
shown to activate the EGF receptor (Massague, 1983; Pike etal, 1983; Derynck,
1986) and therefore its presence in various types of cancer which express EGF
receptors should also be evaluated. As mentioned previously the identification of
TGF-a in germ cell division by Treeds et al (1990) must also raise the question of
TGF-a involvement in the development of germ cell tumours.
1.2 The Testes
1.2.1 The Function of the Testes.
There are two main functions performed by the testis. Firstly it is the site of gamete
production in the male. Each day millions of gametes are produced by the testes and
stored in the epididymis until ejaculation takes place. Each gamete is produced for the
sole function of fertilising an oocyte, subsequendy leading to the propagation of
human life (reproduction).
Secondly the testes is the principle organ producing testosterone and
other androgens which are required for anabolism and the development ofmale
3
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sexual characteristics. Such characteristics include development of the reproductive
tract and the genital organs as well as secondary sexual characteristics such as hair
and bone growth, haemoglobin production, nitrogen balance, libido and erectile
potency, muscle development, vocal register and psyche.
1.2.2 Hypothalamic Control of the Testes via the Pituitary Gland.
Testicular function is controlled by the hypothalamus via gonadotropin releasing
hormone (GnRH) which in turn stimulates the anterior pituitary to release the
luteinising hormone (LH) and follicle stimulating hormone (FSH). GnRH is a
decapeptide which is released from axons of hypothalamic neurones in pulses (Steinberger
and Steinberger, 1972). GnRH stimulates the production of LH and FSH which are
glycoproteins of molecular weights 38,000 and 29,000 respectively, and consist of
two dissimilar sub-units a and (3 (Steinberger and Steinberger, 1972). The a subunit
is common to both FSH and LH, while the (3 subunit specifies the biological activity
of the hormone (Pierce and Parsins, 1981). Both of these gonadotrophins have the
testis as their target organ, but their functions differ in that FSH acts almost
exclusively on the tubules to control the process of spermatogenesis, whereas LH acts
on the Leydig cells to stimulate androgen biosynthesis (Means et al, 1976; Ewing
and Brown, 1977). Negative feedback loops exist for the regulation of both hormones
(Figure 1). Inhibin is a peptide hormone synthesized by the Sertoli cells which is
thought to feed back to the anterior pituitary to regulate FSH production. Evidence
however, is now available to suggest that this concept of inhibin as a testicular
negative feedback regulator, is overly simplified (Sharpe et al, 1988b). LH secretion
in contrast is controlled by the feed-back action of testosterone on both the
hypothalamus and pituitary (Naess et al, 1977). Both FSH and LH are required for
4
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GnRH - Gonadotrophin Releasing Hormone
FSH - Follicle Stimulating Hormone
LH - Luteinising Hormone
Figure 1
Hypothalamic control of the testis is via GnRH which
stimulates the anterior pituitary to secrete LH and FSH. LH and
FSH act on the testis; LH to stimulate steroidogenesis and FSH
to stimulate spermatogenesis. Feedback from the testis to the
hypothalamus and the anterior pituitary occurs via the secretion
of inhibin and testosterone into the systemic circulation.
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the successful initiation and maintenance of spermatogenesis.
The FSH receptor is located on the basal membrane of the Sertoli cell.
FSH binds to the receptor to activate a membrane bound adenylate cyclase system
which then rapidly activates protein kinase (Davies, 1981). FSH has subsequently
been shown to have multiple effects on Sertoli cell function. For example FSH has
been shown to stimulate the production of androgen binding protein (ABP) in the rat
testes (Bardin et al, 1981, Ritzen et al, 1982) as well as stimulating lactate,
pyruvate (Jutte etal, 1982) and transferrin (Skinner and Griswold, 1982)
production.
LH is synthesized in the anterior pituitary gland and acts upon the
Leydig cell. It is the primary regulator of testosterone secretion and acts by
stimulating testosterone synthesis and secretion through specific LH receptors located
on the surface of Leydig cells. It is therefore evident that testosterone secretion is
also regulated by the number of LH receptors available for LH to activate (for review
see Sharpe, 1982). It has been shown that LH (or hCG another peptide hormone
which acts on the LH receptor) negatively controls the number of LH receptors
expressed by the Leydig cells (Sharpe, 1984a).
Prolactin is also involved in the normal endocrine regulation of the
testis although its role is still poorly understood. Its target cell in the testis is the
Leydig cell where it regulates the number of LH receptors. Induction of
hyperprolactinaemia in the rat has been shown to produce an increase in the number
of LH receptors expressed with a concomitant decrease in circulating LH, producing
overall no change in testosterone secretion (for review see Sharpe, 1982). However in
the human hyperprolactinaemia is associated with impotence and infertility. It appears




1.3 The Gross Anatomy of the Testes.
The mammalian testes are bilateral organs which are suspended in the scrotal sac, the
scrotal sac being situated at the base of the penis (Figure 2). The parenchymal tissue
of the testis is enclosed by the tunica albuginea and can be conveniently divided into
two functional compartments, the seminiferous tubules and the vascularized
interstitium (see section 1.4 ). Spermatogenesis, the process of gamete formation,
takes place within the seminiferous tubules. The tubules are long convoluted
structures connected at both ends to the rete testis. The rete testis merges into the
efferent ducts near the cranial pole of the testis. The efferent ducts then connect with
the epididymides which in turn connect with the ductus deferens which finally merge
with the urethra (Figure 3). At the point at which the ductus deferens merge with the
urethra an ampulla is formed in which secretions from the prostate gland and the
seminal vesicles have been identified and are believed to be stored. As shall become
evident later (section 1.4.7) such secretory products along with those from the
epididymis are necessary for the maturation and motility of normal sperm (Cooper,
1986).
In the young adult human the testes have been found to weigh between
10 and 16 g each. In this study it was found that the testes obtained from men aged
55-78 weighed between 4 g and 10 g each. Harman and Tsitouras (1980) and
Tsitouras (1987) reported having found a decrease in testicular mass with advancing
age, whereas in other studies performed by Johnson et al (1986) and Neaves et al
(1984) in which the data from men with concomitant chronic illness were excluded, it
was concluded that no relationship was apparent between decrease in testicular mass
and increasing age. Although there is no general consensus in the relationship
between advancing age and testicular mass, it does appear that in this study the
weights of the testis collected were in the lower normal range.
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Figure 3 Cross section of the human male genitalia.
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1.3.1 The Supporting Structures and the Vascular Supply to the Testes.
As described in section 1.3 the parenchymal tissue of the human testes is enclosed by
the tunica albuginea. The scrotal covering layers external to the albuginea are the
skin, dartos muscle and Colles' fascia, external spermatic fascia, and the parietal layer
of the tunica vaginalis (Figure 4). A small fluid filled space exists between the
parietal tunica vaginalis and the visceral tunica vaginalis which is adjacent to the
tunica albuginea. The parenchymal tissue consists of the tunica albuginea which in
turn merges with the tunica vascularis and the numerous fibrous septa that divide the
testis into the two compartments ie. the avascular seminiferous tubules and the
vascular interstitium (Figure 4). A posterior thickened portion of the capsule (the
mediastinum) contains the blood vessels, lymph vessels and the intratesticular portion
of the rete testis from which 15-20 efferent ductules connect with the epididymis. The
blood supply to the testis is through the internal spermatic arteries. These arise from
the abdominal aorta on the right and the renal artery on the left. There is also a
secondary blood supply via the vas deferens artery. The blood supply is in indirect
contact with the seminiferous tubules through a capillary plexus. A number of
veins/venules emerge from the testis and together with the venous branches from the
epididymis unite to form the plexus pampiniformis, which ascends along the
spermatic cord. The vascular supply to the testes plays an important role in regulating
of the temperature of the testes as a counter current exchange mechanism of heat
between in-coming arterial blood and the out-going venous blood is apparent. It is
thought that the testis only function properly at a temperature which is 2-3°C lower
than body temperature as increased temperature, has been shown to produce
disruption of spermatogenesis (Moore, 1974 ). Hence the cooling process of the testes












Figure 4 Cross section of the scrotal sac and testicular capsule.
Compartmentation of the parenchymal tissue of the human testes into the
vascular interstitium and die avascular seminiferous tubules is also
illustrated.
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1.4 The Intrinsic Anatomy of the Testes.
The parenchymal tissue of the testis which in this study is referred to as the "testicular
tissue" is comprised of various different cells and structures. As discussed previously
it is divided into two compartments; the avascular seminiferous tubules and the
vascular interstitium (for review see Sharpe, 1982).
The seminiferous tubules are long convoluted cylindrical structures
which contain Sertoli cells and several generations of differentiating germ cells which
together comprise the seminiferous epithelium. Within the seminiferous tubules is a
fluid filled lumen. The tubules are separated from the interstitium by multiple layers
of peritubular cells.
1.4.1 The Interstitium
The interstitium of the testis is the area surrounding the seminiferous tubules. It
contains Leydig cells, macrophages, fibroblasts, capillaries and lymphatic vessels
amongst sparse loose connective tissue with interstitial fluid (Christensen, 1975;
Setchell and Sharpe, 1981). In close contact with the interstitium are the peritubular
cells which surround the seminiferous tubule (Figure 5 ). The cells appear as spindle
shaped and form multiple layers around the outer edge of the basement membrane of
the seminiferous tubules. The peritubular cells shall therefore be classified as part of
the interstitium since they are exterior to the basement membrane .
1.4.2 Leydig Cells
Leydig cells differentiate from the mesenchymal elements of the testicular stroma.
After 15 weeks of gestation, abundant well defined Leydig cells are clearly evident in
the foetal testis and fill the interstitium. In this early stage of foetal growth the Leydig
cells increase rapidly in number and display marked metabolic activity with the















Figure 5 Cross section of the cellular composition of the
spermatogenic cycle in the seminiferous tubules in man.
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cell is the most widely investigated cell of the interstitium because of the major role
which it plays via the production of testosterone. Studies have shown that of the
intracellular organelles of the Leydig cell, the smooth endoplasmic reticulum, is the
site of many of the enzymes required for steroidogenesis (Mori and Christensen,
1980). The cells themselves have a large distinguishable spherical nucleus and often
occur in clusters. According to Neaves et al (1984) the Leydig cell population
declines by approximately 44% in older individuals, although this is in conflict with
the work of Kothari and Gupta (1974) and Deslypere and Vermeulen (1984) who
reported an increase in Leydig cell number in men of 55-65 years of age when
compared to a similar population of younger men. As yet no consensus regarding the
relationship between the change in Leydig cell number and advancing age has been
reached. In relation to this study however the possibility of a change in testicular
structure with age must be considered. It may be for instance that certain factors are
present at different concentrations in younger testicular tissue than in older testicular
tissue.
As discussed earlier the Leydig cell is the main site of steroidogenesis
(Purvis et al, 1981). Testicular steroidogenesis is stimulated by LH which is released
from the pituitary gland, which in turn acts upon the LH receptor located on the
surface of the Leydig cell (Hall, 1970; Catt and Dufau, 1973) (for review see Tahka,
1986)). The stimulation of steroidogenesis by LH is therefore dependent on the
number of LH receptors expressed by the Leydig cell (see review by Sharpe, 1982).
There is evidence to suggest that LH negatively regulates the number of its own
receptors expressed by the Leydig cell (Sharpe, 1984a). Binding of LH to its receptor
is followed by an increase in cAMP and the secretion of testosterone (Hansson et al,
1975; 1986).
Numerous other agonists have also been found to interact with the
Leydig cell. These include IGF-I (Bernier et al, 1986; Lin et al, 1986; DeMellow et
9
INTRODUCTION
al, 1987), LHRH-like peptide (Sharpe etal, 1981; Sharpe 1984a; 1984b), arginine
vasopressin (Sharpe and Cooper, 1987) EGF (Welsh and Hsueh, 1982; Lloyd and
Ascoli, 1983; Ascoli et al, 1987; Verhoeven and Cailleau, 1986) and TGF-(3 (Lin et
al, 1987; Benahmed etal, 1988). Of these growth factors LHRH-like peptide
(Sharpe et al, 1981) and IGF-I (Hall etal, 1983) are produced by the Sertoli cell.
Leydig cells also produce a number of other factors besides androgens.
Opiates (P-endorphin in particular) are known to be produced by the rat Leydig cell
and are thought to act on the Sertoli cell (Fabri et al, 1988). It has been illustrated by
Fabri et al (1988) that hCG and testosterone may increase the synthesis and release
of P-endorphin from rat Leydig cells. Oxytocin is also produced by the Leydig cells
in both the rat and the human. It is known to act on the peritubular myoid cells that
surround the seminiferous tubules to bring about their contraction and thus is thought
to aid in the transport of shed spermatids to the rete testis (Wathes, 1984).
Vasopressin or vasopressin-like peptide is also present in the testis and in cultures of
mixed testicular cells and has been shown to produce inhibition of Leydig cell
testosterone secretion (Sharpe and Cooper, 1987).
1.4.3 Peritubular Cells
The peritubular cells are arranged in layers around the seminiferous tubules and
gradually increase in number with age. They differentiate from the mesenchymal
elements of the testicular stroma as do the Leydig cells (see section 1.4.2). Although
currently relatively little is known about the function of the peritubular cells it is
apparent that they too play a fundamental role in testicular function. The peritubular
cells are also known to secrete a factor called P-Mod-S while under the control of
androgens and this is known to modify Sertoli cell function (Skinner and Fritz, 1985;
1986; Verhoeven and Cailleau, 1988a; 1988b). The P-Mod-S factor has been shown
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to stimulate transferrin, ABP and cAMP production by rat Sertoli cells in vitro to the
same extent as did maximal hormonal stimulation. P-Mod-S was then further
characterised by Skinner et al (1988) who identified two forms of different apparent
molecular weight of 54 - 56 kDa and 59 kDa respectively. The physiological
significance of P-Mod-S as a possible paracrine regulator has yet to be elucidated and
shall be discussed later in paracrine regulation of testicular function (section 1.6).
1.4.4 Organization within the Seminiferous Tubules.
The human seminiferous tubules are comprised ofmultiple cell types of which the
Sertoli cells are ofmajor importance (Setchell, 1978). Sertoli cells are columnar in
shape with extensive cytoplasm extending from the basement membrane to the lumen
of the seminiferous tubule between developing germ cells (Figure 5). The nuclei of
the Sertoli cells are located toward the basal aspect of the tubule adjacent to the nuclei
of spermatogonia. The spermatogonia differentiate to become gametes by the process
termed spermatogenesis. (This will be discussed in more detail in section 1.4.7). In
any one section of the human seminiferous tubule the seminiferous epithelium
consists of four or five distinct generations of germ cells at different stages of the
spermatogenic cycle (Clermont, 1963). It has been shown using cytological
examinations that at any point in the seminiferous tubule the specific cells formed
during the developmental stages of spermatogenesis are not randomly arranged but
form cellular associations which are repeated (Schulze and Rehder, 1984). The
activities of the several generations of germ cells are cyclical, the duration of which
cycle and the number of stages involved vary in different species (Clermont, 1972). In
man each cycle occupies about sixteen days (Heller and Clermont, 1964) and
comprises six different cell associations or stages (Clermont, 1963) ^Figure 5 V
In the rat, the cycle comprises fourteen different stages lasting approximately
twelve days (Le Blond and Clermont, 1952).
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Despite the stages of spermatogenesis being different in the human in
comparison to the rat there is evidence to suggest that some hormonal requirements
for spermatogenesis in the human are similar to those in the rat (Sharpe, 1986).
However while the rat testes is a well established model for investigating testicular
function, human testicular tissue should be employed wherever possible as animal
models do not always represent accurately the human situation.
1.4.5 The BIood-Testis Barrier.
Evidence for a blood-testis barrier first came from the realization that seminiferous
tubule fluid and rete testis fluid were very different in composition from blood plasma
and testicular interstitial fluid (Setchell, 1969). The blood-testis barrier exists
between adjacent Sertoli cells in the seminiferous tubules (Setchell, 1980). It
plays an important part both in the maintenance of the intratesticular environment and
in controlling the entry of peripheral hormones and the exit of endogenous hormones.
The barrier is impermeable to many large molecules, and at the level of the basement
membrane it functionally separates the tubules from the interstitium. The main
function of the barrier, however, is thought to be to maintain a specific ionic and
hormonal environment which enables the complex process of spermatogenesis to be
supported (Waites and Gladwell, 1982).
The cell-cell barrier is made up of tight junctions (Bawa, 1963; Ross,
which
1976) between adjacent Sertoli cellsjseparate the Sertoli cells from the differentiating
spermatogonia, dividing the tubule into basal and adluminal compartments. The
former compartment consists of the spermatogonia and the preleptotene
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spermatocytes; the latter containing the remaining primary spermatocytes, secondary
spermatocytes and spermatids. A third and transient chamber is formed by adjacent
Sertoli cells as germ cells move from the basal compartment to the adluminal
compartment. (Bellve, 1979; McGinley etal, 1979). The tight junction complex
then forms once again behind the germ cells and between the adjacent Sertoli cells,
sealing off the intracellular space and thus ensuring the integrity of the blood-testis
barrier (Fawcett, 1975; Russell, 1978). Substances required by the maturing germ
cells must therefore pass through the Sertoli cell cytoplasm before entering the
luminal compartment. Intracellular junction-like structures have also been described
between Sertoli cells and germ cells ( McGinley et al, 1979; Russell, 1980 ). Their
function is as yet unknown but it is presumed that information is transmitted from the
Sertoli cell to the germ cell, thereby regulating spermatogenesis. Factors produced by
the seminiferous tubules in turn are transmitted to the interstitium via or from the
Sertoli cell cytoplasm. Certain factors produced by the Sertoli cells have been shown
to regulate Leydig cell function (example LHRH-like agonist) (Sharpe et al, 1981).
This factor although distinct from LHRH acts upon specific receptors present on the
Leydig cell via which it has been found to exert both an inhibitory and stimulatory
effect on Leydig cell steroidogenesis (Sharpe, 1986). Similarly certain factors
secreted by the seminiferous tubules have also been shown to effect Leydig cell
function and vice versa (Bergh, 1982; Bergh, 1983; Sharpe et al, 1988c; Vihko and
Huhtaniemi, 1989).
1.4,6 Sertoli Cells
As discussed in the previous section the Sertoli cells form part of the blood-testis
barrier and thus provide a means through which messages from the interstitium can be
passed to the differentiating germ cells (Ritzen, 1983). However evidence is now
available which suggests that certain factors produced by the Sertoli cells are in fact
13
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secreted in a bidirectional manner (Sharpe, 1988). That is to say that secretions occur
via the apical and basal aspects of the Sertoli cells into the seminiferous tubule fluid
and interstitial fluid. Such factors include inhibin (Maddocks and Sharpe, 1989) and
testibumin (Cheng and Bardin, 1986).
Sertoli cells secrete a whole range of factors which include various
growth factors, endocrine hormones, enzymes and matrix components as well as
certain materials whose functions are as yet unidentified (for review see Grootegoed,
1987 and Ritzen et al, 1989). Some of the substances with particular reference to this
project include seminiferous growth factors (Feig et al, 1980; 1983; Bellve and Feig,
1984; Brown et al, 1982; Holmes etal, 1984; 1986; Lamb etal, 1987), insulin like
growth factor -I (or somatomedin- C, Hall et al, 1983; Benhamed et al, 1987),
TGF-(3 (Benhamed et al, 1988), inhibin (de Jong and Robertson, 1985), ABP (Hsu
and Troen, 1978; Lee et al, 1980) and transferrin (Holmes et al, 1984).Furthermore
factors produced by the peritubular myoid cells and germ cells may also act on the
Sertoli cell.
With respect to testosterone action on the Sertoli cell the picture is still
very unclear. Little is known about the effect of testosterone on the expression of
specific genes in Sertoli cells although the Sertoli cell is known to contain receptors
for testosterone (Sharpe, 1982; 1983; 1986). It has been suggested that the action of
testosterone on the rat Sertoli cells involves the androgen-dependent production of
regulatory proteins by the peritubular myoid cells (P-Mod-S) (Skinner and Fritz,
1985). There is still no general consensus about the intratesticular level of
testosterone that is required to maintain spermatogenesis, although there is general
agreement that testosterone maintains spermatogenesis in co-operation with other
regulatory factors (Huang and Nieschlag, 1986; Sharpe etal, 1988a). Several authors
have indicated that there is remarkable specificity with respect to the action of
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hormones on Sertoli cells and hence on germ cells at different stages of the cycle of
the seminiferous epithelium (Russell and Clermont, 1977; Parvinen, 1982; Rommerts
et al, 1982)
A Sertoli cell mitogen referred to as the seminiferous growth factor
(SGF) has also been identified in both human and rat testes and is thought to play a
role in the paracrine regulation of germ cell mitosis (Bellve and Feig, 1984). However
as yet little is known of the mechanisms of SGF secretion and particularly whether it
is produced at only specific stages of spermatogenesis.
Characterization of a growth factor secreted by rat Sertoli cells in
culture was also reported by Holmes et al, (1986). He found that conditioned
medium from rat Sertoli cells had the ability to displace gQp binding to its
receptor. The amount of EGF competing activity was also positively correlated with
mitogenic activity. Feig and Bellve (1980) have also characterised a Sertoli cell
growth factor which is thought to possibly act in an autocrine manner upon the Sertoli
cell itself.
Grinsted and Byskov (1981) have also reported having identified a
meiosis stimulating and a separate meiosis-inhibiting factor which are produced by
the Sertoli cells at certain stages of the spermatogenic cycle. This was confirmed by
Parvinen (1982) and Parvinen etal (1986).
IGF-I has also been found to be secreted by immature rat Sertoli cells
in culture and is thought to act in a paracrine manner. It has also been found that the
Leydig cells of rat testis express IGF-I receptors (Handelsman et al, 1985) and that
both IGF-I and IGF-II can stimulate gonadotropin-induced steroidogenesis in vitro
(Bernier et al, 1986; DeMellow et al, 1987; Kasson and Hsueh, 1987). Similar
results have also been reported using porcine interstitial cell cultures (Benhamed et
al, 1987; Perrard-Sapori et al, 1987). Hence these growth factors may be involved in
the paracrine regulation of Leydig and Sertoli cell functions.
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TGF-P secretion by Sertoli cells and testicular somatic cells was first
1 ike
discovered by the identification of TGF-f) activity in the conditioned medium from
these cells and by the presence of TGF-P mRNA in rat Sertoli cells (Sporn etal,
1986). TGF-p has also been found to have a significant degree of homology with
inhibin. With reference to other cells in the testes TGF-P has also been found to
inhibit steroidogenesis by the Leydig cell (Lin et al, 1987).
The glycoprotein hormone inhibin, which is part of the negative
feedback mechanism identified in regulating the hormone FSH and is secreted by the
Sertoli cell, is present in two forms. Inhibins A and B exist, consisting of a common
alpha-subunit and a similar but distinguishable beta-subunit, both of which act to
suppress the secretion and cell content of FSH (see review by Ying, 1989). However
the possibility of dual regulation of the pituitary by inhibin has been raised by the
observation that the heterodimer (formed by the combination of the a and P subunits
of inhibin) inhibits FSH production by the pituitary whereas the homodimer (formed
from the combination of the P subunits of inhibin /.e.activin) stimulates FSH
production. Activin was indeed found to inhibit Leydig cell steroidogenesis as did
TGF-P in vitro, whereas inhibin produced a dose dependent stimulation (Hsueh et
al, 1987). Inhibin may also regulate germ cell division according to the work
reported by Hsueh et al, (1987).
Testicular interstitial fluid (IF) has also been shown to be a potent
stimulant of steroidogenesis but as yet the active material in IF has not been
identified, purified or fully characterised (Sharpe and Cooper, 1984; Sharpe et al,
1986).
In contrast oestradiol has been shown to have an inhibitory effect on
Leydig cell steroidogenesis and is produced by the Sertoli cells of the immature rat
testis. However in the adult rat oestradiol has been shown to be produced by the




An LHRH-like factor has also been identified within the rat testis, and
is thought to be secreted by the Sertoli cells and has been found to exclusively act on
the Leydig cells as these are the only cell type within the testes known to possess
LHRH-like receptors (Sharpe 1984a; 1984b; Rommerts and Themmen, 1986). It
appears that the LHRH-like substance is distinct from that known to be secreted by
the hypothalamus but as yet attempts to purify it have failed (see review by Sharpe,
1986). However using LHRH agonists it has been found that in the short term (24
hours) LHRH agonists stimulate Leydig cell testosterone secretion in vivo where as
in the longer term (greater than 3 days) an inhibitory effect on testosterone secretion
is apparent which if treatment is continued can lead to severe atrophy of the testis (see
review by Sharpe, 1986).
As with the Leydig cells, Sertoli cell function and number are also
thought to be influenced by age. According to studies by Rowley and Heller (1971)
the Sertoli cell population remains stable throughout the postpubertal years. However
Johnson et al (1984; 1986) found that men aged 20-48 had significantly more Sertoli
cells than did men aged 50-85 years. Furthermore these authors also suggested that
the decline in spermatozoa production identified in the elderly may have been caused
by the decrease in Sertoli cell number as a relatively constant relationship between
Sertoli and germ cells was reported in studies upon the rat (Johnson et al, 1984;
1986). As well as a decrease in Sertoli cell number with advanced age, a decrease in
sperm production and in the number of spermatid-containing tubules was also noted,
from 90% in the third decade to 50% in the 5-7 th decades. As suggested earlier this
may indicate that Sertoli secreted products are present at different concentrations in
the older human testis in comparison to the younger human testis. As yet however no
general consensus between Sertoli cell number and age has been reached.
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1.4.7 Germ Cells and Spermatogenesis
For normal spermatogenesis to take place the environment in which it occurs must
have a functional endocrine system. The central nervous system influences the
hypothalamic secretion of GnRH which in turn stimulates the secretion of LH and
FSH from the pituitary, the two major hormones which act on the testis. The
hypothalamic control of spermatogenesis in mammalian testis appears to be via
hormonal action on gonadal somatic cells without direct actions on germ cells. For
instance in the rat and the human, LH acts directly on Leydig cells and FSH on Sertoli
cells. Similarly although testosterone produced by Leydig cells is essential for
spermatogenesis and fertility it does not directly act on germ cells but on the
peritubular and Sertoli cells. The exact mechanism by which the hormonally regulated
gonadal somatic cells influence spermatogenesis remains to be elucidated but it is
likely that multiple interactions between somatic cells are required to create an
environment for the propagation of spermatogenesis.
As mentioned previously in section 1.4 the type A spermatogonia are
the stem cells from which all germ cells are derived, the spermatogonia themselves
being descended from the primordial germ cells which reach and multiply in the
genital cords in the developing testis. In the fully differentiated testis the
spermatogonia are situated along the basement membrane of the seminiferous tubule.
In man, three basic types of spermatogonia can be distinguished; dark type A, pale
type A and type B (Clermont, 1963). Dark type A spermatogonia divide to maintain
the basic store of spermatogonia and also give rise to some pale type A cells which
divide and differentiate into type B spermatogonia. Type B spermatogonia divide to
produce the primary spermatocytes. The spermatocytes then proceed through a long
prophase which shows characteristic configurations of the chromosomes (leptotene,
zygotene, pachytene). This prophase is then followed by the subsequent steps of the
first reduction division that yields the secondary spermatocytes containing diploid
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number of chromosomes. Each secondary spermatocyte then undergoes the second
reduction division to produce two haploid round spermatids. These spermatids then
go through a series of nuclear and cytoplasmic modifications to produce spermatozoa
(Figure 6). The spermatozoa then pass via the rete testis to the epididymis where they
mature and gain motility (Cooper, 1986).
1.5 Steroids and Steroidogenesis
LH is the major hormone secreted by the anterior pituitary to regulate Leydig cell
steroidogenesis. The original precursor for the production of steroids is cholesterol
(for review see Rommerts and van der Molen, 1989). Cholesterol is converted to
and microsomes
pregnenolone (the parent compound for androgen biosynthesis) in the mitochondriajof
the Leydig cell by two hydroxylases and a lyase enzyme. There are two pathways
through which androgen biosynthesis can be achieved from the parent compound.
One of these involves 5a-ene-3P-hydroxysteroid metabolites such as
17a-hydroxypregnenolone the other 4a-ene-3P-oxosteroid metabolites such as
progesterone (Figure 7). The final conversion in either pathway is to the potent
androgen testosterone. However it is now known that in some tissues
5a-dihydrotestosterone (5a-DHT) is the active form of testosterone which binds to
the nuclear receptor in the androgen dependent cell to achieve the physiological and
biochemical reactions. One example of an organ which contains such cells is the skin.
5a-DHT is then metabolised in the cells cytoplasm to 5oc-androstane-3a,17p-diols
and 5a-androstane-3p,17P-diols. However, whether 5a-DHT is the active reagent in
the testis is as yet unknown. Androstenedione is also produced during the
biosynthesis of testosterone but is a less potent androgen than testosterone. The
steroids then leave the testis via the blood supply to be circulated around the body. In
a normal male of age 18-31 years the average concentration for testosterone in plasma
is in the range 10-31 nmol/1.
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Figure 6 Diagramatic illustration of the cellular composition of six stages (I-VI)
of the cycle of the seminiferous epithelium in man. The stages
correspond to cell associations which succeed one another in time in any
given area of the seminiferous tubule according to the sequence I-VL
after which the sequence starts again.
Ad, Ap, B - dark type A, pale type A, type B spermatogonia; PI, L, Z, P
preleptotene, leptotene, zygotene, pachytene primary spermatocytes; II -
secondary spermatocytes; S - spermatids; SZ - spermatozoa.
From: Y. Clermont (1970), In: The Human Testis. Eds. E. Rosemberg
and C.A. Paulsen, Plenum Press.
Figure 7
The biosynthesis of testosterone from pregnenolone in the mammalian
testis can occur via several routes. The testicular rate of conversion of
pregnenolone through theA4-pathway (involving progesterone,
17a-hydroxy-progesterone and 4-androstene-3,17 dione) and
A5-pathway (involving pregnenolone, 17a-hydroxy-pregnenolone,
dehydroepiandrosterone and 5-androstene-3p, 17p-diol) is different in
different animal species. In the human testis the 5-pathway is the most
significant.
Key
1 = cholesterol side-chain cleavage complex
2 = 3J3-hydroxysteroid dehydrogenase
3 = 17a-hydroxylase
4 = steroid C17-20"lyase
5 = 17P-hydroxysteroid dehydrogenase
6 = 20a-hydroxysteroid dehydrogenase

























Although the production of testosterone by the body is well
understood the influence which it has on the testes themselves is somewhat complex
and less well understood. Testosterone is a hormone native to the testis and one on
which spermatogenesis completely depends; in its absence spermatogenesis can not
be maintained (Sharpe etal, 1988a). It has been shown that testosterone can
stimulate the Sertoli cells to secrete ABP and seminiferous tubule fluid, but neither of
these are believed to be involved in the actual process of spermatogenesis (Sharpe,
1983; 1986). Skinner and Fritz (1986) have also reported that testosterone acts on the
peritubular myoid cells to stimulate the production of macromolecules which then act
on the Sertoli cells to modulate ABP and transferrin secretion. It has since been
established that some of the actions of testosterone on the testis may be mediated by
the peritubular cells. The effect of testosterone on the Leydig cell (the cell from which
testosterone is secreted) is unclear, although numerous other factors have been
reported to effect steroidogenesis and subsequently spermatogenesis. Verhoeven and
Cailleau (1985) demonstrated that spent media derived from Sertoli cell-enriched
cultures contains a protein that stimulates androgen production in adult and immature
rat Leydig cells. Transforming growth factor-(3 like activity is also present in Sertoli
cell-conditioned media and has been found to inhibit steroidogenesis
(Benhamed et al, 1988). Inhibin whose (3-subunit gene displays homology with
TGF-(3 and mullerian duct inhibiting substance is secreted by the Sertoli cell
(Steinberger and Steinberger, 1976a; 1976b ) and has been shown to inhibit the LH
stimulated androgen production by cultured testicular cells (Hsueh et al, 1987).
Fibroblast growth factor has been shown to inhibit 5a-reductase activity in cultured
immature rat Leydig cells thus inhibiting the conversion of testosterone to 5a-DHT .
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1.6 Paracrine Regulation of the Testis
As previously mentioned the two main testicular functions, androgen secretion and
spermatogenesis are predominantly controlled by the pituitary hormones, FSH and
LH. However, increasing evidence indicates that subtle regulation of testicular
function can be locally modulated. Thus pituitary hormones provide the basic stimuli
but the time and the intensity of the response itself appears to be modulated by
complex interactions between the cells within the testis. Such interactions are
mediated by the release of soluble factors and occur between various cell types
within the testis including Sertoli cells, germ cells, peritubular cells, Leydig cells and
vascular endothelial cells.
1.6.1 Interactions Between Sertoli and Germ Cells.
Under physiological conditions the initiation and maintenance of spermatogenesis is
under the control of FSH and testosterone. Because androgen receptors are present in
Sertoli cells (Tindall et al, 1977) but have not been identified in germ cells
(Grootegoed et al, 1977) it has been proposed that the effect of testosterone on
spermatogenesis is mediated by Sertoli cells (Saez et al, 1985). The functional
activity of Sertoli cells is also modulated by the stage which the germ cells are at in
their spermatogenic cycle. For example towards the end of the spermatogenic cycle
Sertoli cells have the highest secretion rates of androgen binding proteins (Ritzen et
al, 1982) and minimal binding of 1^1 p$p[ (Parvinen, 1982). These multiple and
bidirectional interactions which exist between Sertoli and germ cells can be mediated
either by direct cell to cell contact which is very developed between these cells
(Russell, 1980; Russell and Peterson, 1985) and/or through diffusible paracrine
factors. Nerve growth factor (NGF) acts upon the
Sertoli cell and has been found to be synthesized in germ cells by Persson et al
(1990). NGF receptor mRNA has been identified in Sertoli cells and the receptor is
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modulated by androgens. Hence it has been suggested that NGF produced by the male
germ cell could regulate testicular function via an interaction between germ cells and
Sertoli cells (Persson et al, 1990).
Although there has been no specific characterization of factors
produced by the Sertoli cells which act on the germ cells and vice versa^there is
evidence supporting the existence of communication between the two groups of cells.
As detailed above NGF is produced by the germ cells and acts on the Sertoli cells.
It has been further demonstrated both in vivo and in vitro that when germ cells are
destroyed there is a concomitant decrease in Sertoli cell specific functions (Jegou et
al, 1984; Fritz and Tung, 1987). Variations in Sertoli cell secretions have also been
identified on the addition of certain stages of differentiating germ cells to Sertoli cell
monocultures. For example in rat Sertoli cell monocultures FSH stimulates ABP
production by Sertoli cells, which is enhanced in the presence of pachytene
spermatocytes (Le Magueresse et al, 1986) but not by co-culture with round
spermatids (Galdieri et al, 1984). A Sertoli cell secreted growth factor has also been
characterised by Holmes et al, (1986) which is thought to be secreted by Sertoli cells
and thought to have an effect on germ cells.
1.6.2 Interactions Between Sertoli and Leydig Cells
These two cell types are located in two different compartments of the testes, without
direct cell to cell contact and therefore all interactions between Leydig and Sertoli
cells must be mediated by diffusible factors.
Papadopoulos et al (1986; 1987) reported that a Sertoli secreted factor
or factors were shown to modulate Leydig cell function in the rat. Saez et al (1987)
also describes in detail possible interactions between Sertoli and Leydig cells by
looking at the experimental models used and the results which were obtained. For
example a co-culture of Leydig and Sertoli cells was established and from this it was
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found that the stimulatory effect of Sertoli cells on Leydig cell function depended on
the Sertoli/Leydig cell ratio in the coculture (Benhamed et al, 1985). A body of
evidence now points to a growth factor secreted by Sertoli cells although it is not yet
clear on which cell or cells this growth factor acts.
Several investigators have described the presence of a factor from
Sertoli cell spent media distinct from the LHRH-like factor which increases
testosterone secretion by Leydig cells in vitro (Grotjan and Heindel, 1982, Janecki
et al, 1985; Papadopoulos etal, 1985; 1987; Verhoeven and Cailleau, 1985) These
factor(s) modulate LH action on Leydig cells and are thermolabile, FSH-dependent
and have molecular weights between 10 kDa and 50 kDa.
As previously indicated testosterone is the most prevalent factor
mediating the effects of Leydig cells on Sertoli cells. However pro-opiomelanocortin
(POMC) derived proteins have also been investigated in the testis as P-endorphin was
postulated to be secreted by the Leydig cells (Bardin et al, 1987) and act as a
paracrine modulator of pubertal Sertoli cell function.
A number of studies have also reported the presence of the renin-
angiotensin system in Leydig cells. Leydig cells have specific angiotensin-II receptors
and angiotensin-II binding activates the subunit of adenylate cyclase, thus inhibiting
gonadotropin stimulation of cAMP, resulting in decreased testosterone production
(Khanun and Dufau, 1988). The significance of this is as yet unknown but if it were to
produce a decrease in the level of testosterone then this could in turn affect Sertoli
cell and peritubular cell function.
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1.6.3 Interactions Between Sertoli, Peritubular and Leydig
Cells.
Because of the close proximity between Sertoli and peritubular cells the peritubular
cells are capable of influencing the morphology and organization of rat Sertoli cells in
vitro as well as stimulating the secretion of ABP (Tung et al, 1980; Hutson and
Stocco, 1981; Skinner et al, 1989b).
Skinner and Fritz (1985) discovered that in addition to a Sertoli
secreting growth factor influencing peritubular cells in the rat testes there was a
peritubular secreted paracrine factor termed P-Mod-S which modifies Sertoli cell
function. It could therefore be concluded from this that androgens act at two levels on
Sertoli cells via a direct action on the Sertoli cell androgen receptors and via an
indirect action on the peritubular cell androgen receptors via P-Mod-S. Furthermore
TGF-a which is produced by both the Sertoli and peritubular cells (Skinner 1989;
Skinner et al, 1989a,) may possibly act as an important paracrine growth stimulant
for almost any of the cells previously mentioned. It may also act in an autocrine
manner. Transforming growth factor-(3 is also produced by Sertoli and peritubular
cells and it too may act as an important paracrine/ autocrine inhibitor (Skinner and
Moses, 1989).
The evidence available on Leydig/peritubular cell interactions is
somewhat limited. However Skinner and Fritz (1985; 1986) have shown that
androgens secreted by Leydig cells exert an effect on peritubular cells by increasing
the apparent production of P-Mod-S.
The significance of Sertoli/peritubular/Leydig cell communication is
not yet clear but as peritubular cells are positioned between the Leydig and Sertoli
cells, it is possible that these cells may mediate some of the effects of Leydig cell
secretory products which act upon the Sertoli cells and vice versa. Therefore such
factors as (3-endorphin, angiotensin, prostaglandins and oestrogens which are
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produced by the Leydig cell may have an effect on peritubular cells as well as
possibly on the Sertoli cells.
1.6.4 Summary of Paracrine Regulation of the Testes.
In summary, there are complex inter-relationships between the various components of
the testes, the nature of which we are only just beginning to understand. It appears
that through endocrine, paracrine and autocrine mechanisms, the function of each cell
is modulated to integrate its activity with that of other cells. However without
endocrine support, on which the whole system depends, spermatogenesis would break
down. It appears that the interactions between different cell types within the testes
have an important role in the maintenance and control of tissue function and growth.
The fact that some of the interactions which are initiated by the endocrine hormones
LH and FSH, secreted by the pituitary, are under the fine control of the peptide
growth factors has prompted this investigation to look at EGF and its receptors in
normal human testicular tissue.
1.7 Growth Factors
1.7.1 Introduction
The role of polypeptide growth factors in differentiation, development, chemotaxis
and activation of inflammatory cells, tissue repair and disease has been increasingly
appreciated. Subsequently the gene structure, cDNA sequence and complete amino
acid sequence of several growth factors have been reported. The receptors for several
growth factors have also been isolated and characterised. Activation of these receptors
by growth factors has been shown to lead to gene activation, transcription and
ultimately cell division. It is with this in mind that several investigators have looked
towards growth factor research as a possible way of gaining insight into the
development and maintenance of certain types of cell growth including cancer. At the
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same time it is also recognized that growth factors play an important role in the
development of normal tissue growth and function.
Many peptides with potent stimulatory effects on the proliferation of
either epithelial or mesenchymal cells have been identified in the past ten years.
Because of their regulatory action on tissue growth these peptides have been termed
growth factors. Growth factor classification is complex, since in most cases their
denomination is linked either to the target cell which revealed the mitogenic activity
of the factor, or to the producing cell. For example platelet derived growth factor was
isolated by Ross and Vogel (1978). It is stored in alpha granules of platelets and is
released during blood clotting and is a 30-32 kDa glycoprotein composed of two
peptide chains. Similarly the fibroblast growth factor obtained its name because its
mitogenic activity was first demonstrated on a Balb/c-3T3 fibroblastic cell line. It is a
16.5 kDa single polypeptide chain isolated for the first time in 1974 from the bovine
pituitary (Gospodarowicz, 1975; Gospodarowicz etal, 1986a; 1986b) and is
synthesized by most tissues ofmesodermic origin and is active on many cell types of
both mesodermic and neuroectodermic origin.
This study was therefore undertaken to establish if EGF receptors and
indeed EGF were present in normal and cancerous human testicular tissue. EGF was
chosen because of its involvement in both cancer of the breast and of the prostate.
1.7.2 Epidermal Growth Factor
Epidermal growth factor (EGF) was first discovered by Stanley Cohen in 1962. EGF
was recognized by its ability to accelerate the eruption of mouse teeth and the opening
of eyelids in new-bom mice. Later EGF was purified and its amino acid sequence
determined in 1972 by Savage et al (1972, 1973). Although no human equivalent
had been identified at that time it was known that a similar concentrate was present in
human urine and in 1975 Gregory purified and analysed this compound giving it the
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name urogastrone. He later concluded that "urogastrone and human epidermal growth
factor are one and the same". EGF is a 6 kDa single polypeptide chain of 53 amino
acids (Taylor et al, 1972; Cohen and Carpenter, 1975). It is synthesized in the form
of a macromoleculer 128 kDa precursor (Gray et al, 1985). The development of
radioreceptor (Carpenter et al, 1975; 1985) and radioimmunoassays (Dailey et al,
1978) quickly made it possible to associate urogastrone, found in human urine, to
EGF. Subsequently the two peptides were found to elicit identical biological effects
in vivo and in vitro. EGF is strongly mitogenic for many cell types ofmesodermic
and ectodermic origin. It has been shown to act in synergism with other growth
factors such as platelet derived growth factor (PDGF) and IGF-I (Rose et al, 1975).
EGF is also a powerful mitogen for embryonic and adult cells. Cloning of the EGF
gene (Scott et al, 1983) and the use ofmessenger RNA probes (Scott et al, 1983)
have shown that this factor is present in many tissues. EGF has also been found to
cultured
inhibit steroidogenesis in A rat Leydig cells (Hsueh et al, 1981).
EGF stimulates the proliferation of various cultured cells from many
different species (Carpenter and Cohen, 1979) and in addition to its mitogenic
response EGF induces both early and delayed responses. Early responses include
stimulation of ion and nutrient transport (Hollenberg and Cuatrecasas, 1973) and the
enhancement of the phosphorylation of endogenous membrane proteins ( Carpenter
et al, 1979). Delayed responses include the activation of the enzyme ornithine
decarboxylase (Stastny and Cohen, 1970; Statsbury and Cohen, 1972) and the
enhancement of the biosynthesis of fibronectin (Chen et al, 1977) and keratin
(Rheinwald and Green, 1977). As with other growth factors EGF acts on target cells
to produce an effect by means of specific receptors.
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1.7.3 Transforming Growth Factors
Joseph De Larco and George Todaro discovered that the retroviral transformation of
murine fibroblastic cells was associated with the secretion of a molecule they termed
sarcoma growth factor [SGF] (De Larco and Todaro, 1978; Spom and Todaro, 1980).
Subsequently purification procedures have revealed that SGF consists of two active
components termed transforming growth factors, TGF-a and TGF-p (Roberts et
al, 1980). TGF-a was characterised by its ability to bind to the EGF receptor
(Carpenter et al, 1983). Later its amino acid sequence was also determined and found
to be very similar to that of EGF (Spom et al, 1986). Twenty five of the 50 residues
of human TGF-a, including all six cysteines, were found in corresponding positions
to that found in the human EGF sequence. Recently various forms of TGF-a have
been identified (Bringman, 1987; MacDonald pers. commun. 1990). TGF-p however
was found to have no structural relationship to TGF-a, but was found to modulate the
availability of the EGF/TGF-a receptor. Transforming growth factor-[3 was first
identified by its ability to cause phenotype transformation of rat fibroblasts (Roberts
et al, 1981a; 1981b; 1985). It is a homodimer consisting of two identical 12.5 kDa
subunits held together by disulphide bonds with 112 amino acids in each (Assoian et
al, 1983; 1986; 1987; Derynck, 1986). Subsequently it has been shown to have both
growth-inhibitory and growth-stimulatory properties (Anzano et al, 1985; Massague,
1987; Moses et al, 1988; Spom and Roberts, 1988). It has also recently been
established that in fact three forms of TGF-P exist; Pi, P2 and P3 (Chiefetz et al,
1989 ). The potential role of TGF-P on gonadal function has been reported in
publications by Avallet et al (1987) where TGF-P was found to inhibit primary
cultured pig Leydig cell function. This was further supported by Lin et al (1987) who
discovered that TGF-p actually inhibited Leydig cell steroidogenesis in primary rat
culture. TGF-P cDNA has also been found in both normal and transformed cells




1.7.4 Insulin-Like Growth Factors
First described by Salmon and Daughaday (1957) as a "sulfation factor",
somatomedin C (IGF-I) is the best known member of the family of insulin-like
peptides; other members include insulin and IGF-II. IGF-I is human somatomedin C
and IGF-II is human somatomedin A and rat multiplication-stimulating activity.
IGF-I is the most active form in the adult where as IGF-II is thought to be the most
active somatomedin during embryogenesis. In vitro IGFs have been found to be
potent stimulants ofmesenchymal cells proliferation. IGF-I is a progression growth
factor which allows DNA synthesis in cells previously exposed to other growth
factors termed commitment growth factors, for example PDGF (Van Wyk et al,
1981). It is produced in response to circulating growth hormone and can be found in
serum and plasma (Svoboda et al, 1980) and is active in stimulating a large number
of cultured cells (VanWyk et al, 1981). IGF-I's effect on cell growth has been
explored employing membrane assays (VanWyk et al, 1975) and it has been
purified from human serum and sequenced (Rinderknecht and Humbel, 1978). It is a
single chain of 70 amino acids with three internal disulphide bonds.
IGF-I and IGF-II bind to two distinct receptors. IGF-I has a higher
affinity for the IGF-I receptor in comparison to the IGF-II receptor and similarly
IGF-II a greater affinity for the IGF-II receptor. However cross reaction can be seen
at high concentrations of the two growth factors (Massague and Czech, 1983). The
cellular receptor for IGF-I shows homology to the insulin receptor, a
450 kDa complex consisting of two transmembrane (3-subunits (98 kDa each), each
disulphide bonded to one a-subunit (130 kDa) (Pilch and Czech, 1980). The
a-subunits provide the insulin or IGF binding domains (Pilch and Czech, 1979)
whereas the (3- subunit possesses ATPase and tyrosine kinase activities (Van
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Oberghen et al, 1983). The a-subunit (the extracellular region) shows homology to
the extracellular domain of the human EGF receptor. The (3-domain shows homology
with the src family of tyrosine kinases, although homology is highest with the ras
oncogene (Ullrich et al, 1985 ). These homologies suggest that that one or more of
these oncogenes may encode growth factor receptors. The IGF-II receptors
(preferential for IGF-II) are simpler, exhibiting only a 250 kDa component which
may be a single chain (Kasuga, 1981). Type-II IGF receptors may not undergo ligand
induced down regulation (Massague, 1985).
IGFs are thought to stimulate growth in an autocrine fashion (Temin
et al, 1972). However BRL-3A cells (derived from buffalo rat liver) secrete large
amounts of IGF-II into the medium (Dulak and Temin, 1973) yet do not require the
IGF-II for proliferation and therefore do not satisfy the autocrine hypothesis (Nissley
et al, 1977). IGFs are also thought to play a role in testicular cell-cell communication
as immunoreactive sites and IGF-I have been identified in rat Sertoli-spermatogenic
cell co-cultures (Tres et al, 1986).
1.7.5 Nerve Growth Factor.
NGF is involved primarily in the maintenance and differentiation of sensory and
sympathetic neurons and because of this its inclusion in a strict list of growth factors
does not always appear correct. Nevertheless, NGF fits into the general scheme of
growth factors in many ways. Indeed recent evidence points to NGF playing a
mitogenic role for example in cultured rat adrenal chromaffin cells (Folkman, 1983).
NGF was first detected as a substance released from transplanted tumours (Levi-
Montalcini and Hamburger, 1951). It was then purified from snake venom and then
subsequently from mouse submaxillary gland. NGF isolated from submaxillary gland
is found in a 7S complex , containing three protein sub species labelled a, (3, y
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(Bradshaw, 1978). NGF activity resides in the {3-chain, which comprises of a 26 kDa
dimer of two identical NGF chains (118 amino acids per chain) which has been
sequenced (Angeletti and Bradshaw, 1971).
Receptors for NGF are present on a variety of normal sympathetic and
sensory neurons as well as normal and neoplastic chromaffin cells. The rat
pheochromocytoma cell line PC12 has been used extensively in studies concerning
NGF. Proliferation of PC 12 cells is inhibited by NGF whereas the differentiation of
the cells is stimulated (Greene and Tischler, 1976) the mechanism controlling this
response is presently unknown. The PC12 receptor has been defined as a single chain
protein of 130 kDa , although a smaller receptor of 100 kDa is also present which is
possibly a degraded form of the receptor. On the A875 melanoma cell line however
two receptors with different affinities and molecular weights for NGF have been
detected. The affinity constants of the two receptors are 2.0 pM and 2.0 nM and the
molecular weights 98 kDa and 138-190 kDa respectively (Puma et al, 1983;
Landreth and Shooter, 1980; Costrini and Bradshaw, 1979).
1.8 The EGF Receptor and Characteristics of EGF Binding.
The EGF receptor is a 170 KDa protein. It comprises of three major binding domains;
an EGF-binding domain which lies external to the plasma membrane, a
transmembrane domain and a cytoplasmic domain (Figure 8). Epidermal growth
factor receptors have been found on various tissues both normal and cancerous
(Hollenberg and Cuatrecasas, 1973; O'Keefe et al, 1974; Taketani and Oka, 1982;
Lai et al, 1984; 1986). However the reports on the affinity of the ligand for its
receptor are not always consistent. Furthermore it has often been reported that two
binding sites exist rather than simply one. For example in human prostate tissue
Maddy et al (1987) reported finding two binding sites, one with a high affinity of 0.8


















The EGF receptor: the structure and the polypeptide. EGF binds to the external
domain of the receptorto initiate a signal which is transmitted via the
transmembrane domain to the internal domain of the EGF receptor. In progressing
to the internal domain, tyrosine kinase is stimulated.
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binding site reported by Traish and Wotiz (1987) on rat prostate tissue which
expressed a Kd of 1.16 nM. In this case the difference in binding sites observed could
be accounted for by the difference in species but there are numerous other examples
which could be referenced. For example in characterization of the EGF receptor in
human meningioma two binding sites with dissociation constants of 0.9 nM and 5.0
nM were detected (Weisman et al, 1987). Similarly in leiomyomas two binding sites
of 0.1 and 3.7 nM were detected (Hofmann et al, 1984) whereas on normal uterine
tissue (myometrium) only one EGF receptor was characterised with a Kd of 0.7 nM.
From the aforementioned data there appears to be two groups of EGF receptor
populations. The first population consists of two receptors with affinity constants in
the range 0.1-0.9 nM and 3.7-7.6 nM and the second population just one receptor with
an affinity constant in the range 0.7 nM to 1.16 nM.
1.8.1 Activation of the EGF Receptor and Regulation
On binding of EGF to its receptor it is known that a signal is passed through the three
domained binding site to initiate a reaction at the second messenger. The human
epidermal carcinoma cell line A431 which has >10^ EGF receptor sites per cell
(Fablicant etal, 1977; Haiglerera/, 1978; 1979; Stoscheckand Carpenter, 1984)
has been used to identify phosphoproteins of 150 and 170 kDa which are believed to
represent the EGF receptor. EGF has also been found to stimulate tyrosine
phosphorylation of these proteins (Carpenter et al, 1978; 1979; King et al, 1980).
The EGF receptor was purified from A431 cells and shown to be a
tyrosine-specific protein kinase with the capacity for autophosphorylation and activity
for exogenous substrates (Cohen et al, 1980; 1982; Erhart et al, 1981). It is an
integral membrane protein of 170 kDa (Cohen et al, 1982), the non-glycosylated
precursor polypeptide is approximately 130 kDa. In addition to glycosylation, other
modifications include serine, threonine and tyrosine phosphorylation (Hunter and
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Cooper, 1981; 1985; Pike and Krebs, 1986). The endogenous kinase mediates tyrosine
phosphorylation, whereas other kinases are responsible for phosphorylation of serine
and threonine residues, including protein kinase C (Cochet et al, 1984) which
preferentially phosphorylates threonine 654 (Hunter et al, 1984; Davis and Czech,
1985). Phosphorylation of the EGF receptor by protein kinase C inhibits the intrinsic
tyrosine kinase activity, reduces the apparent affinity of the receptor for EGF and
stimulates internalisation of the receptor (Lee and Weinstein, 1978; Fox et al, 1979;
Downward et al, 1984a; Davis and Czech, 1985; Whitley and Glaser, 1986). Thus
protein kinase C has a negative influence on the EGF receptor. The EGF receptor is
internalised when activated by EGF and is subsequently degraded (Carpenter and
Cohen, 1976). In the absence of ligand the EGF receptor is distributed randomly over
the cell surface. Following binding of EGF at 37°C, the receptor becomes localised in
coated pits, internalised in endosomes and delivered, possibly via the Golgi bodies to
lysosomes, where it is rapidly degraded (Stoscheck and Carpenter, 1984a; 19841^.As
well as stimulating protein kinase C the intrinsic kinase activity is also able to
phosphorylate other proteins such as phosphatidylinositol kinase (Walker and Pike,
1987) which in turn effects transmission of the second messenger signal. The EGF
receptor has a half-life (T 1/2) of approximately 10 hours in human fibroblasts, but in
the presence of EGF this value is reduced to approximately 1 hour (Stoscheck and
Carpenter, 1984a; 1984b). The recycling of the EGF receptor has been found to be
insignificant by Stoscheck and Carpenter (1984a; 1984b) and Teslenko et al (1987),
consequently the interaction of EGF with its receptor provides a negative feedback
loop that down regulates the potential for additional signalling by EGF.
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1.8.2 The v-erb B Oncogene.
Structural studies carried out by Downward et a\ (1984a) have demonstrated that 74
of the 83 EGF receptor amino acid residues sequenced are identical to those of the
transforming protein encoded by the v-erb B oncogene of avian erythroblastosis
virus. Several lines of evidence suggest that the v-erb B oncogene encodes the
transmembrane region of the EGF receptor and the domain associated with the
tyrosine kinase activity (Hayman et al, 1983; Hayman and Beug, 1984; Lax et al,
1985; Nilsen et al, 1985; Akiyama et al, 1986; Hayman et al, 1986).
Viral oncogenes are known to be directly responsible for the
transformation of some cell types (Slamon, 1987) and therefore it is plausible that the
proto-oncogene as well as the EGF receptor may encode information with the
potential to induce cancer. For example in the literature it has been suggested that the
protein kinase activity of the v-erb B protein is constantly active and therefore
presumably provides a permanent proliferative signal (Hayman et al, 1986). As well
as the v-erb B oncogene the neu oncogene (Coussens et al, 1985; Schechter et al,
1985) and the Her-2 oncogene also show
extensive homology to the EGF receptor although theneu gene is distinct from and
unlinked to the gene encoding the EGF receptor, and yet it is homologous to the
erb B gene (Schechter et al, 1985).Oncogeneshave also been identified in germ cell
tumours (Sikora et al, 1987) although the oncogenes found were not of the src
family of which erb B is a member (Yamammoto et al, 1983). The Her-2 and neu
oncogenes have however been shown to be amplified in some human breast cancer?
(Slamon et al, 1987; Zeillinger et al, 1989).
1.9 Autocrine and Paracrine Modes of Action of Growth Factors
There is now much circumstantial and direct evidence to support an autocrine method
of action by certain growth factors. For example, many types of tumour cells release
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polypeptide growth factors into their medium when grown in vitro and these same
tumour cells often possess functional receptors for the released peptide. The peptide
growth factors which are known to function via an autocrine mechanism in cancer
cells include TGF-a and PDGF. Similarly evidence is also now available to support
the paracrine hypothesis whereby a growth factor secreted by one cell can act on a
neighbouring cell. Growth factors which act in this way include both EGF and
TGF-a. In contrast growth factors that act on distant tissues accessed via the blood
stream are said to act in an endocrine fashion (Figure 9).
The term paracrine was proposed by Feyrter in 1938 to describe the
action of a network of epithelial clear cells throughout the gut that he thought might
be peripheral endocrine glands (Feyrter, 1946). He speculated that they exercised
local paracrine effects on gut function in addition to their endocrine effects on distant
tissues.
The concept of autocrine secretion was introduced by Sporn and
Todaro (1980) to explain the endogenous production of autostimulatory growth
factors by transformed cells. Since then autocrine control mechanisms have also been
observed in normal cells.
More recently greater consideration has been given to the possibility
of intracrine regulation of the nucleus by growth factors. Logan (1990) recently
published a report suggesting another category for the mode of action of growth
factors. Growth factors which act in this way apparently need not be secreted, nor do
they require receptors located on the cell surface to mediate their activity. Rather they
remain within the cell of origin and act directly themselves as intracellular
messengers to regulate cellular function. A number of cytoplasmic growth factors
have now been characterised which lack classical consensus signal peptide sequences
to direct their secretion. These include the precursors of Interleukin-la and
Interleukin-1 (3 (Auron et al, 1984; March et al, 1985), ciliary neurotrophic factor
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Endocrine, Paracrine and Autocrine mechanisms of action for growth factors. In
the endocrine system growth factors are secreted into the blood stream to act on
distant targets. In the paracrine system growth factors are secreted to act on
neighbouring cells and in the autocrine system growth factors are secreted by the
cells on which they are going to act.
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(Stockli et al, 1989) and the newly discovered platelet derived endothelial cell
growth factor (Ishiwaka et al, 1989). Other members of this group include some of
the fibroblast growth factors. Secretion has conventionally been considered to be a
prerequisite of growth factor bioactivity but in light of the above evidence this now
appears to be open to question.
1.9.1 Interaction between Growth Factors
In any organ or tissue containing multiple cell types, local co-ordination of the
functions of the different cell types is fundamental to the efficient working of the
organ in question. Such local or paracrine regulation must by definition involve
agents which are produced by one cell type and act on another. Even in a single cell
the action produced by the growth factor may depend on the context set by other
substances which are present. For example TGF-(3 stimulates growth of fibroblasts in
the presence of PDGF, but inhibits their growth in the presence of EGF (Roberts et
al, 1985). The action of growth factors can also depend on the state of the
differentiation of the target cell. For example TGF-(3 stimulates or inhibits the
expression of cartilaginous phenotype in embryonic mesenchyme according to the
development stage of the cell (Seyedin etal, 1986; Rosen etal, 1988).
1.9.2 Interaction between Receptors
The ability of a receptor for a specific peptide to alter either the cellular distribution
or the binding affinity of a neighbouring receptor for a second peptide growth factor,
independent of any direct crossreactivity of the peptide themselves upon the two
receptors, is now also apparent. For example PDGF can decrease the affinity of EGF
receptor for its ligand (Bowen-Pope et al, 1983, and Zachary and Rosengurt, 1985).
This phenomenon is termed transmodulation ("receptor-cross- talk") to distinguish it
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from the reduction in receptor numbers caused by homologous ligands, known as
down regulation or down modulation. In addition EGF receptors on some tissues have
been shown to be controlled by other substances apart from growth factors. For
example Mukku and Stancel (1985a) reported finding that the EGF receptor on
uterine membranes could be regulated by estrogen. Similarly Murphy et al (1986)
reported that progestin regulated EGF receptor in human mammary carcinoma cell
lines. In the case of steroids it is likely that regulation of the EGF receptor
occurs via stimulation of the internal steroid receptor present within the same cell. In
the study of Murphy et al (1986) this was indeed the case for it was found that the
expression of the EGF receptor in some breast cancer cells was regulated in part by
mechanisms mediated via the progesterone receptor. The effect was correlated with
the affinities of a series of progestins for the progesterone receptor.
1.10 Cancer and Growth Factors
Over the past fifteen years various hypothesesfor the involvement of growth factors
in the development and progression of certain types of cancer have been put forward.
A number of these hypothesis have in turn been substantiated. Growth factors are
involved in multiple types of cancer (Kawamoto et al, 1983; Sainsbury et al, 1985a;
Bepler et al, 1988). In MCF-7 human breast cancer cells IGF-I and EGF are released
into serum-free culture medium (Dickson et al, 1986a; 1986b; 1986c). Treatment of
MCF-7 cells with 17(3 oestradiol, which is required in vivo for MCF-7 tumour
growth in the nude mouse and stimulates MCF-7 growth rate in vitro, resulted in
selectively increasing growth factor concentrations in serum-free medium (Dickson
et al, 1986b). Autostimulatory growth promoting activity was elevated at least
two-fold, and concentrations of EGF-like polypeptides were elevated 5-fold while
IGF-I immunoreactivity was not elevated. Lippman et al (1986) hypothesised that
oestrogen control of hormone dependent breast cancer was mediated by autocrine and
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paracrine growth factors secreted by breast cancer cells. Human breast cancer cells
were found to secrete a collection of growth factors (IGF-I, TGF-a , TGF-P, a
PDGF-like competency factor, and at least one new epithelial colony stimulating
factor) (Lippman et al,1986). However not all of these factors were found to be
regulated bycestrogen although they are constitutively increased in cells which acquire
hormone independence either spontaneously or by ras transfection. Collectively the
secreted growth factors were found to to be capable of promoting tumour formation
by MCF-7 cells in nude mice, though not to the same extent as oestrogens. There
would therefore seem to be some potential in the autocrine and paracrine control of
breast cancer cells, including some cells which are no longer dependent on
oestrogens.
In primary breast cancers it has been established that there is an
inverse relationship between EGF receptor and oestrogen receptor (ER) status. For
example the relapse-free survival and overall survival times for patients with EGF
receptor positive tumours were found to be significantly worse. The tumours of
patients with positive EGF receptor identification also illustrated a significant
association between tumour size and differentiation (Sainsbury et al, 1985d; 1987).
Relapse-free and overall survival times were also worse for ER negative tumours.
EGF receptor positive and ER negative in fact indicated the poorest overall survival
and relapse-free times. From this it was suggested that EGF receptor status was the
most important variable in primary tumours for predicting overall survival time.
Similarly EGF receptor expression has been of prognostic significance in oesophageal
squamous cell carcinomas (Ozawa et al, 1989). In the study by Ozawa et al (1989)
it was found that the survival rate of the high EGF binding group was significantly
lower than that of the low EGF binding group. In carcinoma of the prostate EGF
receptors have been identified and are expressed in much higher numbers in the
tissues which are poorly differentiated (which are also possibly more aggressive) than
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in tissues which are well differentiated. In a report published by Traish and Wotiz
(1987) it was found using prostatic membranes from rats that EGF receptor
expression could be modulated by androgens. Similarly in the study performed by
Ewing et al (1989) in which breast cancer cell lines were used it was found that EGF
receptors could be regulated by both progestins and glucocorticoids acting via their
respective receptors to induce increases in EGF receptor mRNA levels. One principle
aim of this study would therefore be to investigate the presence and possible role of
EGF and its receptor in cancerous human testicular tissue.
1.11 Cancer of the Testes.
Testicular tumours are infrequent, but most often malignant. They are the commonest
type of cancer in men under 40 years of age and there appears to be an increase in
incidence (pers. commun. Mr T.B. Hargreave). They account for approximately 0.5 to
1.0% ofmalignant tumours in the human male. The large majority of primary
testicular tumours, the so called germ cell tumours, originate from testicular germ
cells. Rare testicular neoplasms like Leydig cell tumours originate from testicular
stroma and are therefore classified as gonadal stromal tumours. To this day there is
still controversy concerning classification of testicular germ cell tumours.
Consequently for the purposes of this study the tumours have been classified as
seminoma, teratoma and Leydig cell as shown in Figure 10 and in accordance with
the classification ofMostofi (1974) as slightly modified by the World Health
organisation (Bergami et al, 1977).
Both benign and malignant tumours are less common in children than
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Choriocarcinoma Yolk-sac tumour Teratoma
Figure 10 - Classification of Germ Cell Tumours.
Germ cell tumours arise from the germ cells of the testis. A germ cell tumour
may be classified primarily as a seminoma or an embryonal carcinoma. In the
latter case the embryonal carcinomas can be subdivided due to them having the
ability to differentiate in multiple directions, primarily to resemble
extraembryonic or embryonic tissue. An embryonal carcinoma which takes on
the appearance of embryonic tissue is classified as a teratoma.
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1.11.1 Embryonal Carcinoma
Embryonal carcinoma or yolk sac tumour forms a network of undifferentiated
embryonal tubular structure (Karamehmedovic et al, 1975). It is thought by some to
belong to the germ cell tumour category and by others to represent a teratoma (Sabio
et al, 1974; Brown, 1976).
1.11.2 Seminoma
Seminomas are the most common tumours of the testis. They generally occur in men
of between 30 and 50 years of age. They occur more frequently in maldescended
testes than in normal descended testes. During adulthood malignant tumours are
approximately ten times more common in undescended testes than in scrotal testes
(Jones and Campbell, 1976; Davies, 1980; Depue et al, 1983; 1984). However even
after an undescended testis has been transferred into the scrotum it still has a
predisposition to tumour growth. Histologically seminomas consist of clusters of
cells. The cells are large possessing ill defined clear cytoplasmic edges and rather
large round nuclei, giving a similar appearance to the germ cell from which they
arose.
1.11.3 Teratoma
The term teratoma in this study is used to classify the tumours composed of tissues
representing different germinal layers. They occur somewhat less frequently than
seminomas and in a much younger age group. In this study the age group of the
teratoma tissues investigated ranged from 14 to 33 years of age. In the past teratomas
have been shown to be capable of producing hCG as well as progesterone and
oestrogens. If the levels of hCG and oestrogen are high enough then this can manifest
itself in the patient as gynaecomastia. Teratomas histologically can be seen to contain
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keratinising tissue and nerves (Mostofi and Price, 1973). The usual microscopic
pattern however is representative of a wide variety of tissues derived from all three
germ cell layers; glial and retinal tissues are not uncommon. Mesodermal structures
include muscle cartilage and bone. Numerous mitoses may be observed, but areas
resembling embryonal carcinoma are rarely present. In adults, teratomas are almost
always malignant whereas in adolescent males malignancy is not as common as they
represent a different subgroup of teratoma tissues (pers. commun. Mr T. B.
Hargreave). The group of testicular tumours represented in this study by teratoma
consisted of both mature and immature teratomas as well as those with malignant
transformation and those identified as illustrating embryonal carcinoma. Adolescent
teratomas however can often behave like adulthood teratomas and consequently may
often be malignant.
1.11.4 Leydig Cell Tumour
Leydig cell tumours are very rare and as the name suggests are composed of cells
resembling Leydig cells. The tumours vary in size and are usually well separated from
the rest of the testicular tissue. They have a firmer consistency than the testis and are
usually unilateral and benign. Hormone production is often increased; high levels of
plasma testosterone with low levels of gonadotropins (Wegienka and Kolb, 1967). In
some cases other androgenic steroids such as androstenedione may be increased (Root
et al, 1972; Wegienka and Kolb, 1967). One clinical indicator of a Leydig cell
tumour is the level of 17a-ketosteroid excretion. Increased amounts of oestrogens
may also be excreted in the presence of these tumours which in turn may become
clinically manifest in the development of gynaecomastia or infertility which is




In 1972 a possible link between an abnormal germ cell pattern in seminiferous tubules
and the subsequent development of germ cell tumours was described in the literature
(Holstein et al, 1987; Skakkebaek, 1972; 1975). This finding led to the suggestion
that the abnormal germ cells did in fact represent a carcinoma in situ (CIS). CIS cells
are characteristically located in a single row inside seminiferous tubules of decreased
diameter with thickened basal membranes. Usually Sertoli cells are the only other
cells present in the tubules. CIS cells have a distinct appearance as they are much
larger than normal spermatogonia.
In the last 18 years a considerable weight of evidence has confirmed
the theory that CIS germ cells are precursors of all types of testicular germ cell
tumours except the spermatocytic seminoma (Skakkebaek et al, 1987). It has also
been found that in a study of men with CIS, 50% developed invasive tumours within
5 years of diagnosis. An identical figure was also found for CIS in the contralateral
testes ofmen with unilateral testicular cancer who had not been given chemotherapy
(von der Maase et al, 1986; von der Maase et al, 1987 ). Subsequently high risk
groups have now been identified for CIS. These include men with unilateral testicular
cancer patients with a history of cryptorchidism (Waxman, 1976), infertile men
(Pryor et al, 1983), intersex patients (Muller and Skakkebaek, 1988) and patients
with extragonadal germ cell tumours (Daugaard et al, 1987).
1.11.6 In vitro Models for Testicular Cancer
Relatively few human teratoma cell lines have been established in vitro and the
characteristics of these are poorly understood. SuSa (Hogan et al, 1977), Tera-1 and
Tera-2 (Holden et al, 1977; Fogh and Trempe, 1975) and PA1 (Zeuthen et al, 1980)
are four human teratoma cell lines which were established in the late 1970s. Human
embryonal carcinoma cell lines GCT 27, GCT 35 and GCT 48 have more recently
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been established by Pera et al (1987). The Tera-2 cell line was chosen particularly
for this study because it expresses the EGF receptor (Engstrom et al, 1985).
It is a human embryonal carcinoma cell line (Tera-2) and was originally established in
1971 by Fogh and Trempe (1975). It was cultured from a lung metastasis from a
primary testicular embryonal carcinoma. Engstrom (1986) not only performed ligand
binding experiments but also cell proliferation studies performed under serum-free
conditions. No effect was seen on proliferation of the cells although cell locomotion
was found to be stimulated by EGF (Engstrom, 1986). When culturing in serum-free
medium the cells had to be plated at a high density to survive because of a low
plating efficacy while under the serum-free conditions. This could have in fact
hindered any proliferative effect which EGF may have had on the Tera-2 cells
because of the lack of space available for growth. The cells must be cultured in
serum-free medium due to the multiple factors present in serum which are as yet
unidentified (Kaplan et al, 1982).
The cell types present in the teratoma tumours vary greatly. Frequently
they contain embryonal carcinoma, seminoma and cells that resemble those found in
extra-embryonic foetal tissues, for example placental trophoblast and yolk sack. Less
frequently, there are groups of cells that look like embryonic and adult tissues, such as
muscle, cartilage and nerve (Mostofi and Price, 1973; Pugh, 1976). In the mouse it
has been established that these multiple cell types arise from a single malignant
pluripotential embryonal carcinoma cell (Kleinsmith and Pierce, 1964). This may also
occur in human germ-cell tumours since cloned cell lines derived in vitro from such
tumours can form a variety of cell types in vivo and in vitro (Andrews et al, 1983;
Thompson et al, 1984). It is known that the Tera-2 cells possess an aneuploid
karyotype with a near triploid number of chromosomes (Thompson et al, 1984). The
cell line has also been found to differentiate into neuron-like cells in the presence of
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INTRODUCTION
1.12 Summary
Interest in growth factors was greatly stimulated by the discovery that transformed
cells generally have lower serum requirements than their normal counterparts.
Subsequently the possibility of growth factor involvement in the growth of normal
and transformed cells in vitro was investigated in the hope that not only would this
shed some light on the control of normal cell growth but also cancerous cell growth.
As previously stated EGF does indeed stimulate the proliferation of cultured cells,
obtained from many different species (Carpenter and Cohen, 1979). It was therefore
in this context that the main aims and objectives of this study were defined.
The aims of this study were therefore to
a) characterise and localise the EGF receptor on normal and cancerous human
testicular tissue by biochemical and immunohistochemical techniques.
b) ascertain whether there was any relationship between hEGF, hTGF-a and
androgen concentrations in normal and cancerous human testicular tissue.
c) characterise the EGF receptor on Tera-2 cells.









i) Na^I ( Specific Activity [S.A] 15-20 GBq/mmol)
ii) 125i mEGF (S.A. 20-25 TBq/mmol)
iii) 125i hEGF (S.A. 45-50 TBq/mmol)
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iv) (1,2,6,7- H) Androstenedione (S.A. 3.0-4.1 TBq/mmol)
v) (1,2,6,7- ^H) Dihydrotestosterone (S.A. 1.8-2.2 TBq/mmol)
vi) (1,2,6,7- ^H) Testosterone (S.A. 3.0-3.9 TBq/mmol).
vii) [methyl ^H] Thymidine (S.A. 74 GBq/mmol)
were purchased from Amersham International pic. (Berks, U.K.)
2.1.2 G rowth Factors
Mouse Epidermal Growth Factor (mEGF)
Rat Transforming Growth Factor alpha (rTGF-a)
Snake Venom Nerve Growth Factor (vNGF)
Bovine basic Fibroblast Growth Factor (bFGF)
were purchased from Sigma Ltd (Dorset, U.K.)
Human Insulin-Like Growth Factor-1 (hIGF-I) was purchased from Sera
Labarotories, Sussex, U.K. and urogastrone (hEGF) was kindly donated






Human Luteinising Hormone (hLH)
Human Follicle Stimulating Hormone (hFSH)
Human Growth Hormone (hGH)




were purchased from Sigma. Mi bolerone
(7,17P-dimethyl-19-nortestosterone) was purchased from Amersham.
2.1.4 Monoclonal Antibodies
The monoclonal antibody for the external domain of the human EGF
receptor (EGF-Rj) was kindly donated by Dr M.D.Waterfield, Imperial
Cancer Research Fund Laboratory, London (Waterfield et al, 1982). The
anti-mouse EGF receptor monoclonal antibody (EGF-R) for the external
domain of the receptor for use on paraffin sections was kindly donated by
Dr F. Hay, Imperial Cancer Research Fund Laboratory, Oncology Group,
Western General Hospital, Edinburgh who had previously purchased it
from Oncor, MD, USA (Starkey et al, 1975). The third monoclonal
antibody recognising the internal domain of the receptor (F4) was a gift
from Dr WJ. Gullick of the Imperial Cancer Research Fund Laboratory
Oncology Group, Hammersmith Hospital, London (Gullick et al, 1986).
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2.1.5 Enzymes and Enzyme Inhibitors
i) Trypsin - Type 1 (bovine pancreas) 10,000 BAEE units per mg protein.
One BAEE unit produces an A253 of 0.001 per min with BAEE as
substrate at pH 7.6
ii) Hyaluronidase - Type 1-S (bovine testes) 300 units per mg solid.
One unit produces color equivalent to lpg glucuronic acid per hour from
hyaluronic acid using 3,5-dinitrosalicylic acid to develop color. The enzyme
randomly cleaves J3-N-acetyl-hexosamine-[l- 4] glycosidic bonds in
hyaluronic acid, chondroitin and chondroitin sulphates.
iii) Collagenase - Type 1A (Clostridium Histolyticum) >125 collagen
digestion units per mg solid.
One unit liberates peptides from collagen equivalent in ninhydrin colour to
1.0 pinole of leucine in 5 hours at pH 7.4 at 37°C in the presence of
calcium ions.
iv) Trypsin Inhibitor - Type 1-S (soybean)
1 mg of trypsin inhibitorwill inhibit 1-3 mg of trypsin with activity of
approximately 10,000 BAEE units per mg protein.
The above were all purchased from Sigma. All other reagents which were
used were of analytical standard unless otherwise stated.
2.2.1 Specific Reagents
a) Iodination
i) Iodogen reagent was made by dissolving 1,3,4,6 Tetra chloro-3,6
diphenyl glycouril in methylene chloride to give a final concentration of
150 pg/ml.
ii) 0.05 M Phosphate buffered saline (PBS) [ 0.05 M Na2HPC>4.2H20,
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0.05 M NaH2 PO4.H2O and 0.9% NaCl (w/v) in distilled water ] pH 7.4
and 0.1% BSA /PBS (w/v) were also prepared. Bovine serum albumin
(BSA) (fraction V) was purchased from Sigma.
iii) Sephadex G50 was purchased from Pharmacia, Milton Keynes, U.K.
2.2.2 Homogenisation, Protein Estimation and Ligand Exchange
Assay
i) Buffer A - 10 mM Tris-HCl, ImM Ethylenediaminetetra-acetic acid
(EDTA), 1 mM Ethyleneglycol-bis-(P-aminoethyl ether) tetra-acetic acid
(EGTA), 0.25 M sucrose and 0.05 mM Phenylmethylsulfonyl fluoride
(PMSF) in distilled water (pH 7.4). Note PMSF (0.1 mM) was prepared
fresh each week in ethanol and the appropriate volume added to the
required volume of buffer A to achieve a concentration of 0.05 mM.
ii) Buffer B - 10 mM Tris-HCl, 0.9% (w/v) sodium chloride and 0.1%
(w/v) BSA in distilled water (pH 7.4).
iii) Bradford Reagent -100 mg Coomassie Brilliant Blue G was dissolved
in 50 ml of 95% (v/v) ethanol in distilled water. To this 100 ml of 85%
(v/v) phosphoric acid in distilled water, was added. The solution was then
made up to 1 litre with distilled water and thoroughly mixed before being
filtered through Whatman filter paper.




2.2.3 Crosslinking and Electrophoresis
The procedure of sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) was based on the discontinuous Tris-Glycine
buffer system described by Laemmli (1970) and was performed in a vertical
slab gel electrophoresis tank (Protean-II slab electrophoresis cell, Bio-Rad
Laboratories Ltd, Watford, U.K.). A molecular weight standard kit with
molecular weight markers of 45, 66, 97.4, 116 and 205 kDaltons was
purchased from Sigma.
Buffers:
i) 1 mM Disuccinimidyl suberate (DSS) [ Pierce and Warriner, Chester,
U.K.] dissolved in 5% (v/v) Dimethyl sulphoxide (DMSO) in H2O.
ii) Sample Buffer - 4% (w/v) Sodium dodecyl sulphate (SDS), 10% (v/v)
glycerol, 5% (v/v) 2(3-mercaptoethanol, 0.25% (w/v) Bromophenol Blue R
in 0.06 M Tris-HCl Buffer (pH 6.8).
iii) 30% (w/v) Acrylamide- 29.2 g acrylamide and
0.8 g N'N'-Bis-methylene-acrylamide dissolved in 100 ml distilled water.




v) Preparation of Gels
4% Stacking Gel (20 ml)
30% Acrylamide/Bis (2.6 ml)
0.5 M Tris (pH 6.8) (5 ml)
10% (w/v) SDS (200 pi)
Distilled water (12.2 ml)
TEMED (20 pi)
10% Ammonium persulfate (freshly prepared) (100 pi)
7.5% Seperating Gel (100 ml)
30% stock Acrylamide/Bis (25 ml)
1.5 M Tris Buffer (pH 8.8) (25 ml)
10% (w/v) SDS (1 ml)
Distilled water (48.5 ml)
TEMED (50 pi)
10% Ammonium persulfate (freshly prepared) (500 pi)
v) Staining solution - 0.1% Coomassie Brilliant Blue R 250 (w/v) in 20%
(v/v) methanol and 10% (v/v) acetic acid in distilled water.
vi) Destaining solution - 20% (v/v) methanol and 10% (v/v) acetic acid in
distilled water.
2.2.4 Immunohistochemistry




i) Tris Buffered Saline (TBS) - 0.9% (w/v) sodium chloride in 50 mM
Tris-HCl (pH 7.6).
ii) Michaelis Veronal Buffer - 0.14 M sodium acetate trihydrate, 0.14 M
sodium barbitone, 0.04% (v/v) formaldehyde in distilled water.
iii) Streptavidin alkaline phosphatase substrate (ICN Biomedicals, High
Wycombe, U.K.) /chromagen in Michaelis Veronal Buffer -1.3 mM Fast
Red ITR (Sigma), 1.0 mM levamisole, 0.75 mM Napthol ASBI phosphate
(Sigma) in Michaelis Veronal Buffer.
iv) Glycerine jelly
13% (w/v) gelatine in distilled water, diluted 1:1 (v/v) in glycerol with the
addition of six crystals of thymol.
2.2.5 Epidermal Growth Factor Radioimmunoassay.
Normal rabbit serum (NRS) and donkey anti-rabbit antiserum (DARS) were
obtained from the Scottish Antibody Production Unit, (Carluke,
Lanarkshire, U.K.).





i) TEP Buffer - 50 mM Tris-HCl, 10 mM EDTA, 5 |iM PMSF (pH 7.2)
(A concentrated solution of PMSF was prepared fresh each week in ethanol
and the appropriate amount added accordingly).
ii) RIA Buffer - 0.5% (w/v) BSA in 0.04 M Phosphate Buffer, 0.15H
lis
sodium chloride, 0.01 M EDTA (pH7.2).
iii) Digestion Buffer - 1 mg trypsin inhibitor, 225 x 10^ units
collagenase, 125 x 103 units hyaluronidase and 1.2 g bicarbonate in ^
100 ml RIA buffer.
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2.2.6 Transforming Growth Factor-a Radioimmunoassay.
Rat Transforming Growth Factor-a Radioimmunoassay kit (rTGF-a RIA) was
obtained from Peninsula Laboratories (Merseyside, U.K.). In using the rTGF-a
RIA kit to detect hTGF-a an assumption was made regarding the crossreactivity of
the rTGF-a antibody for hTGF-a. Experiments by Peninsula to determine the IC50
values for rTGF-a and hTGF-a had shown that the antibody cross reacted
32% with hTGF-a compared to 100% with rTGF-a (Moores pers. comm. 1990).
However no data was presented which showed that the antibody bound to hTGF-a
with the same affinity as it did to rTGF-a. The assumption therefore made in this
study is that the the antibody binds with the same affinity to hTGF-a as it does to
rTGF-a. In multiplying the concentration of TGF-a detected in tissue samples by
approximately 3.3 the amount of hTGF-a present in the sample was calculated.
Values which are quoted are therefore not absolute values until this assumption
has been clarified. The experiment was not performed as part of this study due to
the lack of finance available.
2.2.7 Steroid Radioimmunoassays.
Lyophilised polyclonal sheep anti-human androstenedione and
dihydrotestosterone (DHT) antiserum were purchased from Guildhay
antisera Ltd., Surrey, U.K. The lyophilised material was dissolved in 10 ml PBS
Gel Buffer to give a nominal titre of 1:100. The solution was then stored in 1 ml
aliquots at -20°C until required. The DHT antibody was used to detect both DHT
and testosterone by employing the antibody at two different titres.
i) PBS-Gel Buffer - 0.1% (w/v) Gelatine in 0.01 M Phosphate buffered saline
(PBS) [ 0.9% (w/v) NaCl and 0.1% (w/v) NaN3 in 0.01 M Na2HP04 and
0.01M KH2PO4] (pH 7.4).
ii) Dextran Coated Charcoal Buffer - 0.025% (w/v) Dextran and 0.25% (w/v)
charcoal in PBS-Gel Buffer.
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iii) A Triton X-14 scintillation cocktail was purchased from A.M.Vickers
Laboratories Ltd. (Burley-in-Wharfedale,U.K)
2.2.8 Western Blot Analysis
i) Lysis Buffer-10% (v/v) Triton-XlOO in distilled water with the addition
of 0.5mM PMSF in ethanol.
ii) Sample Buffer-10% (w/v) glycerol, 2% (w/v) SDS, 5% (v/v)
2(3-mercaptoethanol and 0.0013% (w/v) bromophenol blue in 0.06 M
Tris-HCl, pH 6.8.
iii) Transfer Buffer - 20% (v/v) methanol in 48 mM Tris-HCl, 39 mM
glycine, pH 9.2. (Note- the buffer pH ranged from 9.0 to 9.4. If the pH
did not fall in this range then the buffer was discarded as acid or base could
not be added to the buffer. This was because the addition of ions present in
the acid or base would aid the flow of the electric current in the transblotting
apparatus and could possibly lead to scorching of the membrane).
2.2.9 Tissue Culture
Hydrocortisone-21-hemisuccinate, human insulin (tissue culture grade),
human transferrin, O-phosphylanolamine, tri 3,3,5, iodo-L-thyronine,
penicillin (10,000 IU/ml) and streptomycin (10,000 (ig/ml) were all
obtained from Sigma. Glutamine, nutrient broth, foetal-calf serum, RPMI
1640 media, Dulbeccos solution and trypsin/EDTA (5.0 g trypsin and 2.0 g
EDTA in 1 litre 0.9% (w/v) sodium chloride in distilled water)were
purchased sterile from Gibco, Paisley, Scotland. Mibolerone was
purchased from Amersham International p.I.e. (Berks. U.K.)
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i) 10% FCS RPMI media - 0.2% (v/v) Penicillin/Streptomycin solution,
10% (v/v) Foetal-Calf Serum and 1% (v/v) Glutamine solution in RPMI
1640.
ii) Serum-Free Medium (SFM) -
bovine insulin (10 pg/ml)
human transferrin (10 fig/ml)
hydrocortisone (1 pg/ml)
O-phosphylanolamine (50 ng/ml)
tri 3,3',5, iodo-L-thyronine (26 ng/ml)
glutamine solution 1.0% (v/v)
penicillin/streptomycin solution 0.2% (v/v)
in RPMI 1640.
iii) RPMI media -0.2% (v/v) Penicillin/Streptomycin solution and 1%
(v/v) Glutamine solution in RPMI 1640.
iv) 0.5% (v/v) Foetal-Calf Serum (FCS) in RPMI media and 5% (v/v)
FCS in RPMI media.
v) Trypan Blue solution - 5% (w/v) of trypan blue (Direct blue 14 - dye
content 40% ) in distilled water.
vi) Freezing Medium - 10% (v/v) Dimethylsulphoxide (DMSO) in RPMI





2.3.1 Iodination of Mouse EGF (mEGF).
The iodogen method first described by Fraker and Speck (1978) was used to radiolabel
mEGF with 125i. Briefly, iodogen mixture (200pl) was placed in an eppendorf tube in
order to coat the inside of the vessel. The excess iodogen was then evaporated off by
placing the tube under a fine stream of nitrogen gas. A number of tubes were treated in this
way, then wrapped in foil and stored at -20°C for later use.
Mouse EGF [10pg in buffer B (lOOpl) ] was placed in the eppendorf tube
along withNa^I (5 pi, 18.5 GBq/mmol). The mixture was gently agitated and the
reaction allowed to proceed for at least 20 min. The solution was then purified on a
Sephadex G-50 column chromatogram (1 x 46 cm). The Sephadex was pre-soaked in
0.05 M PBS overnight prior to packing the column and once packed the column was
equilibrated with 0.1% (w/v) BSA in 0.05 M PBS immediately prior to iodination. 1 ml
fractions were collected over a 2-3 hour period every 2 min using a Pharmacia Fraction
Collector Frac 300 (Figure 11) and were counted in a Packard Crystal 2 Multidetector
Gamma System Model 5412, along with the radioactivity still bound to the reaction vessel,
the administering pipette tip and the column. The experiment was performed at room
temperature. The specific activity of the compound could then be calculated as
follows:-
2.3.2 Determination of the Specific Activity of 125j mEGF and the
Percentage of 125j Bound to mEGF.
The formula used in calculating the specific activity of the radiolabeled peptide was as
follows:-
The amount of radioactivity used to combine with 10pg mEGF was




Figure 11 - Chromatography labelled EGF.
Mouse EGF was radiolabeled with Na 125 I, using the iodogen
method described by Fraker and Speck (1978). Fractions of eluted
product from the G50 Sephadex packed column (1 x 46 cm) were
collected after an intitial run out period of 45 min, at 3 min intervals
over a 150 min period. Two peaks of radioactivity were eluted at
approximately fraction 18 (peak A) and fraction 25 (peak B).
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The actual amount of radioactivity used in the experiment was calculated by measuring the
radioactivity of:-
a) the reaction vessel = a
b) the pipette tip = b
c) the column = c
d) the eluted fractions = d [The radioactivity eluted from the column appeared in two peaks
A (dl) and B (d2)]
The total amount of radioactivity (e) used in this experiment was therefore a+b+c+d= e
Therefore the specific activity of Peak B which was shown by Maddy et al (1987) to
produce the optimum specific binding of mEGF to its receptor was
x M = V Bq/qg
e
It is necessary then to convert Bq to cpm (0.84 was the efficiency of the gamma counter
used and there are 60 dpm in 1 Bq), therefore,
S.A.= V x 60 x 0.84 =W cpm/[ig mEGF
Therefore in 200,000 cpm (lOOql) there must be 1 x 200,000 = Y qg of mEGF
W
200,000 cpm was shown by Maddy et al (1987) to produce sufficient specific binding for
counting.
The molarity of Peak B therefore = Y x 10,000 = Z nM MW ofmEGF = 6045
6045
The percentage of ligand bound was also measured using the TCA method described by
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Fraker and Speck (1978). Briefly, labelled mEGF (200,000 cpm in 100 |il buffer B) was
mixed with TCA [ 20% (w/v) in distilled water, 1 ml] in a test tube previously soaked in
0.1% (w/v) BSA in distilled water and spun down at 1,780 g for 20 min. This was
followed by aspiration of the supernatant. TCA [10% (w/v) in distilled water, 1 ml)] was
then added and the tube vortexed and spun at 1,780 g for 20 min before aspirating off the
supernatant and the remaining pellet counted in the Gamma counter. The percentage of
mEGF bound to was then calculated as described below
final cpm x 100 = approximately 50% (n=6)
200,000 cpm
In using the method described in section 2.3.1 for radiolabelling mEGF an adequate supply
of radioactive mEGF was never produced and consequently 125j rriEGF was purchased
from Amersham Ltd as well. Eventually it was decided to purchase all 125j mEGF from
Amersham with its specific activity pre-evaluated.
2.4 Characterisation of the EGF Receptor on Human Testicular
Tissue
2.4.1 Tissue Collection and Storage
Tissue was collected from theatre immediately after surgical removal from the patient. It
was transported to the laboratory on ice and washed in ice cold 0.9% saline (w/v) in
distilled water before being cut into 1 cm^ pieces. The tissue was then used in either
biochemical studies or in immunohistochemical assessment. In the former case the tissue
was either used fresh (within 30 mins of its arrival in the laboratory), or snap frozen in
liquid nitrogen and stored at -70°C until required. Two cross sections of the tissue were
always placed in formalin for obtaining a pathology report or on some occasions for
immunohistochemical studies. On obtaining the pathology report only tissues which did not
show gross atrophic changes or excessive inter-tubular fibrosis were used.
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2.4.2 Homogenisation of Human Testicular Tissue
The procedure adopted in this study was similar to that employed by Maddy et al (1987)
and was performed at 4°C to ensure minimum degradation of the receptor. Approximately
3-5 g of tissue was taken and finely chopped until it resembled a pulp. This was then
homogenised in buffer A (3 equal volumes) using a Ystral homogeniser (Scottish Scientific
Instruments Centre Ltd, Edinburgh, U.K.) for two periods of 20 sec and 15 sec at position
6 with a 2 min cooling interval. The crude homogenate was then filtered through a metal
strainer and the filtrate placed in a 10 ml capacity polycarbonate centrifuge tube (Sorvall,
Du Pont, Stevenage, U.K.). Ultracentrifugation was carried out at 105,000 g for 40 min
and the pellet obtained was resuspended in buffer A (3 equal volumes) and homogenised in
a glass dounce homogeniser using 15 strokes of a loose fitting pestle. A second
ultracentrifugation was then performed at 105,000 g for 20 min and the resultant pellet (the
particulate fraction) was resuspended in buffer B (2 vols) and homogenised using a tight
fitting pestle. The protein concentration of the particulate fraction was then either adjusted
to 2 mg/ml before freezing in liquid nitrogen and stored at -70°C or alternatively used
immediately and the protein concentration determined later. All preparations of particulate
fractions were treated in this way unless stated otherwise.
Note- In studies in which human testicular tissue was used experiments were performed in
duplicate, employing three tissue samples obtained from three different patients unless
otherwise stated.
2.4.3 Subcellular Fractionation
Subcellular fractions were prepared by the method described by Leake et al (1983) with
some modifications. The crude homogenate was prepared according to the method in
section 2.4.3 and then spun at 800 g for 20 min to obtain a crude heavy pellet. The
supernatant from this spin was then recentrifuged at 15,000 g to obtain the mitochondrial
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pellet. The resultant supernatant was then respun at 105,000 g to yield a microsomal pellet
and the final supernatant which corresponded to the cytosolic fraction. All pellet fractions
were subsequently reconstituted in buffer B and where necessary the protein concentration
adjusted to 1 mg/ml. The aliquots were then frozen in liquid nitrogen and stored at -70°C
for future use.
2.4.4 Protein Determination.
The protein concentration of the particulate fraction was measured by the Bradford (1979)
method. Concentrations of BSA over a range of 0.25-1.0 mg/ml in PBS (80pl) were
employed and mixed with Bradford Reagent (5 ml). The mixtures were first vortexed and
allowed to sit for 10 min before measuring their absorbance at 595 nM with a Pye Unicam
spectrophotometer (model 5P6-550) against a PBS blank. The absorbance of the particulate
fraction was measured at the same time in the same way except that prior to being added to
the Bradford reagent the particulate fraction was boiled for 5 min with an equal volume of
sodium hydroxide (2.0 M) in order to disrupt the proteins. A standard curve of absorbance
of the Bradford Reagent at 595 nm against the concentration of BSA was constructed
(Figure 12). The protein concentration of the particulate fraction was then estimated by
reading form the standard curve the concentration of protein which was equivalent to the
absorbance measured.
2.4.5 EGF Binding Studies Employing Human Testicular Tissue.
Initially a saturation study was performed to calculate the concentration of labelled mEGF
required to saturate the EGF binding sites on human testicular tissue. lOOjal aliquots of the
particulate fraction were incubated with equal volumes of labelled mEGF (100|il) of
concentrations ranging between 0.2-12.0 nM (3333-200,000 cpm) both in the presence and




A standard curve of absorbance at 595 nM wavelength against protein
concentration of BSA. Values represent mean data (n=3, ± SEM).
MATERIALS AND METHODS
buffer B (200 (il) was added. The mEGF radiolabeled ligand which was used varied in its
molarity (between 1.7 and 2.5 nM). Consequently, in order to achieve a higher molarity
(for example 12.0 nM which was the maximum concentration employed in this study),
unlabelled mEGF was added to the radiolabelled material. In doing this the specific activity
of the radiolabelled material was reduced by a factor related to the concentration of
unlabelled mEGF which was added. From this experiment the concentration of labelled
mEGF required to saturate the EGF binding sites was calculated to be 8 ± 0.76 nM.
All the gamma emitting radioactive samples which were employed in this
study were counted in the Gamma counter which was found to have 84 % efficiency. It
was therefore necessary to convert the level of cpms measured by the counter to dpms by
using the following equation.
Efficiency (%) = cpm x 100
dpm
2.4.6 Time and Temperature Studies
Binding of mEGF to testicular particulate fractions was performed by employing a
modified version of the methods first described by Carpenter and Cohen (1975), Sainsbury
et al (1985) and Mukku and Stancel (1985b).
Aliquots of the particulate fraction (100 pi) were incubated in BSA coated
tubes with equal volumes of labelled mEGF (8 nM, 200,000 cpm) both in the presence and
the absence of 50-fold excess unlabelled mEGF (200 pi). In the latter case buffer B
(200pl) was added to make up the desired volume of 400pl. It was also used for all other
dilutions.
Incubation of the particulate fraction was performed at 4°C, 25°C, 32°C
and 37°C and over a time range of 0-3 hours to assess respectively the optimum
temperature and incubation period for binding. The reaction was terminated by adding ice
cold PEG (20% w/v in distilled water, 1 ml), vortexing the solution and leaving it to stand
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for 10 min on ice before centrifuging at 1,780 g for 20 min. The supernatant was then
aspirated off and PEG [10% (w/v) in distilled water, 1 ml] added to each tube. Again the
mixture was vortexed and allowed to stand for 10 min before centrifuging at 1,780 g for
20 min. Finally the supernatant was aspirated off and the remaining pellet counted in a
Gamma Counter.
2.4.7 The Effect of Protein Concentration on EGF Binding
The effect of protein concentration on EGF binding was investigated by incubating the
particulate fraction (100 pi, at concentrations ranging from 0.5-8.0 mg/ml) with labelled
mEGF (100 pi) in the presence and the absence of unlabelled mEGF (200 pi) as detailed in
section 2.4.6 at 32°C.
2.4.8 Distribution of EGF Binding in Subcellular Fractions
Subcellular fractions were obtained as described in section 2.4.3. Each fraction was taken
out of storage and defrosted at 4°C . A ligand exchange assay as described in section 2.4.6
was then performed on a 100 pi aliquot of each fraction to assess the EGF binding.
2.4.9 Displacement Studies with Unlabelled mEGF
The competition between labelled mEGF and unlabelled mEGF for the EGF receptor site
on the particulate fraction was assessed. Unlabelled mEGF (200 pi) at concentrations
ranging from 10 to 400 nM was incubated with labelled mEGF (100 pi, 8 nM, 200,000




2.4.10 Saturation Analysis and Scatchard Plot
Saturation of the EGF binding site with labelled mEGF was performed by incubating the
particulate fraction (100 pi) with increasing concentrations of labelled mEGF from
1.0-10.0 nM(100 pi, 20,000 cpm - 200,000 cpm). Binding was carried out at 32°C for
40 min. Non-specific binding at each concentration of radiolabel was determined in the
presence of 50-fold excess unlabelled mEGF (200 pi). Total binding at each concentration
of labelled mEGF was determined in the presence of buffer B (200 pi). Binding was
carried out at 32°C for 40 min and the specific binding data analysed by a computer
programme (Munson and Rodbard, 1980) to yield the dissociation constant (Kd) and the
number of specific binding sites.
For the Rodbard and Munson (1980) computer programme the S.A. of the
radioactive ligand used had to be calculated in dpm/mole, therefore,
the specific activity A Bq/pg = A x 60 dpm/ pg
Number of moles in 1 pg mEGF = 1 x 10'^g = 1.65 x 10"^ moles
6045
Therefore dpm/mole mEGF = A x 60
1.65 x 10"10
If unlabelled mEGF is added to Amersham 125 j EGF to achieve a certain molarity, the
S.A. of the radioligand will be reduced as previously discussed in section 2.3.2.
The application of Rodbard and Munsons computer programme 'Ligand' is discussed in
more detail in section 2.20.2.
2.4.11 Competition Studies
The specificity of the receptor for EGF was examined in the presence^the following
competitors: rTGF-a, hIGF-I, bFGF, vNGF, hi ,hPrl, hLH and hFSH at a concentration
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50-fold in excess of the 125i mEGF employed. The methodology of the radioligand
exchange assay in section 2.4.6 was used substituting the aforementioned peptides for
unlabelled mEGF.
2.4.12 Effect of pH on Specific EGF Binding
Buffer B was used at a pH of 7.4 to reconstitute the particulate fraction as well as for
diluting all the other ingredients used in the ligand exchange assay. In order to study the
effect of pH on the specific binding of radiolabeled mEGF to the particulate fraction, the
pH of buffer B was varied over the range 6.8-8.0 and the ligand exchange assay described
in section 2.4.6 performed on three different particulate fractions at 32°C for 40 min.
2.4.13 Effect of Heat and Trypsinisation on Specific EGF Binding
Particulate fraction preparations were either preheated at 4°C, 45°C, 60°C and 80°C for
15 min or preincubated with and without 0.05% (w/v) trypsin in buffer B for 30 min at
32°C, prior to use in the ligand exchange assay. In the case of treatment with trypsin the
particulate fraction mixture had to be washed once in buffer B (1 ml) to remove the excess
trypsin and then spun down at 1,780 g before aspirating off the supernatant. The resultant
pellet was then reconstituted in buffer B to form a homogenate and the protein
concentration adjusted to lmg/ml before being used in a radioligand exchange assay as
described in section 2.4.6.
2.4.14 Effect of Storage at -70°C on Specific EGF Binding
The possible effect of storage at -70°C on EGF binding in tissue and in the particulate
fraction was investigated. The specific binding of EGF on 3 different samples obtained
from three different tissues was assessed when they were fresh and then at various
intervals of storage at -70°C by homogenising them and performing a ligand exchange
assay on the resultant particulate fractions. The time of storage of the tissue prior to
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homogenisation varied between 0 and 6 months. The effect of storage at -70°C on the
particulate fraction was also investigated over a two week period by similarly performing a
radioligand exchange assay on aliquots of the particulate fraction to measure the specific
binding of EGF.
2.5 Molecular Characterisation of the EGF Receptor: Affinity
Labelling and Crosslinking of the EGF Receptor followed by
Electrophoresis (SDS-PAGE) and Autoradiography.
Particulate fraction preparations containing 4-6 mg protein/ml were incubated with labelled
mEGF (100 pi, 8 nM, 200,000 cpm) at 32°C for 40 min both in the presence and absence
of unlabelled mEGF (200 pi, 400 nM). At the end of the incubation each mixture was spun
down at 1,780 g for 10 min and the supernatant aspirated off. Disuccinimidyl sulphate
(DSS; Sigma; 20 mM, 100 pi) in 5% DMSO (v/v) in distilled water was added to each
pellet. The subsequent mixtures were then vortexed and allowed to stand for 20 min at
room temperature before the sample buffer (100 pi) was added.The suspensions were then
boiled for 5 min and spun down at 500 g for 5 min at 25°C . This enabled dissolution of
the receptor and facilitated the removal of undissolved complexes. The resultant
supernatants were then taken up with a Hamilton syringe and loaded onto a 7.5% SDS
polyacrylamide gel (0.75 mm thickness, 16 x 16 cm area) as well as a solution of standard
molecular weights (SDS-6 mix; Amersham) which prior to loading onto the gel had been
heated at 32°C for 3 hours. In total three different samples were typically employed for
each electrophoretic run, each sample having been incubated in the presence and in the
absence of unlabelled mEGF as described above. The gel was then allowed to run at 30 mA
for 8 hours in a Bio Rad Protean II cell electrophoresis chamber while being
simultaneously cooled. The gel was subsequently stained for 20 min with a "staining
solution" containing Brilliant Blue and then washed with a "destaining solution" over a
period of 15 hours.
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The gel was finally rinsed in distilled water and dried on a Bio-Rad model
443 slab dryer connected to a IEC Lyoprep-3000 Freeze Drier. Autoradiography was
performed at -70°C for 3-4 weeks by placing the dried gel in a cassette with 2 intensifying
screens and a hyperfilm TM (Amersham). The hyperfilm was developed in Kodak
Developer LX-24 (1:5.6 dilution in distilled water) and fixed in Kodak X-ray liquid fixer
FX40 (1:5 dilution in distilled water).
2.6 Immunohistochemical Localisation of the EGF Receptor on
Human Testicular Tissue
Immunohistochemistry was performed on both frozen and paraffin embedded sections,
employing monoclonal antibodies to both the external (EGF-R1: frozen; EGF-R:paraffin)
and the internal domains (F4:frozen/paraffin) of the EGF receptor, to ascertain on which
cells within the testes the EGF receptor was being expressed and whether such receptors
expressed both the internal and external domains.
i) Frozen Sections
Frozen sections were cut on a cryostat to a thickness of 5 microns and placed on a lysine
coated slide (0.1% poly-L-lysine hydrobromide, m.w. 150-300 kDa, Sigma). The sections
were allowed to air dry for 10 min before being fixed in acetone for 20 min. After fixation
the sections were used immediately or stored at -20°C. If they were to be used after storage
at -20°C then the sections were allowed to reach room temperature prior to use. This
avoided moisture penetrating beneath the section which in turn would later cause loss of the
section during the washing procedure. Sections were first circled with a wax pen to reduce
the amount of antibody required. They were then treated with an avidin blocking reagent
for 20 min, followed by a biotin blocking reagent for 20 min, after which the slides were
washed twice in Tris Buffered Saline (TBS) for 5 min. The appropriate monoclonal
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antibody was then applied at varying concentrations to assess the optimum staining. In the
case of the EGF-R1 monoclonal antibody, this was used at dilutions between 1:100 and
1:10 (v/v) in TBS. The F4 antibody was employed at dilutions between 1:8 and 1:3 (v/v)
in TBS. It was noted from the titration experiments that the optimum EGF-R1 antibody
dilution was 1 in 30 and that the optimum F4 antibody dilution was 1 in 5. The slides were
incubated overnight in the monoclonal antibody solution at 4°C. The following day
sections were washed twice for 5 min in TBS and then treated with the biotinylated sheep
anti-mouse immunoglobulins (1 in 200 v/v in TBS) for 30 min. The sections were washed
once more and a streptavidin alkaline phosphatase substrate applied for 20 min. Figure 13
illustrates the step by step method previously sited. Finally the sections were washed in
distilled water (1 min) and counterstained in haematoxylin and lithium carbonate and
mounted in glycerine jelly. Photographs were taken of the slides within 3 months as the
staining was found to fade over time.
ii) Paraffin Embedded Sections
A portion of the same tissue used in the frozen section study was also stored in formalin.
By means of a multiple step procedure it was converted to a waxed paraffin block as
detailed below.
The tissue was first trimmed to approximately 1.0 x 0.5 x 0.3 cm and
placed in a Tissue TEK cassette. It was then processed overnight according to the
following procedure in a Miles Scientific Tissue TEK VIP :-
a) 210 min in 40% formalin at 40°C.
b) 50 min in 70% industrial methylated spirits at 40°C.
c) 50 min in 80% industrial methylated spirits at 40°C.
d) 50 min in 90% industrial methylated spirits at 40°C.
e) 50 min in 95% industrial methylated spirits at 40°C.
f) 120 min in absolute alcohol at 40°C.
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g) 120 min in xylene at 40°C.
h) 180 min in paraffin wax at 60°C.
Finally the processed specimen was placed in a steel embedding plate and covered in wax
using a Tissue TEK 111 embedding wax machine before being placed on a cold plate to
solidify.
Sections were then cut from the paraffin waxed block at a thickness of 3
microns using a Leitz 1512 Rotary Microtone and allowed to dry at 37°C for at least 3
hours. The sections were then dewaxed by placing them for two, 2 min periods in xylene
followed by two washes in absolute alcohol and one in methanol. The sections were then
washed in distilled water and trypsinised in a 50 ml solution of 0.01 M Tris HC1 containing
1.8 x 106 ATEE units of trypsin and 9 mM calcium chloride at pH 7.6 for 10 min at 37°C.
The staining procedure described above and in Figure 13 was repeated with the exception
that the monoclonal antibody for the external domain of the receptor EGF-R was used at the
recommended dilution of 1:10 of the stock solution.
For each staining experiment a "negative" control section was included in
which the primary antibody was omitted. A "positive" control employing human prostate
tissue was also examined. As well as looking at EGF receptor expression on "normal"
testicular tissue received from patients who had undergone orchiectomy as first line of
for prostatic cancer,
treatment^ tissue from men who had undergone hormonal treatment as first line therapy
followed by orchiectomy as second line therapy, were also examined . Sections of
testicular
cancerousj^tissue were also looked at to see if they expressed the EGF receptor. Foetal
tissue from between 15 and 19 weeks gestation was also examined as well as biopsy
samples from men who were undergoing an operation for the reversal of vasectomy. In the
latter case the ages of the two patients from which the tissues were obtained, were 30 and
34 years respectively.
At least one section from each of the aforementioned samples was taken for
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Diagrammatic representation of the final immunohistochemical EGF
receptor streptavidin-biotin complex. The streptavidin alkaline
phosphatase substrate binds to the fast red chromagen (A) to produce
the final red staining and subsequently identification of the EGF
receptor.
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histological assessment. The section was stained with Muller's haematoxylin and Putt's
eosin for pathological evaluation.
2.7 Determination of Intratesticular EGF Concentrations.
2.7.1 Titration of the Antibody for Human EGF (hEGF)
Titration of the rabbit anti urogastrone antibody to be used in the EGF radioimmunoassay
(RIA) was performed. Dilutions of 1:500 to 1:100,000 were first employed using a
standard concentration of hEGF of 7 ng/ml (Figure 14a). Following this a second, more
accurate titration experiment over the concentration range 1:1,000 to 1:40,000 of the
antibody was performed employing four different concentrations of hEGF in the range
0.04-20 ng/ml. Titration of the rabbit anti human EGF antibody demonstrated an optimum
dilution of 1/10,000 (v/v) in RIA buffer of the stock solution (Figures 14b,c and d).
2.7.2 Construction of the Human EGF RIA Curve
The method of Bynny et al (1972) was modified in developing the EGF RIA. All test
tubes used in this procedure were presoaked in 0.1% BSA (w/v) in distilled water and
dried to prevent non-specific binding. To the tubes was added human EGF (Urogastrone,
100 pi) at concentrations ranging from 0.04 to 20.0 ng/ml. Human EGF antibody (100
pi at a 1:10,000 dilution) and radiolabelled ^5j human EGF (100 pi, 50,000 cpm, S.A.
49 TBq/mmol, Amersham) were also added and the tubes vortexed and left for 2 hours at
37°C in a Teram (S13.4) shaking bath at 40 rotations per minute. A second antibody was
then added [donkey anti-rabbit antiserum, 250 pi at a 1:20 (v/v) dilution in a 1:200 (v/v)
fdilutionpormal rabbit serum in RIA buffer] to each tube and the tubes vortexed before
being stored overnight at 4°C . Finally, distilled water (500 pi) was added to each tube and
the contents vortexed and then spun at 1,800 g for 30 min.The supernatant in each tube
was then removed by aspiration and the residual pellet counted in a Gamma Counter. Each
concentration of urogastrone or unknown sample was run in duplicate or triplicate in order
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Figure 14
Titration of the antibody for hEGF was performed over the dilution
range 1:500 to 1:100,000 employing a standard concentration of 7 ng/ml
human EGF (a). The percentage of radioactivity bound in the presence
of hEGF (B) in comparison to the radioactivity bound in the absence of
hEGF (Bo) is plotted according to the dilution of antibody employed.
Titration of the antibody for human EGF was further clarified by
measuring %B/Bo at concentrations of hEGF from between 0.1 and
20 ng/ml employing dilutions of antibody from between 1:1,000 to
1:40,000 [ (b)l: 1,000; (c) 1:10,000; (d) 1:40,000). Values represent

























































to calculate a mean value. Two control tubes were also set up: Control 1 contained
radioactivity (100 |ll), 1° Ab (100 |ll), 2° Ab (250 |ll) and RIA buffer (100 |ll) and was
used to measure the radioactivity bound in the absence of hEGF (Bo). Control 2 contained
radioactivity (100 p.1) and RIA buffer (450 |il) and was used to measure the non-specific
binding of the radioactivity to the tube (NSB).
The hEGF RIA curve was set up to detect concentrations of hEGF over a
range of approximately 0.1 to 10 ng/ml. The inter assay coefficient was calculated to be
4.8% and the intra assay coefficient calculated to be 14.1%. The precision ( % error) of the
assay was consistently less than 10% for the linear portion of the RIA curve . The RIA
was specific for hEGF as no cross reaction was apparent with either rTGF-a or mEGF.
The sensitivity of the assay (90% B/Bo) was approximately 0.12 ng/ml and the IC50 value
(achievement of halfmaximal stimulation) approximately 0.9 ng/ml. The standard EGF
RIA curve was constructed by plotting %B/Bo against the concentration of hEGF
employed to achieve the radioactivity measured (B) (Figure 15). Test samples were then
assayed in exactly the same way by substituting 100 pi of the test sample with 100 pi of the
standard concentration of hEGF. The concentration of hEGF required to achieve the level
of radioactivity measured in the tube was then read from the standard curve.
2.7.3 Sample Preparation
The preparation of the sample was performed at 4°C. Tissue (approximately 6 g) was
washed in sodium chloride (0.15 M, 5 ml) and blotted dry. It was then chopped to a pulp
and 5 g weighed out into a large test tube. TEP buffer (3 vols) was added to the tube along
with 1,000 cpm of labelled mEGF (100 fil in TEP buffer) to assess recoveries and the
mixture vortexed for five 10 second periods. Recoveries were calculated following
extraction by measuring the remaining radioactivity in the final extract and reporting it as a
percentage of the initial amount added. The mixture was then homogenised by performing
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Figure 15
Standard curve for hEGF radioimmunoassay set up to detect
concentrations of hEGF over the range 0.1 to 10.0 ng/ml.
Points represent mean %B/Bo (± SEM, n=3).
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four 15 sec bursts at speed 7 with a Ystral Homogeniser. Cooling periods of 2 min were
allowed between each burst. The suspension was then placed in 2 polycarbonate centrifuge
tubes and subjected to ultracentrifugation at 77,000 g for 30 min at 4°C. The resulting
supernatant was decanted and kept at 4°C, while the pellet was resuspended once more in
TEP buffer (1 vol) using a dounce homogeniser with a tight pestle (15 strokes). The
suspension thus obtained was then respun for 30 min at 77,000 g. Finally the supernatant
was decanted off and combined with the previous one and the pooled supernatants counted
in the gamma counter to calculate procedural losses. The solution was then frozen and
lyophi lised and finally reconstituted in RIA buffer (600 |il ), for use in the RIA.
2.7.4 The Effect of Digestion and Sonication on the Release of EGF
from Human Testicular Tissue .
A digestion study was performed using three tissue samples. Following the
homogenisation procedure described in section 2.7.3 the crude homogenates were
incubated overnight with an equal volume of "digestion buffer" (section 2.25)and the
following day spun down as described in section 2.7.3. For the sonication study, each of
the three crude tissue homogenates were separated into five 1 ml samples and sonicated for
either 0, 5, 10, 15 or 20 min using an A180G Sonicator (Ultrasonics Ltd, Manchester,
U.K.) at a tuning level of 5 with the power also set at 5. The samples were then assayed
for hEGF employing the RIA described in section 2.72.
Digestion or sonication of the tissue was shown to be unnecessary. Figures
16a and 16b illustrate that no further liberation of hEGF from the three tissues examined
was apparent after a sonication period of between 5 and 20 min or after a digestion period
of up to 24 hours. Hence neither sonication or digestion procedures were included in the
preparation of the RIA sample.
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Figure 16
a) The mean concentration of EGF liberated from human testicular tissue
(n=3, ± SEM) plotted against the time (minutes) which the tissue was
sonicated for during preparation of the sample.
The dashed line indicates the mean concentration of EGF (n=3) detected in human
testicular tissue without the samples having undergone sonication (ie. as indicated at
time zero).
b) The mean concentration of EGF liberated from human testicular tissue
(n=3, ± SEM) plotted against the time (hours) which the tissue was
digested for during preparation of the sample.
The dashed line indicates the mean concentration of EGF (n=3) detected in human
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2.8 Determination of Intratesticular TGF-a Concentrations.
A radioimmunoassay kit for rTGF-a (Peninsula Laboratories) was used to detect and
measure the presence of hTGF-a in human testicular tissues. The testicular samples were
prepared as for the EGF RIA and as described in section 2.7.3. Because the antibody for
rTGF-a cross reacts 32% with the hTGF-a (pers. commun. Moores, Peninsula
Laboratories) this homology was used to calculate the amount of hTGF-a present in the
tissue by first measuring TGF-a immunoreactivity present in the tissue and then
multiplying the value by 3.3 (see section 2.2.6).
The antiserum to the rat TGF-a in the RIA kit was raised in rabbits and
recognises both rat (100$) and human TGF-a (32%). Ascending rat TGF-a standards
(100 pi, ranging from 10 and 1280 pg/100 pi) were placed in BSA coated tubes along with
rat TGF-a primary antibody (100 pi). The contents of the tubes were vortexed, incubated
overnight at 4°C, then lOOpl aliquots of rat 125j TGF-a (20,000 cpm, S.A. 35.8
MBq/mmol) were added and the vortexing/incubating procedure repeated once more. Two
secondary antibodies [goat anti-rabbit IgG serum (100 pi) and normal rabbit serum
(100 pi)] were then added to each tube, the tubes vortexed and the reaction allowed to
proceed at room temperature for a further 2 hours before the addition of RIA buffer (0.5
ml). Finally the tubes were spun down at 1,780 g for 20 min. The supernatants were then
aspirated off and the pellets counted in a Gamma Counter. Two controls were run; Control
1 which contained radioactivity (100 pi), 1° antibody (100 pi), 2° antibody (100 pi) and
RIA buffer (600 pi) (Bo); control 2 which contained radioactivity (100 pi) and RIA buffer
(800 pi). The %B/Bo was then plotted against the concentration of rTGF-a employed to
achieve the measured radioactivity(B) to construct the standard RIA curve (Figure 17). The





Standard curve for rTGF-a radioimmunoassay set up to detect
concentrations of rTGF-a between approximately 20 and 300 pg/100(il.
Points represent mean %B/Bo (± SEM, n=3).
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2.9 Determination of Intratesticular Steroid Concentrations
2.9.1 Determination of the Quench Curve
Tritiated androgens were employed in the androgen RIAs. In order to convert the tritiated
cpm to dpm a quench curve for the Packard Tri-Carb Liquid Scintillation Spectrometer
(Model 3255) was evaluated. All tritium labelled radioactivity was measured in a Packard
Tri-Carb Liquid Scintillation Counter by placing the radioactive solution (<500 (il) in a vial
with 6 ml of scintillation fluid within the counter which in turn was set to the "adjustable"
channel. ("Adjustable" indicating that both tritium and carbon radioactive isotopes could be
measured on the same channel). The external standard ratio at each measurement was
calculated at the same time as the radioactivity in cpms and plotted accordingly (Figure 18).
The appropriate level of efficiency was then read from Figure 18 according to the external
standard ratio which was measured and the dpms calculated accordingly. The efficiency of
the machine was on average approximately 25% as the external standard ratio usually
ranged between 0.5 and 0.6. For example a typical reading of 4,000 cpm would perhaps
have an external standard ratio value of 0.6. According to Figure 18 such a value indicates
that the tritium counter is working at 25% efficiency. Consequently the 4,000 cpm
measured is equivalent to 16,000 dpm.
2.9.2 Titration of the Polyclonal Antibodies
Titration of the androstenedione and DHT antibodies for the appropriate steroid RIAs had
previously been determined by Mr C. Goodman in these laboratories. However the
appropriate titre of the testosterone antibody had not been determined. Briefly RIAs
employing antibody dilutions of 1:5,000, 1:10,000 and 1:15,000 were performed
employing concentrations of testosterone over the concentration range 7.8-500 pg/100 (il
(Figure 19). A dilution of 1:10,000 was found to provide the optimum RIA curve and




The relationship between the efficiency of the Hewlett Packard
Tri-Carb counter (percentage) and the external standard ratio was
plotted. This relationship was then used to calculate dpm from cpm
for tritium labelled compounds.




Titration of the antibody for testosterone was performed at three
different dilutions of 1:5,000 (□), 1:10,000 (♦) and 1:15,000 (■)
using testosterone concentrations over the range 7 to 500 pg/100pl.
Values represent mean %B/Bo (± SEM, n=3) plotted against the
concentration of testosterone employed.
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2.9.3 Steroid Radioimmunoassays.
The RIA for assessment of steroids in human testicular was adopted from Abraham (1974)
and Habib et al (1976). All the test tubes used in the RIA were coated in 0.1% BSA (w/v)
in PBS-Gel to prevent binding of radioactivity to the tubes. A series of standards, varying
in concentration from 7.8 to 500 pg/100 (ll were then made by serially diluting a standard
solution of non-radioactive steroid (100 jil, 17.48 nM) with RIA buffer (100 (il) at 4°C .
After the addition of each freshly made standard to the required number of tubes (each run
in at least duplicate), the antiserum was added (100 |il). Androstenedione antiserum was
used at 1:10,000 dilution, DHT at 1:15,000 and testosterone at 1:10,000. The appropriate
radioactive steroid (100 (il, 10,000 cpm) was then added to each of the tubes, the tubes
vortexed and subsequently placed in a Teram S13.4 shaking water bath set at 40
revolutions per min and at a temperature of 37°C for 1 hour. Two control tubes were also
used: Control tube 1 which contained radioactivity (100 ji.1), antibody (100 (il) and PBS-
Gel buffer (100 (il) to measure the radioactivity bound in the absence of steroid (Bo);
Control tube 2 which contained radioactivity (100 (il) and PBS-Gel buffer (200 |il) to
measure non-specific binding of the radioactivity to the tube. The tubes were then removed
and placed on ice for 10 min. Dextran coated charcoal (500 |il) was then added to each
tube, the tubes vortexed and once more left on ice for 10 min. Finally the tubes were
centrifuged at 1,800 g for 15 min and 500 |il of each supernatant was carefully pipetted into
a plastic vial for counting. The count was then multiplied by 8/5 as only 500 p.1 of the 800
|il present in the tube had been removed for counting. It was then further modified by
converting the cpms to dpms according to the tritium quench curve (Figure 18)
and /B/feo plotted against the concentration of the appropriate steroid employed.
The standard RIA curves for androstenedione, DHT and testosterone are
shown in Figures 20 a,b and c . The RIA curves were constructed to detect steroid
concentrations in the range 30 to 500 pg/100 (il. All values represent the radioactivity
bound (Xb/Bo) for each standard concentration of steroid assayed. All measurements
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Figure 20
Standard curves were set up for RIA of; (a) androstenedione, (b) DHT
and (c) testosterone. The curves were constructed to detect
concentrations of the appropriate steroid over the approximate
concentration range 30 to 500 pg/100[il. The antibody for androstenedione
was employed at a dilution of 1:10,000, DHT at 1:15,000 and testosterone
at 1:10,000. All values are represented as the %B/Bo (mean ± SEM n=3)

























were performed in triplicate or on occasions duplicate. Table 1 illustrates the inter assay and
intra assay coefficients for each assay. As illustrated the IC50 for testosterone was
approximately 170 pg/100 (il, for DHT110 pg/100 (il and for androstenedione
175 pg/100 (il.
2.9.4 Sample Preparation.
Wet tissue (0.5 g) was chopped to a pulp then lyopholised in a IEC Lyoprep-3000 Freeze
Drier overnight and reweighed. Of this dry tissue approximately 0.05 g was placed in a
quickfit tube with Tris buffer (1.5 ml, 0.5 M) and the tissue redispersed by vortexing for
3x5 min periods. In order to assess procedural losses 1000 cpm of each radioactive
steroid in Tris buffer (100 (il) was added to the quick fit tube which was then vortexed at
half hourly intervals during the 1 hour equilibration period to aid equilibration with binding
proteins. At the final stage of the preparation the radioactivity present in the extract would
then be assessed and expressed as a percentage of the amount originally added. 1000 cpm
of radioactive steroid contained negligible amounts of androstenedione, DHT and
testosterone (approximately 10"^ grammes of each androgen) and therefore this was not
thought to hinder the measurement of the actual steroid concentration.
Diethylether (3 ml) was subsequently added to the quick fit tube, the tube
vortexed, allowed to stand for 10 min and then centrifuged for 10 min at 1,800 g. The ether
phase was then carefully pipetted off and placed in a glass tube. This was repeated once
more and the ether combined to give a final volume of 6 ml. The ether was then evaporated
off in a vacuum oven at 37°C at a vacuum of 36 in.Hg (Towson and Mercer Ltd, Leeds,
U.K.) for approximately 1 hour. The remaining steroids in the glass tube were then
reconstituted in ethanol (50 |il). This was then spotted onto thin layered chromatography
















Inter and intra assay coefficients for androstenedione, DHT and testosterone
radioimmunoassays.
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2.9.5 Instant Thin Layer Chromatography.
Using this chromatographic technique the different steroids were separated according to
their relative mobilities (Rf).
Rf = distance moved by substance
distance moved by solvent
Rf values of 0.52, 0.69 and 0.76 were found for testosterone, DHT and androstenedione
respectively when running with 9:1 dichloromethane:diethylether (v/v). 70 ml of the
solution was used in a 8 x 25 x 25 cm glass chamber. The positions of the sample steroids
were noted by running a standard solution containing 1,000 cpm of tritiated
androstenedione, DHT and testosterone in a final volume of 100 |il on the left and right
hand sides of the instant thin layer chromatographic polysitic acid gel impregnated glass
fibre plate (ITLC plate) ( 20 x 20 cm ) [Gelman Science, Michigan, U.S] on which the test
samples were being run. In this way small sections of the migration path taken by the
standards solution could be cut and counted in order to assess the position of the steroids.
All samples were applied to the plate using micropipettes (Drummond Science, US). Once
the relevant positions on the ITLC plate were located the areas corresponding to the
unknown samples were cut and placed in 100% pure ethanol (2 ml) for extraction of the
steroids. The extraction was repeated and the pooled ethanol placed in glass tubes and dried
down. The extracted and separated steroids were reconstituted in PBS-Gel buffer (400|il)
and 200|il aliquots were removed from each tube to assess recovery . The remainder was
used for the measurement of the steroid concentrations by radioimmunoassay.
2.10 Testicular Cell Culture
The testicular teratoma cell line, Tera- 2 (clone 13, passage 13) was cultured after having
been kindly donated by Professor Graham, Department Zoology, University of Oxford.
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The cell line was originally established in 1971 by Dr Jorgen Fogh (Fogh and Trempe,
1975) and was set up from a lung metastasis of a primary testicular embryonal carcinoma.
The undifferentiated cells are small round carcinomoid cells which appear larger and flatter
(resembling epithelial cells) at low density and have the potential to differentiate into large
flat cells and neurons (Plate 1).
The epithelial cell line A431 was also cultured as its cells have also been
shown to express the EGF receptor (Gregoriou and Rees, 1984). The resultant cells were
then subsequently used as positive controls for the various Tera-2 cell experiments which
were performed.
The cell types present in teratoma tumours vary greatly. Frequently the
tumours contain embryonic carcinoma, seminoma and cells resembling those found in
extra-embryonic foetal tissues, such as placental trophoblast and yolk sack. Occurring with
lower frequency are groups of cells resembling embryonic and adult tissues, such as
muscle, cartilage and nerve (Mostofi and Price, 1973; Pugh, 1976). Cells supplied for the
purpose of this study arrived having been cultured in 10% foetal calf serum (FCS) Alpha
medium. The cell medium was subsequently changed on arrival to 10% FCS RPMI
medium as this was the standard medium used in these laboratories. They were then
weaned gradually through 5% and 0.5% FCS serum-free medium (SFM) to grow finally in
SFM (15 ml) in a 75 ml flask (Gibco) at 37°C in an atmosphere of 5% CO2/ 95% air in a
KEBO Assab AB incubator (Sweden). The defined serum-free medium was adopted from
Mac Donald et al (1990) who had previously developed it from Barnes and Sato (1980).
Each confluent flask contained approximately 5x10^ cells which were divided into four
subsequent to passaging. The doubling time for Tera-2 cells was found to be approximately
48 hours in 10% FCS RPMI media and approximately 96 hours in SFM. On repetition of
the process of changing from FCS conditions to SFM conditions it was discovered that the
5% FCS RPMI media stage could be omitted.
All medium was tested for bacterial contamination. This was performed by
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Plate 1 The Tera- 2 cells were grown in 15ml of 0.5% SFM in 75ml flasks
until confluent before being passaged.
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incubating 2 ml of sterile nutrient broth with 2 ml of the test medium for up to 4 weeks in a
humidified atmosphere of 5% CC>2/ 95% air.
2.10.1 Harvesting of Cells.
Detachment of the cells from the 75 ml flasks was achieved by trypsinisation. The medium
was decanted and the cells washed with sterile Dulbeccos solution (5 ml) for 10 seconds,
the solution decanted once more and trypsin/EDTA (5 ml) added for 10 seconds. This was
subsequently discarded and the residual cells incubated at 37°C for 5 min under an
atmosphere of 5% CO2/ 95% air or until they could be seen to have become detached. The
cells were then taken up in the appropriate volume of medium and used as required. When
the cells were approximately 95% confluent they were split and passaged to facilitate cell
growth. If necessary the cells were washed in Dulbeccos solution (5 ml) to remove dead
cells once they had become reattached after passaging.
2.10.2 Freezing of Cells
Following detachment, the cells were taken up in 10% FCS RPMI media (10 ml) and the
resulting suspension placed in a sterile universal, centrifuged at 800 g for 5 min and the
supernatant decanted off. The cells were then reconstituted in "freezing medium" (0.5 ml)
and transferred to a 1 ml eppendorf tube which was gradually frozen by placing it in a -
70°C freezer overnight before being transferred to a liquid nitrogen storage vessel the
following day.
2.10.3 Setting-Up Cell Culture from Frozen Cells
The cells were thawed from liquid nitrogen by placing the eppendorf tube in a water bath at
37°C for 5 min. They were then reconstituted in 10% FCS RPMI media (10 ml) and placed
in a universal for centrifugation at 800 g for 5 min. The supernatant was decanted off and
the cells reconstituted once more in 10% FCS RPMI media (15 ml) and transferred to a
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75 ml flask. The flask was then placed in an incubator at 37°C in an atmosphere of
5% C02/95% air.
2.10.4 Counting of Viable Cells.
The cells were stained with trypan blue and counted using a haemocytometer. In brief the
cells were harvested as described in section 2.10.1 and reconstituted in an appropriate
volume of SFM. 100 |il of the cell suspension was then diluted with an equal volume of
0.5% (w/v) trypan blue in 0.9% (w/v) saline in distilled water. 100 [ll of the resultant
suspension was then pipetted onto a haemocytometer chamber where it was then taken up
by capillary action into the haemocytometer chamber. The cells were then viewed through a
microscope and the number of cells within each of the four large squares labelled A counted
(Figure 21). The number of cells present per ml ofmedium was then determined according
to the following calculation shown. The cells which appeared clear under the microscope
while in trypan blue solution were interpreted as viable cells whereas those that appeared
blue were assumed dead.
2.10.5 Attachment of Cells
The cells were plated in 24 well plates for all ligand exchange assays and thymidine
incorporation experiments. Initially 2x10^ cells per well were plated down which gave
approximately 85% attachment. Although this was found to be adequate for the ligand
binding assay the cells reached confluency after 24 hours. This was detrimental to the
thymidine incorporation experiments as cell growth was found to be inhibited.
Consequently cells were plated at 0.5 x 10^ and 1 x 10^ cells per well to assess percentage
attachment. 0.5 x 10^ cells were found to provide approximately 30% attachment of the




The number of viable Tera-2 cells was calculated using the equation
and the diagram below which represents the lay out of the
haemocytometer chamber employed.
Calculation of Cell Count
Total aOfVmn = actual count x reciprocal of dilution x correction factor
4
= actual count x 2 x correction factor
4
(The actual count is the number of cells counted in A, B, C and D.
Using the chamber outlined below the correction factor was calculated to
be 1 x 104
This is derived from:
Area of each square = 1 mm-
Area x depth of chamber = lmm^x 0.1 mm = 0.1 mm^
1000mnr= 1 ml
therefore 0.1 = 1 x 10~4







2.11 Characterisation of the EGF Receptor on Tera-2 Cells
2.11.1 Mouse EGF Ligand Exchange Assay for Cultured Cells
The EGF ligand exchange assay was performed according to the method developed by
Engstrom et al (1985) performed at room temperature with some modifications. In brief
2 x 105 cells in 0.5% FCS SFM (1 ml) were plated down in each well of 24 well plates.
After being left overnight (approximately 16 hours) the cells were washed twice with
Dulbeccos solution (1 ml). Labelled mEGF (1.0 nM, 200,000 cpm) in 300 pi RPMI, was
then added to each well and incubated in the presence and absence of unlabelled mEGF
(100 nM) in 200 pi RPMI. RPMI (200 pi) was added in the absence of mEGF to bring the
final volume to 0.5 ml in each well. The cells were then incubated for 90 min at room
temperature with intermittent shaking and the reaction terminated by aspirating off the
medium and then washing twice with Dulbeccos solution. The cells were subsequently
trypsinised by the addition of Trypsin/EDTA (1 ml) over 5 min and the resultant
suspension transferred to a tube and counted in a gamma counter. Non specific binding to
the cell culture tray was also measured in each assay by incubating 200,000 cpm in 500 pi
RPMI in the absence of any cells.
2.11.2 Displacement Studies with Unlabelled mEGF in Cultured
Cells.
In order to assess the concentration of unlabelled mEGF required to give the maximum
specific binding, Tera-2 cells were plated down in 24 well plates at a density of 2 x 10^
cells/ml as described in section 2.10.5. The cells were subsequently incubated with labelled
mEGF (1.0 nM, 200,000 cpm) in 300 pi RPMI, in the presence and absence of increasing
concentrations of unlabelled mEGF ( ranging from 0.1 nM to 300 nM) in 200 pi RPMI.
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2.11.3 Saturation Analysis and Scatchard Plot.
Cells were plated down in 24 well plates at a concentration of 2 x 10^ cells per well in
0.5% FCS SFM for 16 hours. The cells were then washed in Dulbeccos solution and
incubated with increasing concentrations of labelled mEGF ( ranging from 1.0-10.0 nM,
with between 2x10^ and 2 x 10^ cpm) in 300 |il RPMI, in the presence and in the absence
of 100-fold excess unlabelled mEGF (200 jil) as described in section 2.11.1. Four wells
were also run in parallel at the lowest concentration for determination of cell number at the
end of the experiment. The non-specific binding, the total count and the amount of
radioactivity added were measured at each concentration and the specific binding data then
analysed by a computer programme (Munson and Rodbard, 1980) to yield the dissociation
constant (Kd) and the number of specific binding sites.
2.12 Western Blot Analysis
Tera-2 and A431 cells were plated in separate 15 cm diameter petri dishes at a density of
1 x 10? cells per dish and cultured in SFM for 48 hours. Two petri dishes of Tera-2 cells
were cultured and treated as follows, in order to increase the possibility ofEGF receptor
identification. The cells were first washed in sterile Dulbeccos solution (5 ml) and then
scraped off into a small test tube with "lysis buffer" (2 ml for the A431 cells and 1 ml for
each dish of the Tera-2 cells). The lysis buffer produced disruption of the cell structure and
eventual solub i lisation of the receptors. The resultant cell suspensions were spun down at
1,800 g for 10 min and 100 |il of the supernatants boiled for 5 min with sample buffer
(100 |il). 200 |il of the solubi lised receptors were then loaded onto a Laemmli gel, along
with 100 fil of a molecular weight marker solution (range 200-14.3 kDa) and run for 8
hours at 30 mA (see section 2.5). The gel bearing the protein was then removed from the
electrophoresis apparatus and equilibrated with transfer buffer (500 ml) for 30 min. The
proteins from the gel were then transferred to a 0.45 micron thick nitro-cellulose membrane
(Bio-Rad) using a Semi Dry Transfer Cell (Bio-Rad) powered by a Bio-Rad power supply
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model 200/2.0 set at 20 V for 40 min. This membrane with the newly transferred proteins
was then placed in 10% low fat skimmed milk for 10 min at room temperature to block
non-specific binding sites, then washed with TBS (2x15 ml) and the lanes
(3 x Tera -2 and 1 x A431 receptor proteins) sectioned off accordingly. One lane containing
the Tera-2 solubi lised receptors was incubated in the monoclonal antibody EGF-R1
(15 ml, 1:30 v/v in TBS), a second in the monoclonal antibody F4 (15 ml, 1:5 v/v in TBS)
and a third in TBS buffer (15 ml) overnight at 4°C. The lane containing the A431
solubulised receptors was incubated in the EGF-R1 antibody (15 ml, 1:30 v/v in TBS).
The staining procedure as described in section 2.6 was used and the resulting bands
photographed.
2.13 Immunocytochemistry.
Both A431 and Tera-2 cells were cultured for this experiment, the former being used as the
positive control. Cells at 50%, 75% and 100% confluency were detached from 75 ml
flasks and reconstituted in RPMI solution (5 ml) to determine whether the state of cell
growth would effect EGF receptor expression and subsequent identification. Aliquots
(100|il) of the resulting suspension were then pipetted onto slides and allowed to air dry for
approximately 30 min before fixing in 1:1 acetone/methanol solution for 10 min. This
enabled the slides to be stored in foil at -20°C until required. When using the slides after
storage the cells had to be fixed once again for approximately 5 min and then completely
dried to prevent the cells from becoming detached during the washing procedure.
Incubation in the monoclonal antibodies and subsequent staining was performed according




2.14 Preparation of Conditioned Media.
Conditioned medium (1 litre)was collected from six 75 ml flasks of Tera-2 cells which
were growing in SFM (15 ml) for up to 48 hours at near confluency (approximately
5 x 10^ cells). The medium was collected over a period of 4 weeks and each collection (15
ml) centrifuged at 1,800 g for 15 min and Filtered through an acrodisc filter (0.2 |im,
Gelman Sciences Inc. Northampton, U.K.) to remove any debris. The aliquots of
conditioned media were then stored at -20°C with the addition of PMSF (0.3 mM), until
the desired volume had been collected (approximately 1 litre). The conditioned medium was
then dialysed overnight at 4°C against ammonium acetate (1.5 litres, 50 mM), using
Spectrapor-3 dialysis tubing with a cut off molecular weight of 3,500 Da (Pierce-Warriner,
Chester, U.K.) changing the dialysing medium three times during the course of the
dialysis. The dialysed product was then frozen, lyophi lised and reconstituted in Tris buffer
(0.5 M, 3 ml, pH 7.4) before storing it at -70°C . As a control SFM (500 ml) was dialysed
as above and reconstituted in Tris buffer (1.5 ml, 0.5 M) pH 7.4 .
2.15 Competition Studies.
Cells were plated down overnight in duplicate in 24 well plates at a density of 2 x 10^ in
0.5% FCS SFM. The following morning they were washed twice in Dulbeccos solution
before being used in a ligand exchange assay as described in section 2.11.1. The binding
site for EGF was competed for by labelled mEGF (1.0 nM, 200,000 cpm, 100 |il) with
each of the following peptides ; bFGF, vNGF, hIGF-I, rTGF-a (200 |il in RPMI,
100 nM) and concentrated conditioned media (200 (il).
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2.16 Rat TGF-a and Conditioned Medium as Competitors for
Radiolabeled mEGF.
In order to assess the effect of rTGF-a and concentrated conditioned media on the binding
of labelled mEGF to the receptor site, various concentrations of rTGF-a and concentrated
conditioned media were used in the ligand exchange assay described in section 2.11.1 in
place of the unlabelled mEGF. Rat TGF-a was employed at concentrations ranging
between 0.1 and 100 nM and the conditioned media at serial dilutions of the concentrated
solution.
2.17 Radioimmunoassays for rTGF-a and hEGF.
A RIA for hEGF was set up according to section 2.7 to measure the amount of
immunoreactive hEGF present in the concentrated conditioned media (100 pi) as well as in
the concentrated SFM (100 pi). In addition the concentration of rat TGF-a in the
concentrated conditioned media and concentrated SFM was also investigated employing
the commercial RIA kit described in section 2.2.6.
2.18 Effect of M bolerone on the binding of radiolabeled mEGF to
Tera-2 Cells.
Cells were plated down overnight at a density of approximately 200,000 cells per ml in
quadruplicate
0.5% FCS SFM in \ for each concentration ofmi bolerone to be tested. The
following day they were then washed in Dulbeccos solution (2x5 ml) before being
incubated in mi bolerone (1 ml) at concentrations ranging from 0.1 to 100 nM in SFM for
24 hours. The number of cells present at the end of this period were then measured at each
concentration. The remaining cells were washed in Dulbeccos solution (1 ml) and a ligand
exchange assay performed as described in section 2.11.1.
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2.19 Thymidine Incorporation by Tera-2 cells.
quadruplicate
Cells were seeded in ^ tor each individual point in 24 well plates. Parallel plates
were set up to measure total cell count at each point as well as to act as controls. Cells were
plated down at a density of 50,000 per ml in 0.5% FCS SFM and after incubating
overnight the cells were washed twice in Dulbeccos solution(lml) before commencement of
the experiment. Methyl-^H thymidine (500 pi, 0.1 GBq/well in SFM ) and an equal
volume of the appropriate concentration of test substance in SFM was added to each well.
The cells were then incubated for the appropriate period of time and at the end of the
incubation 100 pi of the cell medium was pipetted off for tritium counting. The remaining
medium was then aspirated off and the cells washed in Dulbeccos solution (2x1 ml),
before being exposed to TCA [10% (w/v) in distilled water, 1 ml] for 30 min at 4°C to
remove free radioisotope and then washed once more in Dulbeccos solution (1 ml). The
cells were solubi Used in sodium hydroxide (0.5 ml, 0.5 M) and the solution transferred to
scintillation vials for counting in the tritium counter.
2.19.1 Time Course Studies For Thymidine Incorporation by Tera-2
cells.
Cells were incubated with tritiated thymidine (0.5 ml, 0.1 GBq/well in SFM) as described
in section 2.19 in the presence of 10 nM mEGF (0.5 ml), 10 nM rTGF-a (0.5 ml) and
10 nM mi bolerone (0.5 ml) in SFM both for a period of up to 24 hours and a period of up
to 3 days to assess the length of time required for each substance to affect thymidine
incorporation. Parallel plates were set up as controls to assess the effect of thymidine
incorporation on cells incubated in SFM (0.5 ml) and to determine cell number at each time
interval under the various conditions. All measurements were performed in quadruplicate.
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2.19.2 Effect of mEGF, rTGF-a and Ml bolerone on Thymidine
Incorporation
The effect of mEGF (0.5 ml over the range 0.3 to 100 nM in SFM), rTGF-a (0.5 ml over
the range 1.0 to 300 nM in SFM) and m'« bolerone (0.5 ml over the range 0.3 to 100 nM in
SFM) over a 24 hour period on the incorporation of thymidine by the Tera-2 cells in
comparison to the incorporation of Tera-2 cells incubated in SFM (0.5 ml) was
investigated. The experiment was performed according to section 2.19. Parallel plates were
also set up to determine the effect of each concentration ofmEGF, rTGF-a and
mybolerone on cell number.
2.20.0 Data Analysis.
2.20.1 Mean ± Standard Error of the Mean
All experiments were performed in at least triplicate so that
be calculated according to the following formulae:-
Mean = x = 1 X x x = the variables
n n = the no. variables
SEM = S.D S.D. = I, (x - x)
Vn n
2.20.2 Saturation Analysis
Saturation Analysis was performed using the weighted, nonlinear least-squares curve
fitting program 'Ligand' (Munson and Rodbard, 1980), run on an IBM-PC. The curves
were analysed according to a model of one or two binding sites. Scatchard plot analysis of
saturation curves was not employed due to the difficulty in estimating the lowest ligand
concentrations, which are unevenly 'weighted' in Scatchard analysis (Bennett and
(SEM).
the mean values ± SEM could
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Yamamura, 1985). The programme makes some assumptions: (i) Multiple ligands can bind
to multiple sites, (ii) the binding reaction being analysed is at equilibrium, (iii) the binding
is bi-molecular and reversible and (iv) there is a total and true separation of bound ligand
from free ligand.
2.20.2.1 Statistical Curve Fitting
Curves can be fitted to a single- or multi-site model using the 'extra sum of squares' F-test
criterion. Thus a model for two binding sites is retained only when it fits data significantly
better (P<0.05 partial F test) than a model for a single binding site.
2.20.2.2 Weighting Parameters
Weighting has also been incorporated to reduce the tendency for unreliable points to unduly
influence the location of the curve. Thus, weights are assigned to each point as the
reciprocal of the variance at that point, therefore points with smaller variance (more precise)
usually receive more weight (Rodbard, 1974a; 1974b; Rodbard et al, 1976).
2.20.2.3 Correction Factors
Correction Factors have also been included with this program. The factor (C) in the
program is a fitted parameter which adjusts or scales the values of apparent receptor
concentration for any particular experiment. Thus when comparing experiments the scale




2.20.3 Inter Assay and Intra Assay Coefficients.
The coefficient of variance for RIAs can be calculated as follows:-
CV = 100 S.D.
mean
In the case of a RIA the values for the inter assay coefficient formula are taken from the
group of data representing the unknown samples which were run in the various RIAs. In
contrast the data for the intra assay coefficient is taken from running extra samples
of the standard concentrations which w are used to construct the RIA curve.
Sensitivity was taken as 90% B/Bo.
2.20.4 t-Test
The probability of two measurements being statistically significantly different was
calculated using the following t test formulae:-
t = _xj - xn_ Formula 1
s is an estimate of the standard deviation based on both samples jointly.
Then according to the number of degrees of freedom involved (n-1) and the final value of
A^SEM^ + SEM22)
-*1—2— Formula 2
where s2 = Xj ( x - x^)2 + X2 ( x " x2^
nl n2 ~ 2
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t calculated, the probability of the two measurements being statistically significantly
different from each other can be calculated by looking at the appropriate t table.
Formula 1 was the formula that was used when the two groups were of equal size
whereas formula 2 was used when they were not of equal size.
2.20.5 Calculation for Correlation.
Attempts were made to correlate the concentration ofEGF or TGF-a in particular tissues
with the concentration of androgens present. Correlation (r) measures a co-relation, a joint
property of two variables. This was performed employing the following equations:
r = y.(x-xHv-v)




3.1 Characterisation of the EGF Receptor.
The binding site for EGF was characterised by means of a radioreceptor ligand
exchange assay. The radioreceptor assay was optimised according to a) the subcellular
fraction employed and its' protein concentration, b) the duration, temperature and pH of
the incubation employed in the radioligand exchange assay and c) the concentration of
labelled and unlabelled mEGF used to detect the hEGF binding site. The affinity
(dissociation constant) of the receptor was subsequently determined by Scatchard
analysis and the affinity of mEGF for the receptor site compared with that of other
growth factors. The effect of heat and trypsin as well as storage at -70°C on the EGF
receptor present in the tissues was also investigated.
3.1.1 Subcellular Fractionation
Subcellular fractions were prepared from three different tissues. Following subcellular
fractionation the specific EGF binding in each fraction was assessed using the
radioligand exchange assay. Approximately 72% of the specific binding for hEGF
found in the non-fractionated tissue was associated with the 800 g "crude" fraction
while 12% was associated with the mitochondrial and 18% with the microsomal
fraction (Figure 22). No specific binding was detected in the cytosolic fraction. In all
subsequent experiments the specific binding ofEGF was determined by preparing a
crude homogenate and centrifuging at 105,000 g for two periods of 40 min and 20 min
to yield a particulate fraction. This fraction (the particulate fraction) represented all the
previous fractions apart from the cytosolic fraction and was subsequently shown to
contain 101% ± 6.7 (SEM) (n=3) of the binding sites detected in the tissue prior to
fractionation.
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fraction
Figure 22
Subcellular distribution of the EGF receptor in human testicular tissue was
investigated. Subcellular fractions of human testicular tissue (1 mg/ml
protein concentration) were incubated with labelled mEGF (8 nM,
200,000 cpm) at 32 C for 40 min in the presence and the absence of
unlabelled mEGF (50-fold excess). Each value plotted represents the mean
specific binding of labelled mEGF (± SEM) of three different particulate
fractions, each of which was analysed in duplicate shown as a
percentage of the specific binding detected in the three non-fractionated tissue
preparations.
3.1.2 Time and Temperature Studies.
Figure 23 illustrates the specific binding patterns of labelled mEGF to the 105,000 g
particulate fraction at 4°C, 25°C, 32°C and 37°C over a period of three hours.
Maximum binding of labelled mEGF to its receptor was achieved after incubating at a
temperature of 32°C and 37°C for a period of 40-50 min and at 25°C after an
incubation period of 90 min. The maximum binding achieved at 4°C was
approximately 80% of the maximum binding seen at 32°C and 37°C, after an
incubation period of 180 min.
3.1.3 Protein Concentration.
The effect of protein concentration on the number ofEGF specific binding sites was
investigated. Particulate fractions obtained from three different tissue samples were
examined, over a protein concentration range of 0.5-8.0 mg/ml. The number of specific
EGF binding sites observed rose linearly with increasing protein concentration of the
particulate fractions employed (Figure 24). All measurements were converted to a
percentage of the maximum specific binding achieved with each particulate fraction and
mean data presented ± SEM (n=3).
3.1.4 Displacement of Radiolabelled mEGF with Unlabelled
mEGF.
In order to assess the displacement of radiolabelled mEGF from the EGF binding site,
increasing concentrations of unlabelled mEGF were used to compete with 8.0 nM
labelled mEGF for the receptor. Figure 25 illustrates the percentage bound (% Bound)
of three particulate fractions (mean ± SEM ) which were incubated with labelled mEGF
(8 nM, 200,000 cpm) in the presence and absence of unlabelled mEGF (10-400 nM).
The optimum specific binding for all three samples was obtained when >200 nM of
unlabelled mEGF was used to compete for the EGF binding site.
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Figure 23
Determination of optimal duration and temperature of the ligand
exchange assay employed in measuring the specific binding ofmEGF to
the particulate fraction. Incubation was carried out at 4°C (a), 25°C
(b), 32°C (c) and 37°C (d). Values represent the mean percentage
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Figure 24
The relationship between specific binding of mEGF and the protein
concentration of the particulate fraction employed was investigated.
The data is represented as the mean percentage (± SEM, n=3) of the






Labelled mEGF (8 nM) was competed with various concentrations of
unlabelled mEGF ranging from 10 to 400 nM. The specific binding of
labelled mEGF at each concentration was then converted to % Bound
meaned (± SEM, n=3) and plotted against the log concentration of the
unlabelled mEGF employed.
3.1.5 Saturation Analysis and Scatchard Plot.
In order for a binding site to be described as specific for one ligand the ligand must
show a high affinity saturable interaction with the site in question (Adamson and Rees,
1981).
The saturability of the EGF receptor with radiolabeled mEGF was
investigated as described in section 2.4.10 and saturation was reached with
concentrations >8 nM labelled mEGF.
Figure 26a illustrates the binding of labelled mEGF to the particulate
fraction in the presence and absence of unlabelled mEGF over the concentration range
1.0-10.0 nM of labelled mEGF. Figure 26b illustrates the specific binding determined
at each concentration of labelled mEGF.
The saturation data obtained from the experiments performed in section
2.4.10 were then analysed by the Scatchard method using a computer programme
written by Munson and Rodbard (1980). The maximum confidence limit set was
100%. This limit yielded a single high affinity binding site with a mean Kd of 1.18 ±
0.32 x 10~9 M (n=6) and 528 ±116 fmoles binding sites per mg of protein.
3.1.6 Competition Studies.
The various factors used to compete for the EGF binding site were employed at
concentrations which were 50-fold in excess of the 8 nM labelled mEGF
(approximately 400 nM). Figure 27a illustrates that specifically bound EGF was only
partly displaced by rTGF-oc (24%), hi (11%), hPrl (2%), hLH (5%) and hFSH (16%)
whereas IGF-I, hGH, bFGF and vNGF did not compete for the binding site. As hi,
hPrl, hLH and hFSH did illustrate some competition for the EGF binding site an
experiment was performed in which the aforementioned peptides were used at
approximately 100-fold excess of the radiolabeled mEGF employed (approximately
800 nM) (Figure 27b). It was determined from this experiment that no further
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Figure 26
Saturation of the EGF binding site on human testicular tissue with
radiolabelled mEGF over the concentration range 1.0 to 10.0 nM
was performed. The non-specific binding (NSB) and total binding (TB) (a) and
specific binding (b) were plotted against the concentrations of labelled
mEGF employed. The specific binding at each concentration was then
converted to Bound and Bound/Free to construct a Scatchard plot (c).
From this the Kd of the EGF binding site was calculated to be








Competition of the receptor site with other peptide
growth factors and hormones was performed. The mean
specific binding of labelled mEGF (± SEM, n=3)
achieved with each competitor was compared with the
mean specific binding achieved with unlabelled mEGF
and converted to a percentage. In Figure (a) the
competitor was used at a concentration 50-fold in excess
of labelled mEGF and in Figure (b) at a concentration
100-fold in excess.
To test the specificity of the receptor multiple concentrations
of competitor should be used but unfortunately research
finance does not always permit this.
significant increase in the level of competition was achieved with any of the
aforementioned competitors and therefore binding was not concentration dependent.
All measurements were expressed as a percentage of the specific binding achieved with
400 nM mEGF which on Figures 27a and 27b is represented as the maximum
competition, 100%.
3.1.7 Trypsin and Thermal Sensitivity.
A significant decrease in the binding ofEGF to its receptor was observed when
particulate fractions which had been preincubated with trypsin were employed in a
ligand exchange assay as described in section 2.4.6. The mean reduction in binding of
the three particulate fractions following incubation in trypsin for 30 min at 37°C in
comparison to the control which had not been incubated in trypsin are shown (Table 2).
Preheating of the particulate fractions before assay was investigated.
Preheating of the particulate fractions at 45°C and 60°C for 10 min produced mean
decreases of 49% and 55% in EGF binding in comparison to identical samples which
had been left on ice. On heating the particulate fractions at 80°C the sample became too
thick to dispense accurately through a pipette tip and because of this could not be
assayed.
3.1.8 Effect of pH on the Specific Binding of Labelled mEGF in
Human Testicular Tissue.
The pH of the buffer employed in the ligand exchange assay described in section 2.4.6
was varied between 6.6 and 8.2. As illustrated in Figure 28 this was found to have no
effect on the specific binding of radiolabelled mEGF to three testicular tissue samples
except at the lower pH of 6.6 which produced a slight decrease in the specific binding.
Once again the binding data obtained in each individual tissue sample was expressed as





I mEGF Binding 100% 13.1% ± 1.3
(b)
Heat Control uo 60° C
^
I mEGF Binding 100% 49% ± 8.6 55% ± 14.9
Tabic 2
The effect of trypsinisation (a) and heat pretreatment (b) at 45°C and 60 C
on specific radiolabeled mEGF binding by the 105,000g membrane
particulate fraction was assessed. The results are expressed as percentage
change from the untreated control and the values represent mean (n=3,
± SEM).
Binding was found to be statistically significantly decreased after trypsin
treatment (***, P<0.0001) and after heat treatment at 45°C (**, P<0.01)
but not after heat treatment at 60°C.
8.2 7.8 7.4 7 6.6
pH
Figure 28
The effect of buffer pH on specific binding of labelled mEGF to three different
particulate fractions was investigated. Particulate fractions (100 p.1) were
incubated with labelled mEGF (200 |il, 8 nM, 200,000 cpm) at 32°C for 40 min
in the presence and absence of unlabelled mEGF (200 |il, 50-fold excess)
employing buffers with a pH of between 6.6 and 8.2. Each value plotted
represents the mean specific binding (± SEM, n=3) of labelled mEGF as a
percentage of the maximum specific binding achieved.
Binding was only found to be statistically significantly decreased at pH 6.6
compared to a pH of 7.0 (*, P<0.05).
from all three tissues was then calculated and represented in Figure 28.
3.1.9 Effect of Freezing in Liquid Nitrogen and Storage at -70°C
on the Specific Binding Sites for hEGF in Testicular Tissue
and Particulate Fractions.
Freezing of testicular tissue in liquid nitrogen was found to have no effect on the
specific binding of EGF present in the three testicular tissues examined (Figure 29a).
The tissue once frozen was then kept for a period of up to six months and during this
time no significant loss of the EGF receptors was observed (Figure 29a). However
storage of the particulate fractions prepared from the above mentioned tissues for a
period of 14 days produced a decrease in specific EGF binding after the tenth day of
storage (Figure 29b). Consequently storage of the particulate fractions was limited to
ten days only. The binding data was expressed as a percentage of the maximum specific
binding achieved within each tissue sample and the mean data from all the samples is
shown ± SEM.
3.2 EGF Receptor in Normal, Treated and Cancerous
Testicular Tissue.
The specific binding of EGF to its receptor in individual samples was achieved by
employing the radioligand exchange assay described in section 2.4.6. The specific
binding data is represented in Figure 30 as the molarity of radiolabelled mEGF
specifically bound to the EGF receptor in 2 mg/ml of protein.
a) Normal testicular tissue.
It was found that in all of the 36 normal testicular tissue samples investigated EGF
receptors were expressed (Figure 30). The specific binding ranged from
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Figure 29
a) The effect of freezing human testicular tissue in liquid nitrogen and
its subsequent storage at -70°C on the binding of labelled mEGF to its
over 14 days was investigated. The data is represented as the mean
percentage!! SEM, n=3) of the maximum specific binding achieved.
Binding was found to be statistically significandy decreased after storage of
the particulate fraction for more than 10 days (**, P<0.01).
b) The effect of storage at -70UC on EGF binding in the testicular
particulate fractions was investigated ovep\24 weekperiod. The specific
binding data is represented as the mean percentage (± SEM, n=3) of








































The specific binding of labelled mEGF for each tissue used in the
study was plotted according to their designated group. Each value
was obtained by incubating the particulate fraction (100 |il) with
labelled mEGF (200pl, 8 nM, 200,000 cpm) at 32 C for 40 min in the
presence and the absence of unlabelled mEGF (200 |il, 50-fold
excess). Each value represents the mean molarity (± SEM, n=3) of
EGF bound to each particulate fraction.
Normal testicular tissue was found to express 0.09 ± 0.01
nM EGF receptors in the 36 normal tissue samples which
were assessed, for seminoma 0.01 ± 0.01 nM (n=15), for
teratoma 0.08 ± 0.01 nM (n=5) and for treated tissue 0.03
± 0.01 nM (n=6).
The concentration of EGF receptors expressed in seminoma
and treated tissues was found to be significantly lower than
the concentration expressed in normal tissue (**, P<0.001
and **, P<0.001 respectively).
0.04 to 0.16 nM (mean = 0.09 ± 0.01) in the 36 particulate fractions which were
analysed.
b) Cancerous testicular tissue.
Three types of cancerous testicular tissue were obtained (see section 1.11). In the 15
seminoma tissues which were investigated EGF receptors were found to be either
absent or "poorly" expressed. The number of specific binding sites which were
identified were found to range from 0 to 0.04 nM (mean = 0.01 ± 0.01). In the case of
the 5 teratoma tissues investigated the concentration of binding sites were found to
range from 0.06 to 0.1 nM (mean = 0.08 ± 0.01). One Leydig cell tumour was also
investigated for EGF receptor expression but no EGF binding was detected (Figure
30).
c) Treated testicular tissue.
Treated testicular tissue was obtained from patients who had been treated for prostatic
cancer by orchiectomy as a second line of therapy. Initially the patients had received
either cyproterone acetate or stilboestrol as a course ofmedication. In this group of
tissues specific binding of EGF ranged from between 0 and 0.06 nM (mean = 0.03 ±
0.01) in the 6 tissue samples which were investigated (Figure 30).
3.3 Immunohistochemical Localisation of the EGF Receptor.
Immunohistochemical staining of 21 frozen sections of human testicular tissue with
monoclonal antibodies for the hEGF receptor illustrated that EGF receptors are present
in the tissue. In employing the immunohistochemical streptavidin-biotin technique a
prostate section was included in all the immunohistochemical studies as a positive
control (Plate 2a and 2b). A negative control of each section used in the staining
procedure was also performed (Plate 3a) by emitting the primary antibody. In the early
development
^|of this procedure false positive staining was apparent due to the presence of biotin in
the testes. Consequently an avidin biotin blocking kit was used to eliminate this
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Plate 2 Frozen sections of prostate were used as positive controls for the
F4 and the EGF-R1 monoclonal antibodies. Plate (a) [x400] illustrates
the binding sites detected with the F4 antibody and plate (b) [xl60]
those detected with the EGF-R1 antibody.
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problem. Lipofuskin staining^another common source of false positive was easily
distinguishable from EGF receptor staining and this eliminated a further source of
potential errors (Plate 3b).
In using the streptavidin-biotin technique and the monoclonal antibody
EGF-R1, EGF receptors were located on both Leydig cells and peritubular cells. This
is clearly seen in plates 4a and 4b where the staining appears as strands of red around
both the thin peritubular cells surrounding the seminiferous tubules and also around the
large round Leydig cells present in clusters within the interstitium. This was confirmed
when using 6 paraffin sections with the monclonal antibody for the external domain of
the EGF receptor, EGF-R (Plates 5a and 5b ). In neither procedure was staining
observed in Sertoli or germ cell areas. It was also noted that when using the antibody
for the internal domain of the receptor (F4) no staining was apparent on the paraffin or
frozen sections of human testicular tissue which were employed despite titrating the
antibody over a concentration range of 1/3 to 1/8 (v/v).
Testicular tissues from men in the age group 30-35 (treated for
vasectomy reversal) were also examined for EGF receptor expression using the EGF-
R1 monoclonal antibody and the F4 monoclonal antibody. These were also found to
express only the external domain of the EGF receptor (Plate 6a and 6b). Foetal
testicular tissue obtained from foetus of between 15 and 19 weeks gestation was also
found to express only the external domain of the EGF receptor and not the internal
domain (Plate 7).
EGF receptors were also shown to be present in the 3 teratoma tissues
by immunohistochemical staining with the monoclonal antibody for the external domain
of the receptor (EGF-R1) and the monoclonal antibody for the internal domain F4
(Plates 8a and 8b ). The staining was never diffuse but always appeared in and around
defined structures which were apparent within the teratoma section. This complemented
the biochemical findings previously mentioned where a ligand exchange assay was
95
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Plate 3a Negative controls were used to show the selectivity of the EGF-R1,
EGF-R and F4 monoclonal antibodies for the EGF receptor on human
testicular tissue. The section was incubated in Tris buffer with the
omission of primary antibody. There is clearly no red staining on the
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Plate 4 Immunohistochemical staining using the streptavidin-biotin labelled
method on frozen sections of human testicular tissue was performed (a)
and (b) [x 400] . The primary monoclonal antibody EGF-R1
was used at a dilution of 1:30 (v/v) and the sections lightly
counterstained with haematoxylin. A positive reaction for the EGF
receptor appears as dark diffuse staining in the interstitium both around
the peritubular (P) and Leydig cells (L).
Plate 5 Immunohistochemical staining using the streptavidin-biotin labelled
method on paraffin sections of human testicular tissue [x 400 (a), x 160
(b)]. The monoclonal antibody EGF-R was employed at a 1:10 dilution
(v/v). Leydig cells (L) became stained along with the peritubular
cells surrounding the seminiferous tubules (P).
Staining of frozen sections [xl60 (a), x400 (b)] with the monoclonal
antibody EGF-R. The sections were cut from a biopsy specimen
received from a normal, healthy 34 year old male. The staining appears
to be slightly more dense than that observed in the older specimens
looked at. However it is located in the interstitial areas as previously
seen and around the seminiferous tubules.
Plate 7 Frozen sections of foetal tissue (between 15 and 19 weeks of gestation)
were incubated with the monoclonal antibody EGF-R1 (a) and stained
accordingly. Although the sections were not of the highest quality EGF




Plate 8 Frozen sections of two teratomas were incubated with the EGF-R1
monoclonal antibody (a) [x400] and with the F4 monoclonal antibody
(b) [xl60]. The external domain of the EGF receptor a^vell as the
internal domain of the receptor were both found to be expressed. The
staining was always confined to certain areas of the tissue and often
appeared to be extremely dense.
used to identify the EGF receptor. The immunohistochemical results for the other tissue
groups also confirmed that receptors were either completely absent or distributed in
very small diffuse patches on either the seminoma or treated testes.
Experiments in which the F4 monoclonal antibody was employed for
detection of the internal domain of the receptor on seminoma or treated tissue illustrated
that the internal domain of the EGF receptor on human testicular was not available for
binding.
3.4 Molecular Characterisation of the EGF Receptor:
Affinity Labelling and Crosslinking of the EGF Receptor
Complex Followed by Electrophoresis (SDS-Page) and
Autoradiography.
Molecular characterisation of the EGF receptor by an affinity labelling and crosslinking
procedure enabled visualisation of the EGF binding site. The bound labelled
mEGF/receptor complex was prepared in the absence and in the presence of unlabelled
mEGF, solubilised and then crosslinked before being transferred onto a 7.5% SDS
polyacrylamide gel for electrophoresis. The protein bands of the solubilised receptor
complex which were prepared in the absence of unlabelled mEGF can be seen in lanes
Al, A2 and A3. Lanes Bl, B2 and B3 represent the protein bands of the solubilised
receptor complex which were prepared in the presence of unlabelled mEGF (Plate 9).
In lanes Al, A2 and A3 there are dark bands around the 125 kDa molecular weight
region which are absent in lanes Bl, B2 and B3. These dark bands represent the
labelled EGF receptor/mEGF complex protein. It is absent in lanes Bl, B2 and B3
because in place of labelled mEGF, unlabelled mEGF which was used as a competitor
is bound to the receptor.
The molecular weight of the protein band corresponding to the EGF
receptor complex was estimated by use of standard molecular weight markers which
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Plate 9 Autoradiography was performed on three testicular tissue samples (1,2
and 3) that had been pre-incubated with 8 nM mEGF at 32°C for
40 min in the presence (lane B) and absence (lane A) of unlabelled EGF
at a 50-fold excess concentration. The receptor complex from each
sample was then crosslinked with 1 mM DSS and run on a 7.5% SDS-
polyacrylamide gel, along with standards ranging from 29,000 to
205,000 in molecular weight. The gel was subsequently counterstained,
dried and autoradiography was carried out at -70°C with an Amersham
hyperfilm TM for up to 4 weeks.
RESULTS
were run concurrently on the gel. Labelling of some smaller molecular weight
compounds was also observed although these were thought to be non-specific with
relation to the EGF receptor as unlabelled EGF did not displace binding to these bands.
3.5 EGF Concentrations in Human Testicular Tissue.
ln= 12)
The concentration of EGF in normal human testicular tissue^was statistically greater
than that found in the cancerous seminoma tissues (p<0.05, n=6) or the treated
testicular tissues (p<0.05, n=6) (Figure 31). In the normal group of tissue the
concentrations ranged from 1.4 to 11.5 ng/g wet tissue with a mean of 5.2 ± 1.0 ng/g.
In the seminoma group the concentrations ranged from 2.0 to 3.6 ng/g wet tissue with a
mean of 2.5 ± 0.3 ng/g and in the treated group from 1.5 to 2.5 ng/g wet tissue with a
mean of 2.2 ± 0.2 ng/g. The mean recovery of EGF from normal tissue was
approximately 48%, from seminoma tissue 51% and from treated tissue 53%.
3.6 TGF-a Concentrations in Human Testicular Tissue.
A rTGF-a RIA was established to detect concentrations of hTGF-aover the
concentration range 10 to 1200 pg/100 |il. The sensitivity of the assay was calculated
to be approximately 22 pg/tube and the IC50 value approximately 70 pg/tube.
The hTGF-a concentrations found in normal, seminoma and treated
testicular tissue are illustrated in Figure 32. For normal tissue (n=12) the concentration
of hTGF-a detected was 2.8 ± 0.2 ng/g wet tissue and ranged from 1.8 to 4.0 ; for
seminoma tissue (n=6) 2.1 ±0.1 ng/g wet tissue ranging from 1.6 to 2.5 ng/g and for
treated tissue (n=6) 1.9 ± 0.3 ng/g wet tissue ranging from 1.2 to 3.0 ng/g.
The concentration of TGF-a in normal tissue was found to be
statistically significantly higher than that found in seminoma (p < 0.05) and in treated
tissue (p < 0.001).






The concentration of hEGF in normal (n=12), seminoma (n=6) and treated
(n=6) tissues was assessed. The normal tissues contained a significantly
higher concentration of hEGF than did the seminoma (*, p<0.05) or
treated (*, p<0.05) tissues. Values represent mean concentration (± SEM).
Figure 32
The concentration of hTGF-a found to be present in normal tissue (n=12)
was significantly higher than the concentration found in seminoma (n=6)































T "1 r 1 r
4 6 8




Concentrations of hEGF and hTGF-a in the same testicular tissues were
plotted against each other for the 12 tissues which were analysed in an
attempt to evaluate any correlation which may exist between the two
growth factors in vivo. No correlation was found at the p<0.05 level of
significance.
RESULTS
(n=12) in a number of normal testicular tissue samples, as an attempt to investigate any
possible correlation which might exist between the concentrations of EGF and TGF-oc.
However no statistically significant correlation at the P<0.05 level was illustrated
between the concentrations of EGF and TGF-a within each individual tissue sample.
3.7 Steroid Concentrations in Human Testicular Tissue.
The concentrations of androstenedione, DHT and testosterone were measured in human
testicular tissue. Recoveries of each of the individual steroids were estimated by
measuring half of the final separated extract for radioactive counts as described in
section 2.9.4-. Recovery of the steroids from the normal (n=16 ), seminoma (n=5 ) and
treated (n=4 ) tissues are shown in Table 3.
The concentration of steroid in each sample was read from the
appropriate standard curve according to the %B/Bo value. (%B/Bo was calculated as
previously described in section 2.7.2) This value was then readjusted depending on
dilution factors and the amount of tissue from which the sample was prepared. In
normal tissue the mean concentrations of steroids were: for androstenedione
0.46 ± 0.13 nmoles/g dry tissue, ranging from 0.11 to 1.61 nmoles/g; forDHT 0.29
± 0.06 nmoles/g dry tissue, ranging from 0.05 to 0.44 nmoles/g and for testosterone
15.58 ± 2.55 nmoles/g dry tissue, ranging from 0.45 to 31.8 nmoles/g (Figure 34)
In the 5 cancerous tissues the mean concentration of steroids were: for
androstenedione 0.025 ± 0.005 nmoles/g dry tissue, ranging from 0.012 to 0.042
nmoles/g; for DHT 0.093 ± 0.017 nmoles/g dry tissue, ranging from 0.043 to 0.173
nmoles/g and for testosterone 0.83 ± 0.25 nmoles/g dry tissue, ranging from 0.40 to
1.75 nmoles/g.
In treated testicular tissue the mean concentration of steroids were: for






















Estimated mean percentage recoveries (± SEM) for steroids extracted from
normal (n=16), seminoma (n=5) and treated (n=4) human testicular tissues.
Figure 34
The concentrations of androstenedione, DHT and testosterone in normal
testis received from 16 patients of approximately 72 years of age were
measured. The concentration of testosterone in the normal tissue was
found to be significantly higher than the concentrations ofDHT (***,
p<0.0005) and androstendione (***, p<0.0005). Values represent mean
concentration (± SEM).
RESULTS
for DHT 0.31 ± 0.05 nmoles/g dry tissue, ranging from 0.19 to 0.44 nmoles/g and for
testosterone 14.52 ± 0.40 nmoles/g dry tissue, ranging from 13.86 to 15.56 nmoles/g.
Figures 35a, b and c show the differences between androstenedione,
DHT and testosterone in normal, seminoma and treated tissue. As is illustrated in
Figure 35a the concentration of androstenedione is significantly higher in normal tissue
than in the seminoma tissue (p< 0.0005) but not significantly greater than that in the
treated tissue. Similarly the concentration ofDHT is significantly higher in the normal
tissue than in the seminoma tissue (p<0.01) but not significantly higher than that in the
treated tissue and correspondingly the concentration of testosterone is significantly
higher in the normal tissue than in the seminoma tissue (p< 0.0005) but not
significantly higher than that in the treated tissue.
As steroid secretion has been found to be regulated by growth factors
and similarly growth factor receptor expression by steroids it was important to
investigate the possible correlation which may exist between steroid concentration and
EGF and TGF-a concentrations in each sample analysed. Figures 36a, b and c
illustrate any possible correlation which may exist between the concentration of EGF
and the concentrations of androstenedione, DHT and testosterone. Similarly Figures
36d, e and f illustrate any possible correlation which may exist between the
concentration of TGF-a and the concentrations of androstenedione, DHT and
testosterone. However no statistically significant correlation between any of the
aforementioned factors/hormones at the p<0.05 level was found.
The correlation which may exist between androstenedione, DHT and
testosterone concentrations within the testis was also investigated on an individual
tissue basis (Figure 37a, b and c). However once again no statistically significant




The concentrations of androstenedione (a), DHT (b) and testosterone (c) in normal
[n=16], seminoma [n=5] and treated [n=4] tissue were measured. The concentration
of steroids in the normal group were not significantly greater than those measured in
the treated group. However the concentrations of androstenedione, DHT and
testosterone measured in the seminoma subgroup were found to be significantly
lower than those measured in the normal group (***, p< 0.0005,**, p< 0.01 and






























An attempt was made to correlate the concentration of hEGF found in
human testicular tissues with the intratesticular concentrations of
androstenedione (a), DHT (b) and testosterone (c). A similar
correlation was also attempted between hTGF-a and androstenedione
(d), DHT (e) and testosterone (f). No correlation between any of the
aforementioned factors/hormones was found at a significance level of































































































The correlation between the concentration of androstenedione and DHT
(a), androstenedione and testosterone (b) and DHT and testosterone
(c) within testicular tissue was investigated. No correlation between any
of the aforementioned hormones was found at a significance level of
p<0.05. Values represent mean concentration.
Androstenedione (nmol/gdrytesticular tissue)




































3.8.1 EGF Receptor Radioligand Exchange Assay
EGF binding on Tera-2 cells was identified using the radioligand exchange assay as
described by Engstrom et al (1985). Optimum binding was achieved employing
labelled mEGF at a concentration of 1.0 nM with unlabelled mEGF in 100 fold excess.
In addition displacement studies with unlabelled mEGF followed by saturation analysis
and Scatchard plot as well as competition studies were performed.
3.8.2 Displacement Studies with mEGF
The radiolabelled mEGF specifically bound to the EGF receptor on the Tera-2 cell line
was found to be displaced by competing increasing concentrations of unlabelled mEGF
(0.3-1000 nM) against a single concentration of radiolabelled mEGF (1 nM, 200,000
cpm). Maximum displacement was achieved when the concentration of unlabelled
mEGF was in excess of the labelled mEGF (1 nM) by 100-fold. Radiolabelled mEGF
was displaced in a sigmoidal fashion from the binding site by ascending concentrations
of unlabelled mEGF (Figure 38a).
3.8.3 Displacement Studies with rTGF-a .
The EGF receptor on the Tera-2 cell line was competed for with various concentrations
of rTGF-a (0.1-2000 nM) and labelled mEGF (1 nM, 200,000 cpm ). It was found
that similar concentrations of rTGF-a were required to compete for the EGF receptor




The competition between various concentrations of mEGF, rTGF-a and
the concentrated conditioned media with labelled mEGF for the EGF
receptor on the Tera-2 cell line was investigated. Concentrations
between 0.3 and 1000 nM were chosen for mEGF (a), concentrations
between 0.1 and 2000 nM for rTGF-a (b) and for the concentrated
conditioned media (c) serial dilutions of the stock solution. Mean
percentage bound of labelled mEGF (± SEM, n=3) was then plotted
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3.8.4 Displacement Studies with Concentrated Conditioned
Medium.
Various dilutions of the concentrated conditioned medium were used to compete for the
EGF receptor along with labelled mEGF. The concentrated conditioned media was used
in its most concentrated form (1.0) and then at subsequent dilutions (0.3, 0.1 etc. ).
The sigmoidal shaped curve obtained (Figure 38c) is very similar in shape to the curve
obtained with rTGF-a (Figure 38b). In fact if the two graphs are superimposed then
the concentrated conditioned media (1.0) would represent approximately 50 nM of
rTGF-a activity. According to the RIA study the concentrated conditioned media
contains only 0.28 pg/ml hTGF-a which represents 0.09 pg/ml rTGF-a which is
approximately 0.02 pM of rTGF-a.
3.8.5 Saturation Analysis and Scatchard Plot.
Saturation of the EGF binding site on the Tera-2 cell line with radiolabeled mEGF was
performed over the range 0.2-4.0 nM labelled mEGF (1 x 10^ to 2 x 10^ cpm) with
unlabelled mEGF over the range 20-400 nM. Figure 39a illustrates the I^^mEGF
binding achieved over the concentration range 0.2-4.0 nM while in the presence and
absence of unlabelled mEGF. Figure 39b illustrates the specific binding achieved over
the same concentration range of radiolabelled mEGF. The saturation data was then
analysed by Munson and Rodbards computer programme (1980) to yield a single
binding site with a Kd of 0.21 ± 0.08 x 10"^ (n=3) where a maximum confidence limit
of 100% was enforced (Figure 39c). The number of binding sites per cell was
calculated to be approximately 6.73 ± 0.81 x 10^-
3.8.6 Competition Studies.
Competitors for the EGF receptor which were tested included rTGF-a , hIGF-I,
vNGF, bFGF and concentrated conditioned media (CCM). The results were expressed
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Figure 39
Saturation of the EGF binding site on the Tera-2 cell line was performed
over the concentration range 0.02 to 4.0 nM of labelled mEGF. Mean
nonspecific binding (NSB) and mean total binding (TB) (a) and mean specific
binding (± SEM) (b) measured at the various concentrations of labelled
mEGF were plotted. The specific binding data was than converted to
Bound and Bound/Free and a Scatchard plot constructed (c). The
affinity constant (Kd) of the receptor with respect to EGF was then
calculated and found to be approximately 0.25 nM and the number of


















as a percentage of the % Bound obtained with unlabelled mEGF. Rat TGF-a showed a
near identical competitive reaction to mEGF for the EGF binding site (approximately
99%) (Figure 40). The concentrated conditioned media also showed competition of
84% and vNGF 37% and bFGF 32% competition (Figure 40).
3.8.7 Transmodulation by Mi bolerone.
The effect of various concentrations ofmi bolerone (0.1-100 nM) on EGF receptor
expression on the Tera-2 cells was investigated. The cells were incubated in the various
concentrations ofml bolerone for 24 hours prior to the commencement of the EGF
receptor assay. The specific binding at each concentration was found to be similar to
that found in the control cells which had been incubated in ordinary serum-free medium
prior to the assay (Figure 41). All specific binding data was adjusted according to cell
number at each concentration, although the cell number in the control group was not
found to be significantly different from the cell number in each of the mi bolerone
groups.
3.8.8 Western Blot Analysis.
Lane 1 of Plate 10 shows the positions of the molecular weight markers which were
run on an SDS-PAGE gel alongside solubilised receptors. The protein bands in lane 2
represent the solubilised EGF receptors from A431 cells which were used as a positive
control. The receptors have been immunolabelled with the monoclonal antibody for the
external domain of the receptor (EGF-R1). Bands of protein are identifiable in the 170
and 125 kDa molecular weight regions. A band is also noticeable around the 70 kDa
area which corresponds to the molecular weight of the internal domain of the receptor.
Lane 3 represents solubilised receptors from Tera-2 cells stained in a similar fashion.
The intensity of staining in lane 2 is less than lane 3. Proteins from the Tera-2 cells
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Figure 40
Competition for the EGF receptor was performed by replacing
mEGF in the radioligand exchange assay with other peptide growth
factors. All growth factors were used 50-fold in excess of the
concentration of labelled mEGF employed. The specific binding
obtained with each peptide is represented as a mean percentage
(± SEM, n=3) of the specific binding achieved with unlabelled
mEGF.
To test the specificity of the receptor multiple concentrations
of competitor should be used but unfortunately research
finance does not always permit this.
Figure 41
The transmodulatory effect ofmi bolerone on the expression of EGF
receptors in the Tera-2 cell line was investigated. Cells were incubated
in concentrations of rat bolerone ranging from 0.1 to 100 nM for 24
hours. At the end of the incubation period the cells were employed in a
ligand exchange assay to measure the specific binding of labelled
mEGF. Data is expressed as the mean percentage (± SEM, n=3) of
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Plate 10
Solubilised receptors from the Tera-2 cell line and the A431 cell line
were run electrophoretically on a 7.5% SDS- polyacrylamide gel, along
with standard molecular weights ranging from 14.6 to 200 kDa. The gel
was then equilibriated in transfer buffer before being transferred to a
nitrocellulose membrane. The membrane was then incubated with the
appropriate monoclonal antibody and stained employing the
streptavidin-biotin technique. Lane 1 illustrate the positions of
the molecular weight markers. Lane 2 shows the proteins of the A431
solubilised receptors which were detected by the EGF-RI monoclonal
antibody (the positive control). Similarly lane 3 illustrates the proteins
of the Tera-2 solubilised receptors detected with the same antibody
where as lane 4 illustrates the proteins detected with the F4 monoclonal
antibody. Finally lane 5 was run as a negative control for the Tera- 2
cell line and was incubated in TBS Buffer for 16 hours instead of the
monoclonal antibodies.
RESITI TS
were employed at twice the concentration as the A431 cells. In lane 4 the solubilised
receptors have been immunolabelled with the monoclonal antibody for the internal
domain of the receptor (F4). Finally lane 5 shows a negative control for the Tera-2
solubilised receptors (incubated in Tris buffer) which is completely free of labelled
protein bands and therefore indicates that the procedure is specific only to
immunolabelled proteins.
3.8.9 Immunocytochemistry.
Plates 11a and lib show staining of the Tera-2 cells with both the EGF-R1 antibody
and the F4 antibody . Staining for the external domain of the receptor was not observed
although staining for the internal domain was observed. A431 cells were used as a
positive control for both antibodies both the external and the internal domains of the
EGF receptors were expressed on the A431 cells (Plates 12a and 12b). For the Tera-2
cell line the cells were plated down after being detached from a flask where they were at
approximately 50% confluency. This was investigated further by performing
immunocytochemistry on cells which had been detached from 80 and 100% confluent
flasks. It was however found that the percentage of confluency from which the cells
had been detached had no effect on the EGF receptor expression with respect to
immunolabelling.
3.8.10 Human EGF and hTGF-a Concentrations in Tera-2
Cell Conditioned Media.
The conditioned media obtained from the Tera-2 cell culture mediumwere found to
contain 2.40 ± 0.33 pg of hEGF and 2.55 ± 0.78 pg of hTGF-a per ml of
conditioned media (Figure 42). To detect such small amounts of EGF and TGF-a in
the conditioned media 1000 ml was collected over a 4 week period from 8 flasks of




Plates 11 The internal domain of the EGF receptor was detected on the Tera-2
cells employing the monoclonal antibody F4 (a) the red staining).
However the external domain was not detected (b).
In order to check that both antibodies were working A431 cells were
incubated with the F4 monoclonal antibody (a) and the EGF-R1
monoclonal antibody (b). As illustrated both domains of the EGF
receptor were identified on the A431 cells (ie.the red staining).
hTGF-a hEGF
Figure 42
The concentrations of hEGF and hTGF-a per ml of conditioned
media taken from the Tera-2 cell line were approximately 2.40 pg/ml and
2.55 pg/ml . The conditioned media was collected from eight 75
ml flasks, all grown at near confluency over a 4 week period until
1 litre of the conditioned media had been obtained. Each flask at
near confluency would contain approximately 1 x 10"cells. The
conditioned media was filtered, dialysed, frozen and then
lyophilised. Finally it was reconstituted in 3 ml Tris buffer pH
7.4 and used accordingly in the hEGF and rTGF-a
radioimmunoassays. Values represent mean concentration
(±SEM, n=3).
centrifuged before adding PMSF (0.5 M) and lyophi Using the material. The
lyoph' lised material was then reconstituted in 3 ml RIA buffer. As a control serum-free
medium was processed in a similar fashion and assayed to see if it contained hEGF or
hTGF-a. It was found that the control contained no hEGF or rTGF-a.
3.11 Growth and Thymidine Incorporation Experiments.
Thymidine incorporation experiments were performed in order to assess the growth of
the cells in the presence of certain ligands at various concentrations, over variable
periods of time. At first cells were plated down at a density of 200,000/ml in 24 well
plates (section 2.10.5) However this was found to be too high a number, as after an 8
hour incubation period the cells were found to be dying due to confluency having been
achieved (Figure 43). Consequently a cell attachment study was performed (section
2.1Q5)and from the results (Table 4) a density of 50,000 cells/ ml was chosen for the
thymidine incorporation into DNA experiments.
Cell number in each experiment at each particular point was always
measured concurrently as was the amount of free thymidine still available. Cell number
was of importance because the cells could have been dying at the very high
concentrations of ligand which were used and this could have been observed as a
decrease in cell growth. Free thymidine was also measured to ensure that the cells were
always saturated.
3.11.1 Effect of mEGF and Mibolerone on Thymidine
Incorporation by Tera-2 cells.
No response was noted when the Tera-2 cells were incubated for 24 hours in various
concentrations of mEGF from 0.3-100 nM (Figure 44a) or mi bolerone from
0.3-100 nM (Figure 44b). The viable cell number remained approximately constant for




To perform thymidine incorporation experiments, Tera-2 cells were first
plated down (in quadruplate) at 2 x 10^cells per ml and incubated in the
test substance (mEGF,E]) or in serum-free medium (#) for upto 24 hours.
Thymidine incorporation is represented as the mean ratio (± SEM, n=4) of
the actual thymidine incorporated (dpmA) over the amount initially added
(dpml).
Cell Number/ml 2x 105 1.5 x 105 1 x 105 0.5 x 105
Plating Efficiency 85% ± 3 87% ± 5 78% ± 6 30% ± 10
Table 4
The effect of cell density on cell attachment to 24 well plates was investigated.
Cells were plated down at varying densities and after an interval of 24 hours
the mean number of cells which had actually become attached was calculated.
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Figure 44
The effect of mEGF and mi bolerone on the incorporation of
thymidine by Tera-2 cells was assessed. The concentrations of
mEGF (a) and mi bolerone (b) employed ranged from 0.3 to
lOOnM. The cells were incubated in the presence of these
substances for 24 hours. The mean thymidine incorporation
(± SEM, n=4^ at each concentration of test substance is expressed
as a multiple of the thymidine incorporation observed with the
control (serum-free medium). The mean values were also adjusted
according to the number of cells present in the control and test
groups.
RESULTS
effect on cell growth over a period of either 24 or 72 hours at a concentration of 10 nM
(Figures 45a and 45b). This was also the case for 10 nM mibolerone (Figure 45a and
45b). Cell number at each time point was measured once again and compared to control
but the cells were only found to have increased by an equal amount to that observed in
the control group.
3.11.2 Effect of rTGF-a on Thymidine Incorporation by Tera-2
Cells.
The effect of various concentrations of rTGF-a on cell growth was also investigated.
Concentrations from 1.0 -300 nM were chosen and incubated over a period of 24 hours.
Rat TGF-a was found to stimulate thymidine incorporation at concentrations of 10 nM
and above (approximately 1.95 compared to control at its maximum effect) (Figure 46).
However the cell number was not found to have increased even when compared to the
control group. Time course studies were also performed in which the cells were
incubated for 24 and 72 hours (Figures 47a and 47b). An increase in thymidine
incorporation was apparent after 24 hours, although when incubated for 72 hours no
further significant increase was noted. Once again cell number at each time point was
measured, although despite an increase in the test group this was not found to differ
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Figure 45
The effect of 10 nM mEGF (ZD, 10 nM ml bolerone (0) and serum-free
medium (•) on thymidine incorporation over a 24 hour period (a) and a 72
hour period (b) was assessed. The incorporation of thymidine by the cells in
each group was adjusted according to the number of viable cells present. The
results of each study are expressed as the mean (± SEM, n=4) of the ratio of




The effect of rTGF-a at various concentrations on the
incorporation of thymidine by Tera-2 cells was assessed. The
concentrations of rTGF-a employed ranged from 1.0 to 300
nM. The cells were incubated in the presence of rTGF-a for
24 hours. The mean thymidine incorporation (± SEM, n=4) at
each concentration of test substance is expressed as a multiple
of the thymidine incorporation observed with the control
(serum-free medium). The mean values were also adjusted
according to the number of cells present in the control and test
groups.
Rat TGF-a was found to significandy increase thymidine incorporation at








































































The effect of 10 nM rTGF-a (■) and serum-free medium (#) on
thymidine incorporation over a 24 hour period (a) and a 72 hour period
(b) was assessed. The incorporation of thymidine by the cells in each
group was adjusted according to the number of viable cells present.
The results of each study are expressed as the mean (± SEM, n=4) of
the ratio of the actual thymidine incorporated (dpmA) over the amount
initially added (dpml).
Rat TGF-a was found to significandy increase thymidine incorporation




The results presented above show that EGF receptors are present in human testicular
tissue and that they are located on Leydig and peritubular cells. Using biochemical and
immunohistochemical techniques EGF receptors were also identified in cancerous
testicular tissue. However EGF receptors were only found to be present on tumour
tissues of the subtype teratoma and not on the tumour tissues of the subtype seminoma.
Both cancerous and normal tissue were assayed for EGF and TGF-a like activity.
Both peptides were found to be present in normal tissue and all subgroups of cancerous
tissue. The cell line Tera-2 (derived from a lung metastasis of a testicular teratoma) was
also assayed for the EGF receptor. EGF receptors were expressed and it was further
established that this cell line secreted both EGF and TGF-a like molecules in vitro.
The concentrations of androstenedione, DHT and testosterone were also determined
within each group of tissue although no correlations between the concentration of
androgens and the concentration of EGF or TGF-a were found.
Employing the ligand exchange assay described in section 2.4.6 it was discovered that
8 nM labelled mEGF was sufficient to saturate the binding sites for EGF in human
testicular tissue. Saturation of the binding site was evident by interpretation of the
saturation curve which was found to plateau at concentrations > 8 nM labelled mEGF.
This value is similar to values for EGF receptors identified in human bladder cancer
(Neal et al, 1989), primary human breast tumours (Sainsbury et al, 1985a) and
human prostate cancer (Maddy et al, 1989). In each instance the Kd values for the high
affinity EGF receptor, 1.2 nM, 1.9 nM and 1.6 nM respectively were in close
4.2 The EGF Receptor
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agreement with the affinity constant for human testicular tissue of 1.8 nM in the present
study. In each case a single binding site was detected, represented by a linear Scatchard
plot.
Having evaluated a saturating dose of labelled mEGF, studies were
performed to ascertain whether the binding process was time and temperature
dependent and also to optimise the ligand exchange assay. This was of particular
importance as when measuring mEGF binding in some normal and all cancerous
tissues Scatchard analyses were not performed because of the small quantities of tissue
available. Therefore EGF binding within different tissues was compared, measuring the
amount of radioactivity bound to each sample expressed as dpm/mg protein. Each
sample was assayed under the same optimum conditions. The assay was performed
over 40 min at 32°C. A similar pattern of binding was also reported by Mukku and
Stancel (1985b) who identified the presence of EGF receptors in rat uterus. In that
study an incubation period of 60 min at 25°C was employed.
Specific components of normal testicular tissue were also examined for
the expression of the EGF receptor. As detailed in section 3.1.1 it was found that the
crude fraction, the mitochondrial and the microsomal fractions all contained EGF
receptors whilst the cytosolic fraction did not. In obtaining the crude fraction, the
nuclear fraction was also retained (see section 2.4.3). Ichii et al (1988) had previously
shown that on separation of the nuclear fraction from the crude fraction of rat livers, the
nuclear fraction was found to express the EGF receptor.
The results on EGF receptor cellular distribution in this study are in
close agreement with the results published by Maddy et al (1987) who fractioned
human prostate tissue. Maddy etal (1987) found that 68% of the total binding of EGF
was present in the crude fraction, 21% in the mitochondrial fraction, 10% in the
microsomal fraction and 0% in the cytosolic fraction whilst in this study
approximately 72% of the total EGF binding was found in the crude fraction, 12% in
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the mitochondrial fraction, 18% in the microsomal fraction and 0% in the cytosolic
fraction. For the purpose of this study the binding was maximised by spinning the
homogenised tissue (described in section 2.4.2) twice at 105,000 g to produce what
was termed the 'particulate' fraction which was composed of all the previous fractions
mentioned excluding the cytosolic fraction, i.e.the 'crude' fraction which also contains
the tissue nuclear fraction, was shown to contain the highest percentage of EGF
receptors per mg of protein within the tissue. This may suggest that some EGF
receptors within human testicular tissue are actually located intracellularly (i.e. in the
nucleus) as well as extracellularly]. It has recently been postulated by Logan (1990) that
growth factors may exert their effect by intracrine regulation of the nucleus. Until
recently the majority of polypeptide growth factors have been thought to act by either
paracrine or autocrine modes of action, with some specific examples of growth factors
which may also act in an endocrine manner ( for e.g. IGFs; Holly and Wass, 1989).
However it is now postulated that growth factors may act in an intracrine fashion which
does not require the growth factor to be secreted by the cell, nor does it require
receptors on the cell surface to mediate growth factor activity. It is proposed that
growth factors remain within the cell of origin and act on intracellular messengers to
regulate cell function (Auron et al, 1984, Stockli et al, 1989, Ishikawa et al, 1989).
The growth factors involved in postulated intracrine regulations exist within the
cytoplasm. It would therefore have been of interest to assay the above mentioned
subcellular fractions for EGF-like activity as EGF was later found to be present in the
testis (section 3.5). Ramani et al (1986) who studied the distribution of EGF receptors
in the human placenta organelles found that EGF receptors were expressed in the
lysosomes, rough and smooth endoplasmic reticulum and the Golgi apparatus as well
as microvillus plasma membranes. EGF receptors had previously been detected in
placenta cells by Lai et al (1984; 1986).
The effect of the protein concentration of the particulate fraction on
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specific binding ofmEGF to its receptor was also investigated. Unlike the results
reported by Maddy et al (1987) in which human prostate tissue was used, it was
found that in human testicular tissue the specific binding of EGF rose linearly with the
increasing concentration of protein of the particulate fraction employed. This was useful
as the protein concentration of the particulate fraction could be calculated after a ligand
binding experiment had been performed. The data was then adjusted if a particulate
fraction with a > 2 mg/ml protein concentration had been employed. In using the
fraction immediately after it had been prepared, freezing of the tissue was avoided. It
was found that storage of the particulate fractions at -70°C produced a decrease in EGF
binding over 10 days. However snap freezing and storage of the tissue at -70°C caused
no loss of EGF receptors in tissues which had been stored over a 6 month period.
Subsequently all tissues were used within a six month period and all particulate
fractions either fresh or within 10 days of having been prepared.
The optimum pH of the buffer employed in the radioligand exchange
assay was also investigated. It was found that the buffer could be used at a pH of
between 7.0 and 8.2 with no significant change in EGF binding and although at a lower
pH of 6.6 EGF binding was reduced, this difference was not of statistical significance.
The pH of the buffer was subsequently optimised to pH 7.4. Massague (1983) also
reported that binding of radiolabelled mEGF to A431 and human placenta membranes
was optimal over the pH range 7.0-9.0. However, the binding of radiolabelled rat
transforming growth factor alpha (TGF-a) to A431 cells and human placenta
membranes was highly sensitive to pH only being optimal within the pH range 8.0 to
8.5 (Massague, 1983). This may indicate that the EGF receptor site, although thought
to be common to both EGF and TGF-a, may be in a more advantageous conformation
for binding of TGF-a when the assay is performed at a pH between 8.0 and 8.5.
The optimum concentration of unlabelled mEGF required to compete
with labelled mEGF for the receptor site was also determined. Bennett and Yamamura
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(1985) found the amount of unlabelled mEGF required to compete for the EGF receptor
site to be approximately 100-300 -fold in excess of the concentration of radiolabelled
mEGF employed to produce maximum specific binding. This would ensure that the
pool of unlabelled mEGF available for binding to the EGF receptor would be at a
constant concentration with respect to the competition process taking place, despite
some unlabelled mEGF having been lost to the receptor sites. In this study a 50-fold
excess of unlabelled mEGF was found to produce maximum specific EGF binding and
this accords with Maddy et al (1987).
After optimising the radioligand exchange assay, saturation of the EGF
binding sites on human testicular tissue with radiolabelled mEGF was performed. The
saturation data was than used to construct a Scatchard plot from which the affinity
constant and the number of EGF receptors present per mg of protein was calculated. A
single high affinity binding site was identified with a Kd of 1.18 x 10"^ M and
approximately 528 fmoles binding sites per mg protein. The presence of a high affinity
binding site for EGF was first suggested by the evidence produced by Schechter et al
(1978) who observed that occupancy of a small fraction of EGF receptors resulted in
maximal stimulation of growth using cells. Schechter et al (1978) subsequently
proposed that a small population of high affinity receptors may be responsible for the
growth promoting effects of EGF.
4.3 Low and High Affinity Binding Sites for EGF
EGF binding sites have since been identified in numerous tissues although the binding
site does not always appear to have the same characteristics. King and Cuatrecasas
(1982), Hofmann et al (1984), Fanger et al (1984) and Maddy et al (1987) reported
two EGF receptor sites. King and Cuatrecasas (1982) described two binding sites: a
high affinity site (Kd 0.1-0.3 nM) and a low affinity site (Kd 2.0-15.0 nM). Hofmann
110
DISCUSSION
etal (1984) reported finding two binding sites on human uterine leiomyomas: a high
affinity site (Kd 0.1 nM) and a low affinity site (Kd 3.7 nM). In comparison Fanger
et al (1984) described finding two classes of receptors on HeLa S3 cells: a high
affinity site (Kd 0.16 nM) and a low affinity site (Kd 1.5 nM) and Maddy et al (1987)
found two binding sites on human prostate with a high affinity site (Kd 0.8 nM) and a
low affinity site (Kd 7.6 nM) respectively. In summarising the aforementioned data it
appears that a high affinity site must have a Kd in the range of 0.1-0.8 nM. Edery et al
(1985) however detected a low affinity binding site of 0.5 nM and a high affinity
binding site of 0.08 nM EGF on mouse mammary glands. Both affinities are much
higher than the Kd values previously mentioned.
In evaluating binding data one must consider whether two sites exist or
just one. In some studies (e.g. Edery et al, 1985) the two binding affinities are well
defined whereas in the case of Delarue et al (1988) on breast cancer the binding
affinities were only 2-fold different (3.2 nM and 6.3 nM respectively). In the latter case
it is possible that the data has been misinterpreted and that only a single binding site is
expressed although in the former case the difference in affinities suggests that there are
in fact two binding sites.
Boni-Schnetzler and Pilch (1987) illustrated that the presence of high
and low affinity binding sites was the result of the formation of active receptor dimers
from inactive receptor monomers. The dimer formation being the high affinity site with
a Kd value of 4.9 nM and the low affinity binding site with a Kd of 19.0 nM. Active
dimer formation was postulated to be necessary for the generation and maintenance of
the mitogenic signal elicited by EGF binding to its receptor. This was also confirmed
by the work of Bellot et al (1990) who reported that the high affinity site was
necessary for transduction of the EGF signal. However this was in contrast to the work
published by Biswas et al (1985) who reported that the monomer was in fact the high
affinity binding site and that EGF bound to the dimer to produce an activated monomer.
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In the study performed by Biswas et al (1985) freshly isolated receptors were used as
a source ofmonomers and aged receptors as a source of dimers. This in itself could
have lead to an ambiguous result as the EGF receptor kinase has a low stability which
will be potentiated during the course of time. Schlessinger has also more recently
postulated that the EGF receptor is a multifunctional allosteric protein (Schlessinger,
1988). It has already been established that EGF receptors are randomly distributed on
the surface of certain types of cell (Schlessinger et al, 1978; Haigler et al, 1978; 1979)
and that they undergo rapid lateral (Hillman and Schlessinger, 1982) and rotational
(Zidovetzki et al, 1981; 1986) diffusion. An allosteric oligomerisation model has
subsequently been proposed to explain how ligand binding to the extracellular domain
can activate the tyrosine kinase domain which is on the cytoplasmic side of the plasma
membrane (Schlessinger et al, 1983; Schlessinger, 1986; Yarden and Schlessinger,
1987a; 1987b). According to Schlessinger's model, monomelic EGF receptors are in
equilibrium with oligomeric receptors over the surface of the cell. The oligomeric
receptors are postulated to have a higher ligand binding affinity than the receptor
monomers and that the binding of EGF to the receptorwill act to stabilise the
oligomeric state. This subsequendy leads to the activation of the catalytic properties of
the kinase domain by subunit interaction between neighbouring cytoplasmic domains.
This model provides an explanation for the detection of two binding sites with different
affinities as well as supporting the detection of a single binding site with a high affinity.
In cases where a single binding site was detected the equilibrium between the receptor
conformations is postulated as being well over to the oligomeric receptor conformation.
Bellot et al (1990) recently reported that contrary to the notion that receptor affinity is
regulated by the off-rate of a ligand attaching to its receptor, high affinity binding is due
to an "elevated rate of association", the high affinity EGF receptor being more
accessible or perhaps more electrostatically attractive to diffusing ligand. Bellot et al
(1990) also pointed out that that there is no direct evidence to prove that there are two
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different populations of EGF receptor with different affinities for EGF but only that a
single receptor may exist in either a monomelic or oligomeric form (Schlessinger,
1988) and subsequently exhibit two different affinities. Weber et al (1984) performed
quantitative binding experiments with radiolabelled EGF which indicated that the
stoichiometry of ligand binding to the EGF receptor is 1:1. This agrees with the
findings of Schlessinger (1988) and Bellot et al (1990) that indeed two different
affinity binding sites can exist but that one site exists which associates more quickly
with EGF (i.e. the oligomeric receptor which illustrates a higher affinity for the EGF
molecule by having to available sites). The fact that the receptor may be in a dimeric
form also correlates with the work published by Schreiber et al (1983),
Boni-Schnetzler and Pilch (1987), Schlessinger (1988) and Defize et al (1989).
Defize et al (1989) used a monoclonal antibody to inhibit the lower
affinity binding site (mAb E9) and Bellot et al (1990) a monoclonal antibody
(mAb 108) to inhibit the high affinity binding site. In both cases the results derived
suggested that the high affinity binding site plays the major role in transduction of the
EGF signal. Gill et al (1987) postulated that in comparison to receptor aggregation
suggested by Schreiber et al (1983) and to the disaggregation of dimers to monomers
suggested by Biswas et al (1985), that activation of cytoplasmic tyrosine protein
kinase is the result of a single molecule act transmitted via the transmembrane alpha
helix to alter the ATP binding site. However, this describes an energetically
unfavourable state. In the allosteric model suggested by Schlessinger (1988) the
energetically unfavorable conformational change which transmits the signal through the
transmembrane region is bypassed as monomeric EGF receptors are in equilibrium with
oligomeric receptors which exhibit a higher affinity for EGF and where upon binding
of EGF to the oligomeric receptor the oligomeric state is stabilised. Ligand binding is
the major regulator of the enzyme activity which in turn results in a conformational
change that increases the tyrosine kinase catalytic rate as well as phosphorylation of the
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various cellular substrates and hence regulates signal transduction at the same time as
regulating the affinity of the receptor. Receptor oligomerisation has been confirmed by
various methods including morphological (Haigler et al, 1979), biophysical (Hillman
and Schlessinger, 1982, Zidovetzki et al, 1981; 1985) and biochemical (Boni-
Schnetzler and Pilch, 1987; Cochet et al, 1988; Fanger et al, 1986; Yarden and
Schlessinger, 1987a) approaches.
4.4 Single EGF Binding Sites: Low or High Affinity Binding
Sites ?
Single EGF binding sites have been reported by Banks-Schlegel and Quintero (1986),
Traish and Wotiz (1987) and Schuuramans et al (1988), with respective Kd values of
0.2-2.7 nM, 1.16 nM and 0.45 nM. In the case of Banks-Schlegel and Quintero (1986)
the single binding site is quoted as having an affinity of between 0.2 and 2.7 nM. To
interpret this result as a single binding site is possibly incorrect as there is a 13-fold
difference between the highest and lowest Kds determined. It is possible that the data
represents two binding sites. In researching the literature available on the affinity of the
EGF receptor the majority of the single studies which report Kds are in the range
previously quoted for high affinity binding sites (0.1-0.8 nM) (section 4.3) although on
ovine skin Wynn et al (1989) detected a single binding site with a Kd value of 0.06
nM (a much higher affinity binding site to those previously reported). For instance the
single affinity constants determined by Neals et al (1989) and Sainsbury et al (1985)
are closest to the values quoted as being in the higher affinity binding group
O'.e.between 0.1 and 0.8 nM). However in contrast they are also closer to the values
quoted in the low affinity binding group published by King and Cuatrecasas (1982) of
2.0 to 15.0 nM. It has been suggested that differences in experimental techniques
employed as well as the variance in the methods chosen for analysis of the data may be
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preventing or even biasing the detection of two binding sites. In detecting two different
affinity binding sites one must also consider the possibility of the two sites existing on
two types of cell within the same tissue homogenate. For example Edery et al (1985)
illustrated that two EGF receptors were expressed in the membrane preparation
prepared from mammary gland membranes, but that once the epithelial cells were
separated, only one class of the EGF receptors previously found was identified.
In the studies performed by Mukku and Stancel (1985b) it was
suggested that the various methods used for Scatchard analysis may in fact lead to
ambiguity in the affinity constants which are detected. For example it was suggested
that curvilinear Scatchard plots are sometimes obtained if binding studies are performed
by adding increasing concentrations of unlabelled EGF to the reactions, but that linear
plots are obtained if binding studies are performed by the isotope dilution method (the
latter being the method employed in this study). In this study it was found that the
method whereby radiolabeled EGF was diluted actually limited the range in which the
affinity constant(s) of EGF could be detected. This was because when very low
concentrations of radiolabelled ligand were used the specific binding was difficult to
interpret as much higher standard errors were incurred. In this study the saturation
analysis binding data was analysed using a curve fitting programme written and
developed by Munson and Rodbard (1980) which evenly weights all of the ligand
concentrations used. It therefore eliminates difficulties in interpreting the binding data
which may occur when using Scatchard analysis (Scatchard, 1949) which has
previously been shown to unevenly weight the binding data obtained when very low
concentrations of ligand were employed (Bennett and Yamamura, 1985). Another
advantage gained from using the computer programme was that the data could be
analysed for any number of binding sites. In this study the saturation results were




It is however, likely, that given the data available in the literature both
high and low affinity binding sites for EGF exist but that the high affinity site is an
allosteric binding site. The results which represent single binding sites may be
explained by the dis-association of such oligomeric states during the sample preparation
or alternatively by the possibility that the equilibrium between the oligomeric receptor
and the monomelic receptor is displaced. In turn it is possible that identification of a
single binding site on certain types of tissues could be a characteristic of a non¬
functional binding site as Schlessinger's model postulates that the receptor must be in
an oligomeric state for the EGF signal to be transmitted (Schlessinger, 1988).
4.5 Signal Transduction and Non-functional Receptors
The question of the functionality of the EGF receptor on certain types of tissue has been
discussed by Livneh et al (1986; 1988), Chen et al (1987), Honegger etal (1987a,b)
and Moolenaar (1988). Each have reported that the tyrosine kinase activity of the EGF
receptor appears to be a necessary part of the signal transduction process, because site
directed mutagenesis of this activity results in a receptor that binds and internalises EGF
but is completely dysfunctional in signal transduction and normal receptor routing
(Honegger et al, 1987b). The binding of EGF to the receptor stimulates a series of
rapid responses, including phosphorylation of tyrosine residues within the EGF
receptor itself and within many other cellular proteins to produce hydrolysis of
phosphatidyl inositol and release of calcium from intracellular stores (Carpenter and
Cohen, 1979). However the mutant receptor kinase is unable to stimulate [Na+]/[H+]
exchange, Ca^+ influx and inositol phosphate formation Moolenaar (1988). Whether
EGF receptor affinity (and therefore possibly oligomerisation) is related to functionality
(with respect to kinase activity and signal transduction) remains an open question. It
would be of interest to define whether the single binding site for EGF discovered on
human testicular tissue was functionally active by assessing whether the tyrosine kinase
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enzyme which phosphorylates tyrosine 1173 was stimulated on binding of EGF to the
membrane. It is known that the mechanism by which protein kinase C produces
autophosphorylation of the EGF receptor at threonine*^, js independent of the
tyrosine protein kinase activity which phosphorylates tyrosine 1173 an(j leads to
transduction of the EGF signal (Davis, 1988). However both phosphorylation of
threonine*^ anci tyrosinel 173 lead to agonist induced down regulation of the receptor
(Davis, 1988). It is therefore as yet not clearly understood how the two kinase enzymes
are capable of regulating the expression of the EGF receptor which is known to be
important in the transduction of the signal and yet only tyrosine protein kinase has been
found to be involved in transduction of the EGF signal.
4.6 Further Characterisation of the EGF Receptor
Competition of the receptor site with other unlabelled peptides besides EGF was
performed to further clarify the specificity of EGF for its receptor. Several other growth
factors and hormones of similar composition, and in some instances structure were
used. It was found that only TGF-a competed (approximately 24%) for the EGF
receptor site. It is well known that TGF-a binds to the EGF receptor and therefore
competition for the receptor site on human testicular tissue is not unexpected. However
the fact that only 24% competition was observed may suggest that the receptor site may
favor binding of EGF in comparison to TGF-a. However as reported previously in
section 4.2, pH of the buffer employed in the ligand exchange assay can effect the
relative affinity of the EGF receptor for EGF and TGF-a.
The EGF receptor has in fact been found to be activated by three distinct
growth factors encoded by separate genes: EGF, TGF-a and vaccinia virus growth
factor (VVGF). These growth factors have similar disulphide backbone structures but
their overall sequence is only 24% identical (for review see Apella et al, 1988). All
three growth factors have been found to compete for the EGF receptor and in doing so
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express similar affinities (for review see Apella et al, 1988). This suggests that they
may be binding to a similar region of the EGF receptor. However a report recently by
Winkler et al (1989) suggests that EGF and TGF-a bind to the EGF receptor but in
different ways. Winkler et al (1989) reported that a monoclonal antibody to the EGF
receptor (13 A9) was capable of producing a stable conformation of the EGF receptor
which was not favorable for TGF-a binding. Alternatively, it has been suggested that
the monoclonal antibody blocked a part of the surface of the exterior portion of the
receptor site which was necessary for TGF-a binding but not EGF binding. The results
from this study support the theory put forward by Winkler et al (1989) which suggests
that the EGF receptor can vary in its affinity for EGF and TGF-a according to its
environment.
The EGF binding site on human testicular tissue was further found to be
both heat labile and trypsin sensitive, indicating that the receptor was of a proteinaceous
nature. However the heating process only destroyed 50% of the specific binding
observed with respect to controls . It is possible that the preheating period of 10 min
was not sufficient to produce total inactivation of all the EGF receptors. Hock and
Hollenberg (1980) reported having found irreversible inactivation of the EGF receptor
at 55°C and 65°C respectively in human placenta when the membranes were incubated
for a period of 10 minutes. However they did not report whether the 'irreversible
inactivation' accounted for 100% of the EGF binding previously noted in the control. It
has also been assumed that the consequence of heat shock is always followed by
denaturation of proteins. However Munro and Pelham (1984) have shown that
stabilisation of proteins after heat shock can occur which in this case could explain the
presence of 50% of the EGF receptor sites which remained available for binding after
heat treatment.
Molecular characterisation of the receptor using the crosslinking agent
Disuccinimidyl suberate illustrated that labelled mEGF was binding to a protein and that
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the radiolabelled mEGF/protein complex had a molecular weight of 125 kDa. In the
past such a molecular weight complex has been interpreted as EGF having bound to a
degraded form of the EGF receptor (Weisman et al, 1987). It is possible that in this
study the 170 kDa form of the receptor reported by Mukku (1984) and Cohen et al
(1980) may have been degraded by a protease. In the past it has been shown that a
calcium dependent protease 'calpain' acts by removing a 20 kDa fragment from the
EGF receptor (Cassel and Glaser, 1982). In this study calcium sequestering agents
were incorporated in the appropriate buffers to avoid such degradation. There have
been various other reports identifying degraded forms of the EGF receptor, for example
Decker (1989) identified a 130 kDa, 125 kDa and 105 kDa receptor species using
immunoprecipitation on NIH-3T3 cells. This is in support of the findings in this study.
The 125 kDa and 130 kDa species were shown to have been derived from the 170 kDa
receptor and the 105 kDa species from the 130 kDa species. Similarly, Cohen et al
(1982), Cassel and Glaser (1982) andWeisman et al (1987) reported a 150 kDa
receptor which again was thought to be a proteolytic fragment of the EGF receptor.
Linsley and Fox (1980a; 1980b; 1980c) also reported 160 kDa, 145 kDa and 115 kDa
EGF receptor complexes using the epidermoid carcinoma cell line A431. Weisman et
al (1987) reported finding a receptor complex with a 125 kDa molecular weight in
meningioma
human again confirming the results of this study. Chinkers and Brugge
(1988) had earlier shown that tryptic cleavage (1 (ig/ml) of purified EGF receptors from
A431 cells resulted in receptor fragments ofmolecular weights 165 and 125 kDa. It
may therefore be assumed that the 125 kDa EGF receptor species identified in this
study is a fragment of the 170 kDa form and that a trypsin-like endogenous protease
must be present in human testicular tissue. Weisman et al (1987) however also
illustrated that the 125 kDa species was able to bind EGF in a specific manner. The
125 kDa species although a degraded product of the 170 kDa may therefore still be able
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to function as a functional receptor.
4.7 Location of the EGF Receptor on Human Testicular Tissue
Localising the EGF receptor in normal testicular tissue would provider greater insight
into the the particular cells affected by EGFm vivo. The F4 monoclonal antibody for
the internal domain of the receptor (Gullick et al, 1986) and the EGF-R (Starkey et al,
1975) and EGF-R1 (Waterfield et al, 1982) monoclonal antibodies for the external
domain of the receptor were employed with an indirect immunohistochemical
streptavidin-biotin technique employing alkaline phosphatase (section 2.6). This
method was chosen because of its sensitivity and specificity in contrast to the direct
ABC peroxidase method (Bains and Miller, 1988) which is often employed. In the
ABC peroxidase method the peroxidase enzyme was found to label endogenous
peroxidase which could not be distinguished from the specific staining.
In the alkaline phosphatase streptavidin-biotin method the endogenous
alkaline phosphatase is blocked by levamisole which is introduced in the substrate
reagent. In the case of the ABC peroxidase technique the endogenous peroxidase can be
quenched by incubating the section in 0.6% hydrogen peroxide but unfortunately this
leads to a reduction or even a loss of staining intensity due to the destruction of antigens
which became evident when the sections were processed. This is
particularly a problem when cryostat sections are used. The streptavidin reagents also
have a longer shelf life compared to the ABC peroxidase reagents. The streptavidin
solution has a neutral pH and therefore does not have any preference to charged ions
which may be present within the section, whereas the avidhi in the ABC method has
(pers. commun. Mr Lawrence Brett, M.L.S.O., Western General Hospital).
Streptavidin does also not attach to carbohydrates in the tissue section although avidin
alone does. One other advantage of the streptavidin technique was that it enabled the
areas of lipofuskin to be detected, as when using an ABC peroxidase technique with
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diaminobenzadine (DAB) the staining of lipofuskin could not be distinguished
from the positive staining. In the case of streptavidin alkaline phosphatase the fast
red pigment which was used is only partly absorbed by the
lipofuscin material to take a pink rather than a red stain in contrast to the EGF receptors.
However in employing the peroxidase technique with DAB the lipofuscin becomes
stained to the same extent as true positive staining. The streptavidin biotin procedure
overall provides a much clearer and more specific staining pattern as well as being
more economical.
Employing the indirect streptavidin biotin technique EGF receptors were
found to be located in the interstitium of normal testicular tissue obtained from
orchiectomy samples (mean age 72 years), on foetal tissues (obtained from abortions
carried out after a period of 15 to 19 weeks gestation and on biopsy specimens (mean
age 32 years) obtained from men undergoing vasectomy reversal. It is therefore evident
that EGF receptors are present during the course of human testicular development and
function and therefore may play some role in the intricate control of testicular function.
Localisation of EGF receptors on sections of human testicular tissue
has not been reported before, although, EGF receptors have been reported to be
expressed on rat Sertoli and Leydig cells (Morris and Mather, 1984). A recent report
(Suarez-Quian et al, 1989) identified EGF receptors in testes from mature and
immature rats and immature monkeys. The receptors were found to be present on the
Sertoli cells (mesenchymal) of the immature rats and monkeys and also in the interstitial
areas of the mature rats (Suarez-Quian et al, 1989). This accords with the results of
Skinner (1989) who also found the EGF receptor to be present on the Sertoli cells of
immature rat testes. It is therefore possible that EGF receptors are only expressed on
Sertoli cells in immature mammals, hence the reason why they were not detected on
human testicular samples obtained from men with a mean age of 72 years.
Suarez-Quian et al (1989) employed immunofluorescence as the
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method for detection of the EGF receptor, which in comparison to
immunohistochemical detection is often thought of as more difficult to interpret because
the morphology of the tissue section and the staining itself can not be viewed
simultaneously. Also when using immunofluorescense the clarity of the staining is
often less sharp and a more diffuse pattern is apparent. This in turn can produce
difficulties when determining on which cell the staining is appearing if the cells are in
close proximity (i.e. peritubular and Sertoli cells). As previously reported Suarez-
Quain et al (1989) identified EGF receptor expression on both Leydig and Sertoli cells.
It is possible that the interpretation of Sertoli cell staining may well include peritubular
cell staining as identified in the present study. Also Suarez-Quian et al (1989) used a
polyclonal antibody rather than a monoclonal antibody which can often decrease the
specificity of the detection procedure.
To clarify the location of the EGF receptor on human testicular tissue
two different antibodies EGF-R and EGF-R1 were employed; the former for paraffin
sections and the latter for frozen sections. As a direct comparison frozen sections and
paraffin sections obtained from the same patient were processed and labelled with the
appropriate antibodies. The morphology of the frozen sections was found to be poor.
EGF receptors were clearly present in interstitial tissue although the cell type which
appeared stained could not be positively identified. Subsequently tissue sections were
examined which were cut from paraffin blocks. The morphology of these sections was
superior to that of the frozen sections and while using the antibody EGF-R, the staining
was very similar to that seen with EGF-R 1 on frozen sections. However as staining
was much clearer it could be definitely localised to Leydig and peritubular cells.
However the EGF-R 1 antibody employed on frozen sections produced variable results
in terms of intensity of staining especially when repeated on the same section. Because
of this variation no attempt was made to relate intensity of staining to the level of EGF
receptor expression although this has been done in the past by Maddy et al (1987) on
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prostate tissue. When using the F4 antibody on either the paraffin or frozen sections no
staining was apparent indicating that the internal domain of the EGF receptor was
absent. The absence of the internal domain of the EGF receptor may indicate that the
receptor is non-functional. There is no evidence in the literature to suggest why the
internal domain of the receptor should be absent. It is possible that the internal domain
of the receptor has morphologically changed due to stimulation by endogenous EGF in
the testis which in turn inhibits the F4 antibody from binding to the internal domain.
Alternatively the receptor may have been degraded during the preparation of the section
and thus is not available for binding.
4.8 EGF and TGF-a in Human Testicular Tissue.
As early as 1971 the activity of ornithine decarboxylase in the testes of neonatal mice
was found to be markedly enhanced by EGF (Stastny and Cohen, 1971; Statsbury and
Cohen, 1972). Since then it has been identified in numerous tissues and body fluids
(Hirata and Orth, 1979; Shikata et al, 1984; Gregory et al, 1986). With respect to the
testis EGF has been shown to stimulate lactate production in cultured rat testicular cells
(Mallea et al ,1986) and in the human Leydig cell tumour line MA 10, mEGF has been
shown to potentiate the activation of steroid biosynthesis via hCG and cAMP
stimulation (Ascoli et al, 1981; 1984; 1987). Epidermal growth factor activity has
already been measured in human testicular tissue (Elson et al, 1984) at a concentration
of 3.2 ng of EGF per gram of tissue. In this study EGF was found to be present at a
concentration of 5.16 ng/g wet testicular tissue in normal tissue which was statistically
significantly higher than the 2.23 ng/g detected in treated testicular tissue. This would
suggest that the concentration of EGF in the testis is affected by anti-androgens or
synthetic oestrogens administered systemically. This in turn could reflect the low if not
negligible expression ofEGF receptors previously noted in treated testicular tissue
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employing biochemical techniques (section 4.2). The patients from which the treated
testicular tissue was obtained, had received cyproterone acetate or diethylstilboestrol as
treatment for prostatic cancer.^Proterone an<^ st^k°estroWe known to affect the testis
by acting on the anterior pituitary to inhibit LHRH secretion (Bruchovsky et al, 1988).
In inhibiting LHRH secretion, LH secretion is also inhibited which in turn reduces
steroidogenesis. One may postulate therefore that in the absence of LH or possibly
reduced steroidogenesis the expression ofEGF receptors on the Leydig cell is reduced.
However as suggested previously a decrease in LH secretion would manifest itself as a
decrease in testosterone production. As shall be discussed later, a decrease in
intratesticular concentrations of androstenedione, DHT and testosterone in treated tissue
was seen but it was not statistically significantly different from the concentrations
measured in normal tissue.
Mori et al (1989) also detected endogenous EGF in testicular tissue by
using a monoclonal antibody for hEGF. Human EGF was present in both the
interstitium and the seminiferous tubules of the testis using a polyclonal antibody to
hEGF. Feminised testes were also studied and hEGF was only identified in the
interstitial areas of the tissue. Bartlett et al (1990) reported that in stage synchronised
spermatogenesis in the rat testicular EGF concentrations were higher in testes
synchronised between stages IX and II than at other stages of the cycle of the
seminiferous epithelium. This elevation in testicular EGF concentrations correlated well
with mitotic division of type A spermatagonia at stages IX, XII and XIV of the the
cycle of the seminiferous epithelium. Tsutsumi et al (1986) also reported that
sialoadenectomy in the mature male produced a decrease in the number ofmature sperm
in the epididymis by as much as 55%. The number of spermatids in the testis were also
found to have decreased by 40 to 50% and the number of spermatocytes to have
increased by approximately 20% (Tsutsumi et al, 1986). Administration ofEGF to the
sialoadenectomised mice restored both the sperm content of the epididymis and the
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number of spermatids in the testis to normal. Thus it was suggested that EGF may play
a role in male reproductive function by stimulating the meiotic phase of
spermatogenesis. If this is the case then perhaps EGF is also involved in infertility.
Human epidermal growth factor or urogastrone has already been detected in human
seminal plasma from both infertile and fertile males (Richards et al, 1988).
TGF-a was also detected in both the normal and treated groups of
testicular tissues which were studied. In normal tissue 2.76 ng/g wet testicular tissue
was measured which was again statistically significantly different from 1.92 ng/g
measured in treated testicular tissue. No correlation between the concentrations of
hTGF-a and hEGF in normal testicular tissue was found.
In measuring human TGF-a a rat TGF-a RIA kit was employed
because no human TGF-a RIA kits were available. However it was suggested by the
manufacturers that because there is a high degree of sequence homology between rat
and human TGF-a (as only four amino acids are different in rTGF-a in comparison to
hTGF-a , Connolly and Rose, 1989), the rTGF-a RIA kit could be used to detect
hTGF-a (see section 2.2.6). The difference in
structure of rat and human TGF-a affects antigen antibody interaction, such that only
32% of hTGF-a is detected. This factor was taken into consideration in all hTGF-a
calculations. The fact that hTGF-a was found in the normal and treated groups of
testicular tissue, suggests that TGF-a as well as EGF may play an important role in
testicular function. P-Mod-S, a factor first identified by Skinner and Fritz (1985) and
reported to be secreted by peritubular cells to act on Sertoli cell function
in coculture^may modify TGF-a secretion (Skinner, 1989). The factor
P-Mod-S which was synthesised by the rat peritubular cells and secreted into the




4.9 Other Factors in the Testis
In the past few years various reports have been published on other factors in the testis
which may assist in its normal function. Sertoli cells have been shown to produce an
EGF like substance (Holmes et al, 1986; Buch et al, 1988). Holmes et al (1986)
investigated the ability of conditioned medium obtained from rat Sertoli cell culture to
displace labelled mEGF binding to its receptor. The conditioned medium was found to
contain EGF competing activity as well as producing a mitogenic response when used
in culture of Sertoli cells. However, when the conditioned medium was assayed for
EGF like activity the medium was found to contain no EGF immunoreactivity (Holmes
et al, 1986). This result could have been attributed to the fact that this EGF like
material was in fact TGF-a as recently characterised by Skinner et al (1989) which is
produced by the peritubular cells and competes for the EGF receptor yet has no EGF
immunoreactivity. Skinner et al (1989) also found that this protein has an autocrine
stimulatory effect on the peritubular cells as EGF receptors were also found to be
expressed by the peritubular cells. This is in support of the findings in this study.
Brown et al (1989) have shown that in rams depilatory doses of mouse
EGF temporarily impaired gonadotrophin and androgen secretion by inhibiting LHRH
release from the hypothalamus. Such treatment appeared to have no effect on the
responsiveness of the pituitary to LHRH and it was therefore postulated that an already
established mechanism for decreasing LHRH could have been activated by the EGF
Brown et al (1989). One such regulator is inhibin which is known to be the messenger
involved in the negative feedback mechanism to the anterior pituitary for the control of
steroid production (Hao Li and Ramasharma, 1987). Gonzales et al (1989) recently
found that inhibin secretion is increased by EGF when administered to isolated
segments of rat seminiferous tubules in vitro. Morris et al (1988) also found that
inhibin accumulation is stimulated by EGF when rat Sertoli cells are cultured in vitro.
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It has been established that inhibin is produced by the Sertoli cells which
are in contact with the peritubular cells through the neighbouring basement membrane.
Rat Sertoli cells have also been shown to express EGF receptors by Skinner (1989)
although this was not corroborated for human tissues in this study. It is however
possible that TGF-a which is secreted by the peritubular cells acts in an autocrine
manner to regulate its own synthesis as well as acting in a paracrine manner on the
Sertoli cell to stimulate inhibin production. The fact that EGF receptors were found on
Sertoli cells in rat and not in human may suggest a species difference. However as
mentioned previously in section 4.7 the absence of EGF receptors on Sertoli cells
could be attributed to the fact that the testes employed in this study were mature. In
other studies EGF receptors have only been found to be expressed on Sertoli cells
when the testis under investigation are immature (Mori et al, 1989; Skinner, 1989;
Suarez-Quain et al, 1989).
Skinner and Moses (1989) have found that TGF-p was produced by
both peritubular and Sertoli cells through the identification of gene expression and
protein synthesis. TGF-P was found to have no effect on Sertoli cell function but it did
inhibit the ability ofTGF-a to promote peritubular cell growth. TGF-p has also been
found to inhibit human chorionicgonadotropin (hCG) stimulated steroidogenesis in
primary rat Leydig cell cultures (Lin et al, 1987). In contrast TGF-a had no effect on
either the basal or hCG-stimulated testosterone production and did not modify the effect
of TGF-P on steroidogenesis. The effect of TGF-P on steroidogenesis has been further
supported by the in vitro work of Avallet et al (1987) and Fauser and Hsueh (1988).
The data indicates that inhibin and TGF-p which are released by the Sertoli cells may




In reviewing the literature it has been found that authors have often
commented on the fact that it is the prepubertal cells that seem to be producing the
maximum response being measured. For example Feig et al (1980) found that the
mitogenic activity in the seminiferous tubules isolated from newborn mice is five
times greater than that in the tubules of adult mice. In this study it was found that
the EGF receptors appeared to be much more dense in the foetal tissues (obtained
from abortions carried out after a period of 15 to 19 weeks gestation) which were
employed in the immunohistochemistry procedure in comparison to the adult testis
which were used.
It is possible that EGF-like activity is under the control of androgens and
that an increase in mitogenic activity in the seminiferous tubules of foetal tissue
would coincide with an increase in intratesticular steroids. In the foetal testes it is
well documented that there is a surge of steroid production during the 15-19 weeks
gestation period (Rommerts and van der Molen, 1989) although it is possible that
numerous other factors may contribute or be responsible for this event.
4.10 The Role of Steroids in the Testis
As previously discussed in section 1.5 one of the primary functions of the testes is
the manufacture of androgens. Testosterone, which is the essential androgen
manufactured by the testis, exerts its effects both internally and externally to the testes.
Within the testes spermatogenesis cannot be maintained in its absence (Sharpe et al,
1988). It is understood that testosterone mediates its effect on spermatogenesis via the
androgen receptor located within the Sertoli cell (Sanborn et al, 1975; Grootegoed et
al, 1977; Wright and Frankel, 1980). Testosterone has also been found to stimulate the
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secretion of ABP and seminiferous tubular fluid in the rat (Sharpe, 1983; 1986).
Receptors for testosterone have also been identified in peritubular cells (Verhoeven,
1980). As discussed earlier Skinner and Fritz (1985) reported that androgen stimulation
of Sertoli cell function was enhanced by peritubular cells via P-Mod-S,
EGF receptors have also been found
to be expressed by the Leydig cell. It is therefore possible that Leydig cells are
somehow modulated by TGF-a or EGF via a direct action or via modification of Sertoli
cell and peritubular cell functions. The concentrations of androstenedione, DHT and
testosterone for sixteen individual tissue samples were measured in this study as well as
the levels of endogenous TGF-a and EGF for 12 of these samples. The steroid levels
in normal testes were found to be 0.46 nmoles/g androstenedione, 0.29 nmoles/g DHT
and 15.58 nmoles/g testosterone whereas in the treated tissue they were 0.29 nmoles/g,
0.31 nmoles/g and 14.52 nmoles/g respectively. The levels of androgens in normal
testicular tissue were further supported by the values reported by Purvis et al (1978)
and De La Torre et al (1982) (Table 5). Despite the steroid levels in both papers having
been measured from wet tissue, the results in this study could be converted from the
concentration measured in 1 gram of dry testicular tissue to 1 gram of wet testicular
tissue. This was performed by taking into consideration the mean percentage water
evaporated after lyophi lisation (85%). Purvis et al (1978) and De La Torre et al
(1982) also used a similar age group to the one used in this study. The concentrations
of androstenedione, DHT and testosterone in the treated group of testis were also found
to be similar to those found in the normal testis. However despite no change in
intra-testicular androgen levels the anti-androgens appeared to have produced a decrease
in the expression of the EGF receptor. The effect of the anti-androgens (cyproterone
and stilboestrol) on the body is to produce a decrease in androgen production by acting
centrally on the pituitary to inhibit the secretion of LHRH (Bruchovsky et al, 1988).
Cyproterone acetate for example, owing to its progestational activity, overrides the
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negative feedback inhibition of the hypothalamus by testosterone (Bruchovsky et al,
1988). Stilboestrol (diethylstilboestrol) also acts by overriding the negative-feedback
inhibition of the hypothalamus by testosterone. This again reduces the secretion of both
LHRH and LH accompanied by marked lowering of plasma testosterone levels into the
castrate range (Bruchovsky et al, 1988). However the concentration of androgens
measured in the treated tissues was not statistically significantly lower than the
concentrations measured in the normal tissues. This might best be attributed to the delay
in time of the patients receiving their last dose of drug and them having an orchiectomy.
In addition patients with intact anterior pituitaries can "escape" from anti-androgen
therapy and this is illustrated by an increase in LH secretion which overrides the effect
of the anti-androgen (Varenhorst, 1988). Unfortunately however LH was not measured
as a routine parameter in these patients and hence this theory could not be evaluated.
4.11 Endogenous EGF in the Human Testis and Its Possible
Regulation by Androgens.
In view of EGF receptors having been localised to Leydig cells the possible relationship
between EGF and steroidogenesis was also investigated. This was performed by
comparing the concentration of EGF with the concentration of androgens present within
each individual tissue sample. The results for each tissue sample were then grouped
together and analysed to see if overall there was any correlation between EGF and
TGF-a concentrations and androgen concentrations. No correlation was observed
between any of the steroid hormones and growth factors which were measured. This
can perhaps be attributed to the very small groups of tissues which were involved.
Steroid regulation of EGF production has been illustrated in the
submandibular gland (SMG) of the mouse (Bynny et al, 1974). Tuomela et al (1989)
recently reported that mouse EGF concentrations were altered by gonadectomy and
treatments with oestradiol and progesterone. EGF concentrations were found to
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decrease in either the absence of androgens or in the presence of
oestrogens/progesterones. In support of this is the fact that in the SMG of the male
mouse the concentration of EGF is at least ten times higher than that found in the SMG
of the female mouse. Hiramatsu et al (1988) have shown that castration of the male
mouse produces a marked reduction in the concentration of EGF in the prostate gland
and that this reduction is restored by the treatment of castrated animals with
testosterone. These results indicate that the synthesis of immunoreactive EGF in the
prostate is regulated by endogenous androgens as is the case for its synthesis in the
submandibular gland (Bynny et al, 1974). Pascal et al (1989) reported that castration
of the male mouse produced a decrease in EGF mRNA levels in the submandibular
gland, thus providing further evidence for regulation of EGF gene expression in
response to steroid hormones. EGF has also been found to regulate the production of
certain hormones. EGF stimulated thyroid hormone secretion in the mouse (Ahren,
1987) and decreased progestin production in cultured rat granulosa cells (Jones et al,
1982). EGF has been found to stimulate steroidogenesis in vitro (Verhoeven and
Cailleau, 1986) directly stimulating the output of C19 steroids (testosterone and
androstenedione) and C21 steroids (progesterone, 17a-hydroxyprogesterone and 20a-
hydroxypregn-4-en-3-one) in freshly prepared Percoll-purified Leydig cells from
prepubertal and adult rats and mice, and in interstitial cells from immature rats cultured
in the presence or absence of LH.
In several other types of tissue it has already been reported that EGF
receptors can be regulated by certain steroids (Mukku and Stancel, 1985; Traish and
Wotiz, 1987; Murphy et al, 1986 ). For example, in the prostate gland Traish and
Wotiz (1987) found that androgens decreased EGF receptor expression. Castration of
mature rats resulted in a 3-to 6-fold increase in labelled mEGF binding, while treatment
of 7-day castrated rats with 5a-dihydrotestosterone decreased the number of EGF
binding sites. Mukku and Stancel (1985) looked at the effects of oestrogen on EGF
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receptor expression in vitro within uterine tissue of immature female rats. It was found
that following hormone treatment EGF receptor levels increased between 6 and 12
hours and remained elevated for up to 18 hours before declining between 18 and 24
hours. Non-oestrogenic hormones such as progesterone, dexamethasone and DHT all
failed to elevate EGF receptor levels. In contrast Murphy et al (1986) found that
progestin upregulated EGF receptors in mammary carcinoma cells. It is therefore
evident that EGF receptors can be regulated by steroids but that response is dependent
upon the tissue, the state of the tissue {i.e. cancerous or normal) and possibly the
species. Also steroidogenesis is principally controlled by LH which is regulated
centrally, any possible effects which EGF may have on steroidogenesis are therefore
likely tobe minor in relationship to LH.
4.12 EGF Receptors in Cancerous Tissues.
The possible role of the EGF receptor in oncogenesis has become a major topic of
investigation over the last ten years due to the detection of the EGF receptor on
numerous types of cancerous tissues. For example they have been found to be
expressed by normal mammary glands in mice (Edery et al, 1985), normal human
uterine tissue (Hofmann et al, 1984) and by normal human prostate (Maddy et al,
1987). Receptors have also been found to be present in all of these tissues but in the
cancerous state for example human breast cancer (Sainsbury et al, 1985a; 1985b;
1985c; 1985d; Skoog etal, 1986; Crawford etal, 1987; Macias etal, 1987; Pekonen
et al, 1988; Home et al, 1988; Boluffer et al, 1990), cancerous human uterine tissue
(leiomyomas, Hofmann et al, 1984) and human prostate cancer (Maddy et al, 1989).
Numerous other tissues such as bladder (Berger et al, 1987a; Neal et al, 1985; 1989),
ovary (Bauknecht et al, 1984; 1986), human meningioma cells (Weisman et al, 1987)
gastric and colonic carcinomas (Sugiyama et al, 1989; Yasui et al, 1988a; 1988b),
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lung cancer (Berger et al, 1987b; Bepler et al, 1988) and human eosophogeal
carcinoma (Banks-Schlegel and Quintero, 1986) have also been found to express the
EGF receptor. In some of these tissues EGF receptor mRNA has also been identified
for example in breast cancer (Travers et al, 1988). Derynck (1987) found that the level
ofEGF receptormRNA and EGF mRNA was higher in tumours than in the
corresponding normal tissue and that TGF-a mRNA was also present in higher
concentrations in the tumour tissue.
In human testicular cancer EGF receptors were found to be expressed
on teratoma tissues but not on seminoma tissues which were both investigated using
biochemical techniques. As for Leydig cell tumours, only one specimen was obtained
during the course of the study and this was found to be devoid of EGF receptors using
biochemical analysis. However, having found that the teratoma tissues expressed the
EGF receptor it was unfortunate that the receptor could not be characterised in terms of
its affinity due to the lack of tissue available for biochemical analysis. Therefore in
order to investigate the presence of EGF receptors on teratoma tissue further, a cell line
Tera-2 was cultured. The receptor was again characterised using saturation analysis.
The binding procedure adopted was taken from the methods of Engstrom et al (1985)
who had previously studied the EGF receptor on the Tera-2 cell line. Engstrom et al
(1985) also reported finding a single high affinity binding site of 0.2 nM with 26,000
receptors present per cell. This is similar to the results obtained in this study where a
high affinity binding site of 0.21 nM was detected with approximately 67,000
receptors per cell employing Munson and Robard's (1980) curve fitting programme to
analyse the saturation data.
Breast cancer is one of the more widely investigated types of cancer, the
reason for this being that an inverse relationship between oestrogen receptor (ER)
expression and EGF receptor expression was discovered which was later found to be
related to prognosis of the cancer. That is to say that if ER expression is low then EGF
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receptor expression is found to be high which correlates with a poor prognosis for the
patient (Sainsbury et al, 1983; Sainsbury, 1988). This has also been found to be the
case in breast cancer (Sainsbury et al, 1985b; 1985c; 1987; Macias et al, 1987; Home
et al, 1988; Boluffer et al, 1990) and ovarian cancer (Harding et al. 1989) in which
ER expression correlates with good prognosis and bladder cancer in which high EGF
receptor expression correlates both with poor prognosis and the stage of the tumour
(Berger et al, 1987a). However this is not always the case as Bauknecht et al (1984)
associated a good prognosis with positive EGF receptor status for ovarian carcinomas.
It has further been confirmed that EGF receptors are linked to the status of the
histological subtype of breast cancer (Sainsbury et al, 1987; Perez et al, 1984; Reubi
and Torhorst, 1989). The oestrogen receptor is also used as prognostic indicator on its
own (Crawford et al, 1987) as well as combined with progesterone receptors (Clarke
and McGuire, 1989; Harding et al, 1930). It is already known that patients with
teratomas have a poorer prognosis than patients with seminomas (pers. commun. Mr
T.B.Hargreave, Consultant Urologist, Western General Hospital). This corroborates
the findings in breast cancer where EGF receptor expression is related to poor
prognosis, for as demonstrated in this study, it is the teratoma tissue which expresses
EGF receptors.
4.13 Localisation of the EGF Receptor on Cancerous Testicular
Tissues and Cells.
In employing immunohistochemical techniques to identify the EGF receptor, receptors
were not detected on the various seminoma sections, although they were discovered on
all three of the teratoma sections processed. On the teratoma sections the staining
always appeared in dense localised regions. The presence of EGF receptors on teratoma
tissue is perhaps not unexpected as the cells present are differentiating in multiple
directions to form keratinising epithelium, cartilage and nerve (Hogan and Tilley,
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1981). Thus the growth of these tissues may in fact require EGF receptors to be
expressed for normal development. Detection with the F4 antibody of the internal
domain of the receptor was only observed on the teratoma tissues and not on any of the
other testicular tissues whether normal or cancerous. The apparent absence of detection
of the internal domain of the EGF receptor on such tissues may indicate that the binding
area to which the F4 antibody becomes attached was either changed or missing as
previously mentioned in section 4.7. With the Tera-2 cells the A431 cell line was used
as a positive control and although the Tera-2 cells became stained when using the F4
antibody they did not become stained when using the EGF-R1 antibody. This may
suggest that the external domain of the receptor on the Tera-2 cells was absent and that
the receptors were in fact truncated. The reason for this may be that the cells were
grown in 10% FCS RPMI before plating down. 10% FCS was shown to contain EGF
which could have down regulated the receptors. If this was the case then down
regulation would be accompanied by truncation of the receptor which in turn would
mean that the extracellular domain of the EGF receptor would not be available for
binding by the monoclonal antibody. The fact that this did not hinder detection of the
A431 cell receptors may be explained by the fact that A431 cells express a much higher
number of EGF receptors (10^ in comparison to 6.7 x 10^).
4.14 Further Characterisation of the EGF Receptor on Tera-2
Cells
The EGF receptor on Tera-2 cells was further characterised by performing Western
blot analysis. The receptor was identified in the 170 kDa form and also in the 125 kDa
degraded form. The 125 kDa protein had previously been identified by Decker (1989)
on NIH-3T3 cells where he had used an antiserum prepared against a trypE-EGF
receptor fusion protein to bind to the EGF receptor site in an immunoprecipitation
procedure. The antibody was found to bind to the carboxy terminal of the EGF
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receptor. However if an antibody which bound to the amino terminus of the receptor
was employed then the 125 kDa receptor species was not identifiable. It was also
indicated in Decker's report that proteolysis of the receptor to the 125 kDa form could
be part of the receptors normal function, as before the immunoprecipitation procedure,
the cells had continuously been exposed to 10 nM EGF (Decker, 1989). He proposed
that this treatment lead to proteolysis of the EGF receptor site in a similar fashion to
EGF producing internalisation of the receptor (Carpenter et al, 1976; Carpenter, 1987)
and subsequently degradation of the receptors in lysosomes (Beguinot et al, 1984;
Dunn, 1984). In this study however the cells had not been treated with EGF for at least
4 days.
Competition of the receptor site on the Tera-2 cells with various other
growth factors (vNGF, bFGF, hIGF-I) clarified further that the binding site was
specific to EGF. However rTGF-a and concentrated conditioned medium also offered
similar competition. Venom NGF was found to offer 37% competition and bFGF 32%
competition for the receptor site. This result could possibly be attributed to the cells still
being alive during the incubation period of the assay, as the cells were not
homogenised. Transmodulation of the EGF receptor by vNGF and bFGF could have
occurred affecting the binding of radiolabelled mEGF to the receptor in an indirect way
rather than the growth factors directly competing for the EGF receptor. This could be
investigated by first lysing the cells before use in the radioligand exchange assay. Rat
TGF-a and concentrated conditioned medium offered 99% and 84% competition
respectively for the EGF binding site both of which were not significantly different
from the percentage competition illustrated with mEGF.
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4.15 EGF and TGF-a in Cancerous Tissues
EGF and TGF-a have been found to be present in various cancerous tissues as well as
normal tissues (Osborne et al, 1982; Kawamota et al, 1983; Perroteau et al, 1986;
Stoscheck and King 1986; Salomon etal, 1983; 1987; Connolly and Rose, 1989;
Imanishi et al, 1989; Wilding et al, 1989; Bates et al, 1990). In this study both hEGF
and hTGF-a were found to be present in seminoma tissues as well as in the
conditioned medium of the Tera-2 cell line. Unfortunately the endogenous
concentrations of hTGF-a and hEGF were not identified in the Leydig cell tumour or
the teratoma tumours due to the lack of tissue available. Mori et al (1989) also
identified hEGF in both seminoma and embryonal carcinoma tissues, further
supporting our finding of hEGF like activity in seminoma tissue and the concentrated
conditioned medium from the Tera-2 cell line. Interestingly hTGF-a was found in the
concentrated conditioned medium of the Tera-2 cell line at approximately the same
concentration as that of the hEGF. However no cross reactivity between the antibody
for rTGF-a and hEGF was identified at 95% limit. Human TGF-a as discussed
previously (section 4.3) was also found to be present in normal testicular tissue,
although the concentration was not statistically significantly different from that found in
seminoma tissues. The fact that no EGF receptors were expressed in seminoma tissue
possibly suggests that the growth factor is being secreted in an ectopic manner. The
role of transforming growth factors in the transformation of normal to cancerous cells is
being investigated (Coffey et al, 1986; Keski-oja et al, 1987; Knabbe et al, 1987;
Schuurmans et al, 1988b; Imanishi et al 1989). It has been shown that both EGF and
TGF-a induce differential processing of the EGF receptor (Decker, 1990) and that
certain cells can lose growth responsiveness to EGF with a concomitant increase in
TGF-a production (Salomon, 1987). The EGF receptor has also been shown to be
critical in the regulation of the degree of maturation of malignant epidermal cells (King
and Sartorelli, 1989). Subsequently monoclonal antibodies have been developed to
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block the effects of growth factors in the treatment of cancers which are dependent on
growth factors (Rodeck et al, 1987; Bronchud and Dexter, 1989). However the
majority of human anti-tumour monoclonals to date have been disappointing (Campbell
et al, 1988; Sunada et al, 1990). The effect which anti-oestrogens may exert on EGF
stimulated growth (Cormier and Jordan, 1989) as well as the actions of anti-neoplastic
agents have also been investigated (Hanauske et al, 1987). In Tera-2 cells, IGF-I and
IGF-II have also been shown to stimulate growth (Biddle et al, 1988).
The effect of hEGF, rTGF-a and concentrated conditioned media on
the Tera-2 cell line was investigated further by competing several concentrations of
hEGF, rTGF-a and concentrated conditioned media with a single concentration of
labelled mEGF. It was discovered that hEGF, rTGF-a and the concentrated
conditioned media all compete at various concentrations for the EGF receptor site with
labelled mEGF to produce dissociation curves. However the curves differ in that the
TGF-a curve has a slightly steeper gradient than the EGF curve. This may indicate
that the EGF binding site characterised on the Tera-2 cell line has a higher affinity for
TGF-a than for EGF. Winkler et al (1989) reported that there is a different
conformation of the receptor required in binding of TGF-a to the EGF receptor in
comparison to EGF. This difference in conformation may be dependent on whether the
cell is normal or cancerous. The curve for the competition of concentrated conditioned
media is also of a different shape compared to both the TGF-a and EGF curves. This
could be attributed to both EGF and TGF-a being present in the concentrated
conditioned media and competing for the EGF receptor site synergistically. However
the competition achieved with the 0.14 nM of TGF-a and the 0.13 nM of EGF (present
in the concentrated conditioned media) does not in any way approach the 84%
competition which is observed with the concentrated conditioned media for the EGF
binding site illustrated in Figure 40. Ideally this percentage of competition should be
achieved with concentrations of TGF-a and EGF in the 100 nM range. It is therefore
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possible that other growth factors are present in the concentrated conditioned media
which also compete for the EGF binding site or possibly which augment the effect
which EGF and TGF-a may be having on the receptor.
The fact that EGF and its receptor and TGF-a are found on the Tera-2
cell line suggests that the cells may be responsive to one or both of these substances.
As a result the effect of TGF-a and EGF on the growth of the Tera-2 cell line was
investigated. Tritiated thymidine incorporation was employed to assess the possible
increase in DNA synthesis on addition of EGF or TGF-a. EGF was found to have no
effect on cell growth over a 24 hour period at concentrations ranging from 0.3 to 100
nM. This was also reported by Engstrom et al (1985) who thought that the lack in
response was possibly due to the experiment being performed in bulk cultures as
difficulty was experienced in the plating down of the cells. In this study TGF-a was
found to produce an increase in thymidine incorporation compared with controls. At its
maximum the thymidine incorporation increased by approximately 2-fold in
comparison to the control which was obtained when the cells were incubated in 10 nM
TGF-a over 24 hours. Cell number in both the control and TGF-a treated wells was
also determined and showed no significant difference in actual cell growth between the
two differently treated groups of cells.
Time course studies were also performed to evaluate the effect of
TGF-a and EGF on thymidine incorporation over a 72 hour period, however, no
further increase in thymidine incorporation was noted when cells were incubated over
72 hours. In MCF-7 cells Osborne et al (1980) reported that EGF increased the
proportion of cells active in DNA synthesis by nearly 2-fold . It was found that
stimulation of incorporation of uridine and leucine by the MCF-7 cells was evident after
3 hours, whereas EGF stimulation of thymidine incorporation was delayed until 12-18
hours (Osborne et al, 1980). In this study the increase in thymidine incorporation was
noted after a 24 hour incubation period in 10 nM TGF-a, although this response did
139
DISCUSSION
not alter when the cells were incubated in 10 nM TGF-a over 72 hours. No change in
the response to EGF was noted when the cells were incubated over 24 or 72 hours in
10 nM EGF or at concentrations of 0.3 to 100 nM EGF over 24 hours. Cell number
was again monitored at each individual time point and no significant difference between
the cells incubated in the TGF-a, the EGF and the control wells was noted.
It is well documented that cell lines that produce TGF-a show very little
mitogenic response to exogenous EGF, despite EGF receptors having been expressed
(Coffey et al, 1986; Salomon et al, 1987). Coffey et al (1986) reported that colon
cancer cell lines produced measurable amounts of TGF-a and had detectable levels of
EGF receptors, although exogenous EGF did not enhance cell growth of these cells.
Similarly Saloman (1987) detected levels of EGF receptors in ra.v-transformed mouse
mammary epithelial cells. The cells were unresponsive to exogenous EGF and TGF-a
in a growth assay despite EGF-like material being detected in the concentrated
conditioned medium. The loss of response to exogenous growth factor may, as is
suggested, be due to autocrine secretion of a growth factor resulting in maximal
autostimulation of that cell line. However some human breast cell lines do show a
proliferative response to EGF and TGF-a (Dickson et al, 1986) and also secrete
EGF/TGF-a like material (Bates etal, 1983). In relation to this study the fact that
TGF-a produced an effect on the Tera-2 cells and not EGF suggests that the EGF
receptor when activated by TGF-a initiates a different intracellular signal to that
initiated by EGF binding to the receptor.
4.16 Steroids in Cancerous Tissues
In measuring the concentration of androgens in seminoma tissues it was found that the
levels of androstenedione, DHT and testosterone were lower in comparison to the
concentrations measured in normal tissues. The concentration of androstenedione was
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found to be 0.025 nmoles/g for DHT 0.093 nmoles/g and for testosterone
0.83 nmoles/g of dry testicular tissue. It can therefore be postulated that testicular tissue
loses its steroid producing capabilities in the transformation from normal testicular
tissue to seminoma tissue. However it is not clear from this finding alone whether
seminomas require androgens for differentiation and proliferation. Because such low
concentrations of androgens are present in the seminoma tissue in comparison to
normal testicular tissue one may speculate that seminoma tissue does not depend on
androgens as a source of stimulus which is in contrast to breast cancer and prostate
cancer.
In the progression of prostatic cancer testosterone is thought to be the
main promotor of growth although there is an indication of the possible involvement of
EGF and TGF-oc, as EGF receptors have been found to be present on the epithelial
cells of the tissue (Maddy et al, 1989). At present the main method of treatment for the
prevention of the progression of prostatic cancer is to inhibit the effects of androgens
on the gland. One way of achieving this is to remove the main organ supplying the
testosterone which is the testes (i.e.orchiectomy); the main source from which 'normal
testicular tissue' for this study was derived. Another possible approach is to introduce
anti-androgens (cyproterone acetate) or oestrogens (diethylstilboestrol) into the
systemic circulation in order to decrease the production of testosterone by acting on the
anterior pituitary to decrease the release of LH which normally stimulates the Leydig
cell to increase androgen output (Bruchovsky et al, 1988). LHRH analogues have also
been investigated and are presently being used in treatment of prostatic cancer as they
produce inhibition of testosterone secretion by inhibiting LH release (Bruchovsky et
al, 1988). However in treatment with certain types of steroid analogues there is
evidence that some stimulate rather than inhibit cell proliferation. This raises certain
implications with regard to the selection of patients for hormone therapy aswell as the
long term use of certain analogues (Braunsberg et al, 1987a; 1987b).
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Recently steroid/thyroid type receptor-like proteins have been identified
in tissues which show oncogenic potential (Slusyer, 1990). The receptors are thought
to be mutated or truncated forms of the original steroid/thyroid receptor family
(Slusyer, 1990).
In the case of teratoma tissues experiments were once again performed
employing the Tera-2 cell line to evaluate the possibility of the cells being androgen
sensitive. M i bolerone was the synthetic androgen chosen because of its low
degradability. Its affect on DNA synthesis was investigated by performing thymidine
incorporation experiments. Both time course studies and dose response studies were
performed employing mi bolerone but no response was noted. Cell number was
also measured but no significant difference between controls and mi bolerone
treated cell numbers was apparent. The effect of various concentrations ofmi bolerone
on EGF receptor expression was also investigated. No change in specific EGF binding
was observed when cells were incubated in 0.1-100 nM concentrations ofmi bolerone
over 24 hours. These findings indicate that although EGF and testosterone have been
shown to be required for spermatogenesis (in which germ cells are constantly
dividing), testosterone and EGF are not required in the proliferation of Tera-2 cells.
Steroids have been shown to influence cancerous growth as well as
EGF receptor expression and EGF and TGF-a secretion on other tissues (Bynny et al,
1974; Dickson et al, 1986; Traish and Wotiz, 1987; Schuurman et al, 1988). It has
been shown that androgen independent tissues require different hormones depending
on whether they are normal or tumour epithelial cells (McKeehan et al, 1984; 1987).
In the human breast cancer cell line MCF-7 oestrogen has been found to
stimulate the production of TGF's. When TGF-a concentrations increased an increase
in tumour growth was also noted (Dickson et al, 1986a). Blockade of the EGF
receptor on the MCF-7 cell line was found to inhibit TGF-a secretion but it did not
inhibit growth which was thought to have been oestrogen induced (Dickson et al,
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1986a; 1986b; 1986c). It is therefore likely that as well as hormones and growth factors
acting synergistically they may also act separately in certain types of cancer to augment
their own effects. In the case of seminomas androgens may indeed be present
specifically for this reason. Both androgens and TGF-f3 have been shown to modulate
the growth response of LNCaP cells to EGF (Schuurmans et al, 1988a; 1988b).
4.17 The Role of Steroids and Growth Factors in the
Progression of Cancerous Tissues.
As previously stated EGF and testosterone are both thought to be required in
spermatogenesis (Bartlett et al, 1990; Sharpe et al, 1988). It was therefore of interest
to investigate any possible role which androgens or EGF/TGF-a may have in the
maintenance of germ cell tumours, since, despite the enormous advances made in the
treatment of these tumours, very little is known about their aetiology. The risk factors
that have been identified at present offer little clue as to how to prevent the disease.
Given the increase in incidence reported in 1981 by Davies it is clearly important to try
and understand what causes this form of cancer rather than depend on surgical and
chemotherapeutic treatment. However it is possible that Davies (1981) did not report an
increase in testicular cancer but rather an increase in the number of patients who come
forward for treatment. Returning to the possible increase in testicular cancer,
information is now available from epidemiological studies which indicate a role for
genetic, viral and physical factors in the causation of testicular cancer (Schottenfeld and
Warshauer, 1982; Henderson et al, 1983) although at present the only clearly
identifiable risk factor is a prior history of cryptorchidism (Chivers et al, 1984; Strader
et al, 1988). Investigations have also been centered on the possible involvement of
exposure to oestrogens during the gestation period (Depue et al, 1983 and Depue,
1984) as well as on the possibility of inheritance (Dieckmann et al, 1987). Evidence
has become available which suggests that exposure to certain hormones, for example in
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utero, might have an aetiological role. It is pointed out that the pattern of incidence of
testicular tumours in relation to age is significant as the peak incidence occurs around
the age of 30-35 years. Depue (1984) suggests that as the development of cancer from
initiation to diagnosis usually takes some 20-30 years, it seems reasonable to postulate
that the critical and limiting period for germ cell initiation is the period in utero, as very
few germ cell tumours are diagnosed after 45 years of age. However there is no
evidence in the literature to support the suggestion that the development of cancer takes
up to 20-30 years. It is equally valid to suggest for instance that puberty initiates the
onset of testicular cancer as around that period androgen levels are higher than at any
other time of life in the male. The incidence of testicular cancer in childhood, for
example, is very rare although the cases that are seen may be attributable to the
increasing concentrations of steroids which occur during both foetal development and
through the first few years post gestation (Bidlingmaier et al, 1983; Rommerts and van
der Molen, 1988).
It has been established for a number of years that oestrogens play a
critical role in the aeitiology of breast cancer (Leake et al, 1979; 1981). Furthermore it
has now been suggested that oestrogen control of hormone dependent breast cancer is
mediated by autocrine and paracrine growth factors secreted by the breast cancer cells
themselves. Lippman et al (1986) has shown direct unmediated effects of estrogen on
specific cell functions as well as demonstrating that cancer cells secrete a number of
growth factors (IGF-I, TGF-a TGF-J3, a PDGF-like competency factor and at least
one new epithelial colony stimulating factor). Some of these have been shown to be
oestrogen regulated in hormone dependent cells as well as more numerous in cells
which acquire independence either spontaneously or by ras transformation (Lippman
et al, 1986). It has been shown by Travers et al (1988) that growth factors are
expressed differently in several types of breast tissue depending on whether the tissue
is malignant, benign or normal. This particularly applies to the growth factors TGF-a
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and TGF-p. It has therefore been postulated that such growth factors may play an
important role in controlling growth of human breast cancers, particularly those that are
hormone independent. This was corroborated by the results of Lippman et al (1987)
who illustrated that growth regulation of human breast cancer occurs through regulated
growth factor secretion. The fact that growth factor secretion can also be regulated by
hormones in hormone dependent tissues signifies that there is some interaction between
steroids and growth factors in cancerous tissues. In the past estrogen receptors have
been used as prognostic indicators for breast cancer but now it appears that the more
reliable indicators of prognosis are the proteins which are regulated by or are related to
the oestrogen receptor (Home et al, 1988).
Epidermal growth factor receptor status has in the past been used as a
predictor of early recurrence of and death from breast cancer (Sainsbury et al, 1987) as
have both ER and EGF receptor status (Sainsbury et al, 1985d). It is possible that the
hormones themselves cause the transformation of cells from hormone dependent to
hormone independent. The hormones stimulate an increase in growth factor secretion
which in turn enables the cells to eventually become growth factor dependent and
hormone independent. It has been shown by Westley and Rochefort (1980) that human
breast cancer cells secrete a 46 kDa glycoprotein when stimulated by oestrogen, and
that oestradiol induces EGF related polypeptide production in MCF-7 cells (Dickson et
al, 1986b; 1986c). However in the transformation of tissues from hormone dependent
to hormone independent it has been shown by Arteaga et al (1988) that blockade of the
EGF receptor on MCF-7 cells inhibits TGF-a induced but not oestrogen induced
growth. It is therefore evident that when both growth factors and hormones are present
in the cells environment cell growth is under the control of both of them. It is
interesting to note that in salivary gland tumours no high affinity steroid hormone
receptors were detected indicating that such a cancer is not dependent on endocrine
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secretion. It is however well established that the SMG is one of the major sites of EGF
production.
Clinically the expression of growth factors in hormone dependent
tissues is of significance because it has been demonstrated that tumours arising in
hormone sensitive cells (for example breast) frequently progress from the hormone
sensitive to the hormone insensitive state (King and Darbre, 1989). Often some of the
regulatory controls of their normal progenitors are retained, but even these controls may
be lost or altered during the progression. Altered involvement of growth factor activity
in the transition from endocrine responsive to unresponsive breast cancer is an attractive
idea because of its simplicity and compatibility with two clinical features. Endocrine
insensitive human breast tumours grow faster and recur earlier than their endocrine
responsive counterparts (Hahnel, 1982; Clark and McGuire, 1989). Also the EGF
receptor is over expressed in unresponsive relative to responsive tumours, and over
expression correlates with increased rate of recurrence (Harris, 1989; Nicholson et al,
1989). However this picture is not as simple as it appears. By investigating the
expression of growth factor receptors and growth factor concentrations in both normal





The results from this study indicate the possible involvement of EGF/TGF-a and the
EGF receptor in the regulation of testicular function. It is possible that EGF/TGF-a are
involved in testicular cell-cell communication although LH and FSH are the prevailing
hormones which control testicular function. TGF-amRNA has been found to
be present in both peritubular and Sertoli cells (Skinner et al, 1989a).
It may therefore be assumed that TGF-a is involved in peritubular-Sertoli cell
communication. In this study EGF receptors were not found to be present on human
Sertoli cells but they were found to be present on human peritubular and Leydig cells.
EGF and TGF-a were also both found to be present in testicular extracts. One may
therefore postulate that as well as TGF-a being involved in peritubular-Sertoli cell
communication it may also be involved in peritubular-Leydig cell
communication(Figure 48).
EGF and TGF-a were also found to be secreted by the Tera-2 cell line
and the EGF receptor found to be expressed by Tera-2 cells as well as teratoma tissues.
In performing competition studies with EGF and TGF-a on both normal tissue and
cancerous cells it was found that EGF offered the greatest competition for the EGF
receptor site in normal tissue (100% and 24% respectively) but that TGF-a offered
equal competition for the receptor in the cancerous state (100% and 99% respectively).
In cancerous testicular tissue it may be concluded from the results of this
study, that as yet there is no evidence to suggest that EGF or TGF-a play a role in the
development and progression of seminoma tumours, but that the growth factors may be
involved in teratoma tumour development. As mentioned previously EGF and its





EGF receptors within the testes: As EGF receptors (A) are expressed on
Leydig and peritubular cells one may postulate that TGF-a could be the
missing factor (?) in peritubular - Leydig cell communication. TGF-a has
recently been characterised by Skinner et al (1989a) and is thought
to be involved in peritubular - Sertoli cell communication and vice
versa. Thus it appears that TGF-a may play a significant role in cell-cell
communication within the testes via the EGF receptor.
tissue and the Tera-2 cells and EGF in the media of the Tera-2 cells. In addition TGF-a
also appeared to be secreted by Tera-2 cells (in vitro) and when added to the cells in
vitro pioduced stimulation of thymidine incorporation. This effect was not evoked by
EGF. As discussed previously the EGF receptor identified on cancerous testicular cells
appeared to have a higher affinity for TGF-a than the receptor identified on normal
testicular tissue. It could therefore be postulated that the EGF receptor may be modified
in the transformation of human testicular tissue from normal to cancerous and that in
the cancerous state the EGF receptor has a higher affinity for TGF-a than EGF.
In looking at treated testicular tissue EGF receptors were found to be
absent. This may indicate that in the event of a reduction in circulating androgen levels,
expression of the EGF receptor is decreased. It could therefore be postulated that EGF
receptors within the testes are under the control of androgens and that as demonstrated
by Pascall et al (1989) in the mouse submandibular gland, a reduction in androgen
concentrations can produce a decrease in mRNA encoding the EGF receptor. As
reported by Hiramatsu et al (1988) and Pascall et al (1989) a decrease in circulating
androgen levels also produces a decrease in EGF levels. This is again corroborated by
our findings in which 5.16 ng per gram of EGF were found in normal testicular tissue
in comparison to 2.23 ng per gram in treated testicular tissue. The possibility that EGF
and indeed EGF receptors are regulated by circulating androgen concentrations may
implicate EGF and its receptor in steroid production, especially as the EGF receptor is
located on the Leydig cell, the site of steroidogenesis.
5.1 Future studies
(i) It is now well established that specific peptides (growth factors) bind to cell surface
proteins (receptors) and initiate or maintain the biochemical events required for cellular
proliferation. However these receptors are not always functional, in that the receptor is
not always coupled to the second messenger. Further experimentation should therefore
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be carried out to investigate the possibility of the EGF receptor found on human
testicular tissue being non-functional. This could be achieved by performing
autophosphorylation experiments or a tyrosine kinase assay.
The results of these studies may explain why the internal domain of the
EGF receptor was not detected with the F4 monoclonal antibody.
(ii) The expression of EGF receptors on testicular tissues exposed to cyproterone
acetate or stilboestrol should be investigated with a view to determining whether gene
reduction or receptor down regulation resulted in non-detection of the receptor in such
samples.
(iii) Ideally the role of growth factors in the communication of human testicular cells
should be investigated using a primary testicular cell culture. Unfortunately the tissue
required for such an experiment can not easily be acquired. Juvenile/foetal human
testicular tissue is the most favorable tissue as it is in its growing state, however, ethical
consent for such a study which would employ foetal testicular tissue may present a
problem.
However juvenile/foetal tissue represents the growing state of the testes
where as after puberty the majority of testicular cells are no longer
proliferating. With this in mind post pubertal tissue would perhaps be more
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ABSTRACT
In the present study attempts were made to charac¬
terize the epidermal growth factor (EGF) receptor on
human testicular tissue. A radioligand exchange assay
with 125I-labelled EGF was used to detect a high
affinity, low capacity, single binding site in the
105 000 g particulate fraction of human testicular tis¬
sue. Binding was optimal at 32 °C following a 40-min
incubation with a mean (+ s.D.) dissociation constant
of 327±59pmol/l (d.f. 9). The number of binding
sites ranged from 0 07 to 0-21 pmol/mg protein.
Competition studies with other peptide hormones
including LH, FSH, prolactin, insulin-like growth
factor-I, fibroblast growth factor and nerve growth
factor have confirmed the specificity of EGF for its
receptor. The receptor was also found to be heat-
labile and sensitive to trypsinization. Cross-linking
experiments using disuccinimidyl suberate revealed
major binding species at the 125 kDa region and this
is thought to represent a proteolysed form of the
receptor. Immunohistochemical localization of the
receptors demonstrated their presence in the inter¬
stitial tissue and not within the seminiferous tubules.
The presence of specific EGF binding in the inter¬
stitial tissue suggests that EGF may play some role in
testicular steroidogenesis.
Journal ofEndocrinology (1990) 125, 48 5—492
INTRODUCTION
The epidermal growth factor (EGF) receptor is a
transmembrane glycoprotein with intrinsic protein-
tyrosine kinase phosphotransferase activity (Cohen &
Carpenter, 1975). So far the receptor has been located
on numerous tissues, including the uterus (Hofmann,
Rao, Barrows et al. 1984), placenta (Hock &
Hollenberg, 1980) and prostate (Maddy, Chisholm,
Hawkins & Habib, 1987). On binding to the receptors
the peptide EGF has been found to initiate a variety
of responses according to the cell on which the
receptor is expressed (Carpenter & Cohen, 1979;
McKeehan, Adams & Rosser, 1984). EGF has also
been found in various body fluids, including prostate
fluid (Gregory, Willshire, Kavanagh et al. 1986) and
human seminal plasma (Elson, Browne & Thorburn,
1984) but no one has so far investigated the presence
of EGF receptors in human testicular tissue.
In an earlier study, Bellve & Zheng (1985) reported
the presence of growth factors in the gonads during
the onset and maintenance of spermatogenesis in
pubertal and adult animals. Although EGF was not
singled out it is possible that the peptide might be one
of the growth factors present. However, later reports
by Holmes, Spott & Smith (1986) and Buch, Lamb,
Lipschultz & Smith (1988) on the characterization of a
unique growth factor secreted by human Sertoli cells
suggest that EGF and this secreted growth factor
might not be the same. Nonetheless, evidence is
accumulating on a role for EGF in the testis.
Tsutsumi, Kurachi & Oka (1986) have observed a
50% reduction in spermatid production in the absence
of EGF. Furthermore, EGF has been found to stimu¬
late steroidogenesis in primary cultured Leydig cells
of the rat testes (Verhoeven & Cailleau, 1986).
In an attempt to define the mode of action of EGF
in this target tissue, we have undertaken the present
study to evaluate the presence ofEGF receptors in the
human testis.
MATERIALS AND METHODS
Hormones and growth factors
Mouse EGF, transforming growth factor-a (TGF-a),
bovine fibroblast growth factor (FbGF) and venom
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nerve growth factor (vNGF) were obtained from
Sigma, Poole, Dorset, U.K. Insulin-like growth fac-
tor-I (IGF-I) was obtained from Sera Laboratories,
Crawley Down, Sussex, U.K. Human prolactin,
human follicle-stimulating hormone (hFSH), human
luteinizing hormone (hLH), human growth hormone
(hGH) and human insulin were generously donated
by NIADDK, Bethesda, MD, U.S.A.
Other reagents
EGF was iodinated using the method of Fraker &
Speck (1978). Briefly, EGF (10 pg) reacted with Na125I
(specific activity 350/600 mCi/ml; Amersham Inter¬
national pic, Bucks) in the presence of 1,3,4,6-tetra-
chloro-3a-6a-diphenyl-glycouril (Iodogen; Sigma).
The iodinated peptide was purified by chromato¬
graphy on a Sephadex G-50 column (1 x46cm). The
percentage bound was calculated after precipitation
with trichloroacetic acid at 20% and 10% concen¬
trations. The final specific activity varied between 20
and 70 pCi/pg.
Monoclonal antibodies
The anti-human EGF receptor monoclonal antibody
for the external domain of the receptor for use on
frozen sections was kindly donated by Dr M. D.
Waterfield, Imperial Cancer Research Fund Labora¬
tory, London (Waterfield, Mayes, Stroobant et al.
1982). The anti-mouse EGF receptor antibody for the
external domain of the receptor for use on paraffin
sections was obtained from Oncor, Gaithersburg,
MD, U.S.A. (Starkey, Cohen & Orth, 1975). The third
monoclonal antibody recognizing the internal domain
of the receptor was a gift from Dr W. J. Gullick of the
ICRF Oncology Group, Hammersmith Hospital,
London (Gullick, Marsden, Whittle et al. 1986).
Other reagents
Normal rabbit serum (NRS) was obtained from
the Scottish Antibody Production Unit, Carluke,
Lanarkshire, U.K., streptavidin alkaline phosphatase
from ICN Biomedicals, High Wycombe, Bucks,
U.K. and biotinylated secondary antibody sheep
anti-mouse immunoglobulins from Amersham Inter¬
national pic. Disuccinimidyl suberate (DSS) along
with a molecular weight standard kit for proteins in
the molecular weight range of 50-250 kDa and bovine
serum albumin (BSA; fraction V) were purchased
from Sigma.
Buffers
The following buffers were prepared: buffer A con¬
taining Tris (10mmol/l), EDTA (1 mmol/1), EGTA
(1 mmol/1), sucrose (0-25 mmol/1) and phenylmethyl-
sulphonyl fluoride (0-05 mmol/1), pH 7-4; buffer B
containing Tris (10 mmol/1), sodium chloride (0-9%,
w/v) and BSA (01%, w/v), pH 7-4; 10% and 20%
polyethylene glycol 8000 mol. wt (PEG) made up with
buffer B; 1 mmol/1 DSS dissolved in dimethylsul-
phoxide (DMSO) to give a final concentration of 5%
ofDMSO on the gel for cross-linking. All other cross-
linking reagents are identical to those described by
Laemmli (1970).
In addition the following buffers were also pre¬
pared for immunohistochemistry: Tris-buffered saline
buffer (TBS) containing Tris (10 mmol/1), sodium
chloride (0-9%, w/v) pH 7-6; Michaelis veronal buf¬
fer (pH 9-2) containing sodium acetate trihydrate
(0T4mol/l), sodium barbitone (014 mmol/1), for¬
maldehyde (0-04%, w/v); steptavidin alkaline phos¬
phatase substrate/chromogen in Michaelis veronal
buffer containing Fast Red ITR (1-3 mmol/1), levami-
sole (1-0 mmol/1) and Napthol 6-bromo-2 hydroxy-
3 napthoic acid-2 methoxyanilidine phosphate
(0-75 mmol/1) in 100% dimethylformamide.
Tissue preparation
Human testicular tissue was obtained from patients
with prostatic cancer who had undergone orchi¬
ectomy as first line of treatment. The tissue was used
either fresh or snap-frozen in liquid nitrogen and
stored at — 70 °C until required. Specimens were
examined by a pathologist and only those with a
normal and well-defined morphology were included in
the present study. The following steps were carried
out at 4 °C: 1 g tissue was cut into small pieces and
homogenized with 3 ml buffer A for two periods of 15
and 20 s with an Ystral homogenizer (Scottish Scien¬
tific Instruments Centre Ltd, Edinburgh, U.K.). The
homogenate was then ultracentrifuged for 40 and then
20 min at 105 000 g. At the in-between stage the pellet
was resuspended in 2 ml buffer A and dispersed using
a glass Dounce homogenizer. Following the last
centrifugation the pellet was finally resuspended in
3 ml buffer B and was again redispersed in the glass
homogenizer using a tighter fitting pestle. The protein
concentration was then measured by the Bradford
(1976) method and adjusted to 2 mg/ml. Unless speci¬
fied otherwise this particulate membrane fraction was
used in all subsequent incubations.
Subcellular fractionation of the tissue was per¬
formed according to the method of Leake, Chisholm
& Habib (1983).
Radioligand exchange assay
For each study the assay when used was performed on
at least three different tissues, each in triplicate. Par¬
ticulate fraction (100 pi) containing 2 mg protein/ml
concentration was incubated with 100 pi '~5I-labelled
EGF (8-0nmol/l; 200 000 c.p.m.) in the presence and
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absence of a 50-fold excess concentration of the
unlabelled EGF (200 pi); all dilutions of materials
were made in buffer B. The reaction vessels coated
previously with 0-1% BSA solution were incubated at
32 °C for 40 min and the reaction was stopped by the
addition of 1 ml ice-cold 20% PEG. The mixture was
then vortexed and centrifuged at 4 °C at 3500 r.p.m.
for 20 min. The tubes were then aspirated and the
pellets resuspended in 1 ml 10% PEG. They were then
vortexed and centrifuged again as before. Finally
the supernatant was aspirated once again and the
tubes counted in a Packard Crystal 2 Multidetector
Radioimmunoassay System. The specific binding was
calculated by subtracting the non-specific binding
from the total binding. This standard procedure was
then used in all subsequent binding studies.
For time and temperature studies, binding exper¬
iments were performed at 4, 25, 32 and 37 °C. All
studies were undertaken for varying times up to 18 h.
The concentration of the labelled EGF used was as
above.
The effect of pH on specific binding was also
examined. A pH range between 6-6 and 8-2 was
chosen. Binding studies were performed as previously
described, having adjusted the solutions to the
required pH. In addition the relationship between
increase in protein concentration and the number of
specific binding sites present was investigated. Protein
concentrations varied between 0-5 and 8 0 mg/ml.
Saturation analysis
This was performed over a range of 0-5-8 0 nmol
l25I-labelled EGF/1. Non-specific binding at each
concentration of radiolabel was determined in the
presence of the appropriate unlabelled competitor at a
50-fold excess concentration. Binding was carried out
at 32 °C for 40 min and the specific binding data
was analysed by a computer program (Munson &
Rodbard, 1980) to yield the dissociation constant (Aid)
and the number of specific binding sites.
Competition studies
The specificity of the receptor for EGF was examined
in the presence of 50- and 100-fold excess of the
following competitors: TGF-a; IGF-I, FbGF, vNGF,
insulin, hLH, hFSH and prolactin. The radioligand
exchange assay was used but with the substitution
of the various above-named peptides for unlabelled
EGF.
Effect of heat and trypsinization
Homogenate preparations were heated before use in
the assay at 45, 60 and 80 °C or preincubated with
0-5% (w/v) trypsin for 15 min at 32 °C. After one
wash with buffer B (1 ml), the pellets were spun at
3500 r.p.m. and the supernatant was aspirated. The
assay was then performed as previously described.
Cross-linking and autoradiography
Following the preparation of the membrane-bound
l25I-labelled EGF the supernatant was aspirated off
and 100 pi of the 1 mmol DSS/1 solution was added to
the pellet. The mixture was vortexed and left for 20
min at room temperature. The sample buffer (25 pi)
containing mercaptoethanol (Laemmli, 1970) was
added and the pellet solution allowed to boil for 5 min
following which the solution was once again spun
down at 25 °C for 5 min. The resultant supernatant
was then taken up with a Hamilton syringe and
loaded onto the gel which was set up using a Bio-Rad
Protean 2 Slab Cell along with standards (SDS-6 mix;
Amersham International pic). Each standard had
been heated at 32 °C for 3 h. The gel was then allowed
to run at 30 mA overnight. Gels were subsequently
stained with Brilliant Blue mixture for 20 min and
washed with a mixture of 25% methanol/10% acetic
acid solution over a period of 15 h. The gels ultimately
rinsed in distilled water and dried on a Bio-Rad model
443 slab dryer connected to an IEC lyoprep-3000
freeze drier. Finally autoradiography was performed
at — 70 °C for 3-4 weeks by placing the dried gels in a
cassette along with two intensifying screens and a
Hyperfilm Bmax (Amersham International pic).
Immunohistochemistry
Immunohistochemistry was performed on both
frozen and paraffin sections, employing monoclonal
antibodies to both the external (EGF-R1, frozen;
EGF-R, paraffin) and internal domains (F4, frozen/
paraffin) of the EGF receptor. The methods employed
were as follows.
Frozen sections
The frozen sections were first fixed in acetone for 20
min. They were then treated with streptavidin-biotin
blocking reagents (Vector, Peterborough, Cambs,
U.K.) and then covered with NRS (1:5 dilution) to
block non-specific binding. After 20 min the NRS was
removed and the EGF-R 1 antibody in a 1:30 dilution
or the F4 antibody in a 1:5 dilution were applied
and left overnight at 4 °C. The following day the sec¬
tions were washed for 5 min in TBS and then treated
with biotinylated sheep anti-mouse immunoglobulins
(1:200) for 30 min. The sections were then washed
once more and an alkaline phosphatase-labelled
streptavidin as supplied by ICN was applied for 30
min. Finally freshly prepared streptavidin-alkaline
phosphatase substrate was applied for 20 min. The
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sections were then counterstained in haematoxylin
and lithium carbonate, and mounted in glycerine jelly.
Paraffin-fixed sections
Paraffin sections of the same tissue as used for the
frozen sections were dewaxed and trypsinized in
1-8 x 10-6 ATEE units trypsin and CaCl (9mmol/l)
solution (pH 7-6) for 15 min at 37 °C. (1 ATEE unit=
AA,37 of 0-001/min in 3 ml at pH 7-0 at 25 °C.) The
staining procedure as described above was subse¬
quently followed except that the monoclonal antibody
for the external domain of the receptor EGF-R was
used at a 1:10 dilution of the stock solution.
Haematoxylin and eosin sections were also pre¬
pared for each tissue sample to enable the pathologist
to identify the areas of specific staining. Furthermore,
for each staining experiment a 'negative' control sec¬
tion was included in which the primary antibody was
omitted. Occasionally a 'positive' control employing
human prostate tissue was also examined.
RESULTS
Binding studies
Text-figure 1 illustrates the specific binding patterns
of l25I-labelled EGF to the 105 000# particulate
fraction at 4 and 32 °C. Binding was clearly time- and
temperature-dependent with the maximal binding
attained at 32 °C after 40 min. Although maximum
binding was also achieved at 4 °C this was over a longer
period of time. Binding was also examined at 25 and
37 °C (results not shown) but, in common with the
experiments at 4 °C, the reaction at those temperatures
was slower to yield the maximum binding. The opti¬
mum pH experiments which demonstrated that the
highest levels of specific uptake was achieved at pH 7-4
are also not shown. There was, however, not a great
deal of variation over the physiological pH range
chosen.
In addition, subcellular fractions were prepared
from specimens obtained from three patients and
specific 125I-labelled EGF binding was assessed in each
component. It was found that over 68% of the specific
binding for EGF was associated with the 800 g crude
fraction and that the rest occurred in the mitochondrial
(15%) and microsomal (17%) fractions. No specific
binding of radiolabeled EGF was detected in the cyto-
sol. In order to maximize the binding values, it was
decided to undertake all subsequent incubations on the
105 000 g membrane particulate fraction which would
also contain the 800# crude pellet as well as the mito¬
chondrial and microsomal fractions.
In a separate experiment we also found that the
number ofEGF specific binding sites rose linearly with
protein concentration over the concentration used.
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Time (min)
text-figure 1. Time- and temperature-dependent specific
binding studies for epidermal growth factor (EGF) on
human testicular tissue were carried out at 4 °C (♦) and
32 °C (□) over a period of 3 h. Aliquots (100 pi) of the
particulatemembrane fraction containing 2 mg protein/ml
were incubated with 125I-labelled EGF (8 nmol/1) in the
presence and absence of 50-fold excess unlabelled EGF.
Each value represents the % mean + s.e.m. of the maximum
binding at 32 °C and 4 °C for three different specimens each
analysed in triplicate.
Saturation analysis
Incubation of the membrane fractions with increasing
concentrations of l25I-labelled EGF (0-5-8 nmol/1)
produced a saturation of the binding protein at
8 nmol/1 (Text-fig. 2). Scatchard (1949) analysis of the
data employing a computer program written by
Munson & Rodbard (1980) yielded one binding site
with a mean + s.D. Kd of 327 ± 59 pmol/1 (d.f. 9). The
binding capacity for the same ten patients ranged from
0 07 to 0-21 pmol/mg protein. A typical Scatchard
plot is also shown in Text-fig. 2.
Competition studies
Competition studies showed that the specially bound
EGF was not displaced from its receptor by any of
the other peptides used at either a 50- (Text-fig. 3)
or a 100-fold excess (results not shown) of the
concentration of labelled EGF used.
Effect of heat and trypsinization
Binding of EGF to its receptor was abolished after
preincubation with trypsin but was only reduced by
50% after the homogenate had been preheated at 45
and 60 °C (Table 1). Unfortunately agglutinization of
the homogenate occurred at 80 °C and therefore could
not be used to perform a binding assay.
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text-figure 2. Saturation analysis of 125I-labelled epidermal growth factor
(EGF) binding in human testicular tissue. Aliquots (100 pi) of the particulate
fraction suspension were incubated with concentrations of 12SI-labelled EGF
ranging from 0 05 to 8 nmol/1 in the presence and absence of a 50-fold excess
unlabelled EGF at 32 °C for 40 min. The data (insert) were analysed by the







EGF TGF-a vNGF IGF-I FbGF Insulin Prolactin GH LH FSH
Competitor
text-figure 3. Specificity of the epidermal growth factor (EGF) binding sites.
Aliquots (100 pi) of the particulate fraction suspension were incubated with
l25I-labelled EGF (8 nmol/1) for 40 min at 32 °C in the presence and absence of a
50-fold excess of the unlabelled competitor. % Bound was taken as the amount
of 125I-labelled EGF displaced by a 50-fold excess of unlabelled competitor. Each
value represents the mean ± s.e.m. of three different specimens each analysed in
triplicate. vNGF, nerve growth factor; FbGF, bovine fibroblast growth factor;
TGA-a, transforming growth factor-a.
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table 1. Effect of heat pretreatment at 45 and 60 °C and
trypsinization on specific 125I-labelled epidermal growth fac¬
tor binding by the 105 000 g membrane particulate fraction.
Results are expressed as % change from untreated control
and the values represent means ± s.e.m. of three different




Heat (45 °C) 53-0 ±7-7
Heat (60 °C) 52-0+12 0
Trypsin 7-73 + 0-73
Cross-linking and autoradiographic studies
Plate 1 shows that in the presence of labelled EGF
(lane A) there is a much more intense protein band
appearing around the 125 kDa region in comparison
with the band seen in experiments carried out in the
presence of excess unlabelled EGF (lane B).
Immunohistochemical studies
Immunohistochemical staining of a frozen section of
human testicular tissue with the monoclonal antibody
(EGF-R1) is shown in PI. 2, fig. 1. The staining
appears to be around the Leydig cells and the thin
fibroblastic cells of the interstitial tissue. This is also
shown on the paraffin sections on which the external
domain monoclonal antibody EGF-R was used (PI. 2,
fig. 2). In neither procedure was any staining observed
in the Sertoli cell or germ cell area. It was also found
that when using the monoclonal antibody for the
internal domain of the receptor (F4) no staining
became apparent on either of the two types of sections
used.
DISCUSSION
The results from this study show for the first time that
EGF receptors are present in human testicular tissue.
The receptor has been shown to have a single high
affinity binding site with an affinity constant of
327 ± 59 pmol/1 (d.f. 9). The number of specific bind¬
ing sites ranged between 0-07-0-21 pmol/mg protein.
These figures are similar to those already published
by others in human placenta (Hock & Hollenberg,
1980), breast cancer (Sainsbury, Sherbert, Farndon &
Harris, 1985) and human fibroblasts (Carpenter &
Cohen, 1979). However, unlike the reports published
by O'Keefe, Hollenberg & Cuatrecasas (1974),
Hofmann et al. (1984) and Maddy et al. (1987), our
data suggest that there is only one binding site. The
experiments performed also indicate that 68% of the
EGF binding sites exist in the 800 g crude mem-
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brane pellet and that the receptor sites are specific
to EGF and are not displaced by TGF-a, IGF-I,
FbGF, vNGF, prolactin, insulin, EH, FSH or GH.
Specificity is indicated by the fact that the maximum
percentage competition of another peptide for the
EGF binding site was 24% by TGF-a, which is known
to bind to the EGF-R (Derynck, 1986).
Autoradiographic/cross-linking studies also con¬
firm the presence of a specific receptor for EGF in
human testes. However, in direct contrast to previous
reports (Mukku, 1984), the autoradiographic results
suggest that the protein is in the 125 kDa region. Since
earlier reports identify a protein of 170 kDa, we
suspect that the 125 kDa product may be a degraded
form of the receptor, possibly a subunit due to proteo¬
lysis taking place during the experimental procedure
by the calcium-dependent protease calpain (Cassel &
Glaser, 1972). The protease is known to remove a
20 kDa fragment from the receptor, which could
have still occurred despite attention being given to
calcium-sequestering agents in the buffers used in
the present study. Similar results have also been
reported by Weisman, Raguet & Kelly (1987) on the
characterization of the EGF receptors in human
meningioma.
Immunohistochemical studies confirmed the bio¬
chemical results for the presence of EGF receptors in
human testicular tissue. The receptors were exclus¬
ively located in the interstitial tissue of the testes with
no staining in the Sertoli cells; a finding which has not
been reported before in any of the species so far exam¬
ined. The immunostaining was confirmed on both the
frozen and paraffin sections and was of a grainy
appearance. In some instances the staining also
appeared as small strands interwoven between the
seminiferous tubules; this may be due to staining of
the fibroblastic type cells which surround the semini¬
ferous tubules. All of the ten patients included for
immunohistochemistry showed some degree of stain¬
ing in the interstitial tissue when the antibodies for the
external domain of the receptor were used (EGF-R 1,
frozen; EGF-R, paraffin). However, there was no
staining with the antibody to the internal domain of
the receptor. Although no one has so far undertaken
any immunohistochemistry on human testicular tissue
employing antibodies to the EGF receptor, staining
with antibodies to EGF has been reported by Mori,
Naito, Tsukitani et al. (1989) who found an immuno-
reaction in both the Leydig cells of the testes and the
seminiferous tubules, and particularly in spermatozoa
and cells undergoing spermatogenesis.
So far very little work has been published on EGF
in relation to the functioning of the human testes,
although there are a few studies on the rat testes.
Holmes et al. (1986) characterized a growth factor
secreted by rat Sertoli cells in culture. Since then
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Skinner (1989) has identified this EGF-like material as
TGF which has also been found to be produced by the
peritubular cells. In view of the present findings of
EGF receptors probably in human Leydig cells, the
potential action of TGF or EGF on the Leydig cell is
of extreme interest not least because of earlier reports
on the effect of EGF on testicular cell lines. Ascoli
(1981) found that there was a 97% reduction in the
expression of human chorionic gonadotrophin recep¬
tors in MA-10 Leydig tumour cell lines grown in the
presence of EGF. Furthermore, it was also found that
in the same cell line EGF produced an increase in
steroid biosynthesis (Ascoli, Euffa & Segaloff, 1987).
Similarly, Verhoeven & Cailleau (1986) reported a
stimulatory effect of EGF on steroidogenesis in
normal rat Leydig cells.
As a result of this study we can now confirm that
epidermal growth factor receptors are present on
human testicular tissue and that because of their
probable location on the Leydig cell these may have
some control over steroidogenesis—a possibility
which we are at present investigating.
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DESCRIPTION OF PLATES
Plate 1
Autoradiography was performed on a testicular tissue
sample that had been preincubated with 125I-labelled epider¬
mal growth factor (EGF; 8 nmol/1) at 32 °C for 40 min in the
presence (lane B) and absence (lane A) of unlabelled EGF at
a 50-fold excess concentration. The receptor complex was
then cross-linked with disuccinimidyl suberate (1 mmol/1)
and run on 7-5% SDS-polyacrylamide gels, along with
standards ranging from 45 000 to 205 000 in molecular
weight. The gel was subsequently counterstained, dried
and autoradiography was carried out at — 70 °C with an
Amersham Hyperfilm Bmax for up to 4 weeks.
Plate 2
Immunohistochemical staining using the streptavidin-
biotin labelled method on frozen sections of human
testicular tissue.
figure 1. Primary monoclonal EGF receptor (EGF-R1)
antibody was used at a dilution of 1:30. The sections were
lightly counterstained with haematoxylin. A positive reac¬
tion for the EGF receptor appears as dark diffuse staining in
the interstitial tissue area (B) although it is more intense
where there is a large population of Leydig cells (A) (x 280).
figure 2. A paraffin section of human testicular tissue on
which immunohistochemical staining has been performed
using the monoclonal antibody EGF-R at a 1:10 dilution is
shown. Again Leydig cells (A) have become stained along
with fibroblastic cells surrounding the seminiferous tubules
(B) (x 280).
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